Document:

NEITHER
THE ISSUANCE AND SALE OF THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED,
PLEDGED OR ASSIGNED ONLY (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR (II) PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED, INCLUDING
RULE 144 UNDER SAID ACT, IN EACH CASE IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AND, IN CASE OF (II)
OTHER THAN PURSUANT TO RULE 144, IF REQUESTED BY THE COMPANY, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT
SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NOTWITHSTANDING THE FOREGOING, AFTER
THE DATE THAT IS 180 DAYS FROM ISSUANCE, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

MARRONE
BIO INNOVATIONS, INC.

 

Warrant
To Purchase Common Stock

 

Warrant
No.:_________

Number
of shares of Common Stock:________________

Date
of Issuance: August 6, 2019 (“Issuance Date”)

 

Marrone
Bio Innovations, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged,______, the registered holder hereof or its permitted assigns (the “Holder”),
is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then
in effect, at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date,
(as defined below), [____] fully paid nonassessable shares of Common Stock, subject to adjustment as provided herein (the “Warrant
Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any
Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have
the meanings set forth in Section 16. This Warrant is one of the Warrants to purchase Common Stock (the “Reorganization
Warrants”) issued pursuant to the Warrant Amendment and Plan of Reorganization Agreement (the “Warrant Reorganization
Agreement”), dated August 6, 2019 (the “Subscription Date”), by and between the Company, the Lead Investor,
Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval. Capitalized terms used herein and not otherwise defined shall have
the definitions ascribed to such terms in that certain Securities Purchase Agreement, dated as of December 15, 2017, by and among
the Company and the investors referred to therein (the “Securities Purchase Agreement”).

 

    	 	 	 

    	 	 	 

    

 

1.
EXERCISE OF WARRANT.

 

(a)
Mechanics of Exercise. Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder at any time
or times on or after the date six months after the Issuance Date, in whole or in part, by delivery of a written notice, in the
form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise
this Warrant. On or prior to the Trading Day immediately preceding the applicable Share Delivery Date (as defined below), the
Holder shall either (A) pay to the Company an amount equal to the applicable Exercise Price multiplied by the number of Warrant
Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash by wire transfer
of immediately available funds or (B) if the provisions of Section 1(d) are applicable, by notifying the Company that this Warrant
is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)). For the avoidance of doubt, the portion of this
Warrant corresponding to the number of shares referenced in an Exercise Notice shall be deemed exercised upon delivery by the
Holder of such Exercise Notice to the Company. The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall
have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the
remaining number of Warrant Shares. On or before the first (1st) Trading Day following the date on which the Company
has received the Exercise Notice, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation
of receipt of the Exercise Notice to the Holder and the Company’s transfer agent (the “Transfer Agent”).
On or before the earlier of (i) the second (2nd) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period, in each case, following the date on which the Holder delivers the Exercise Notice to the Company, so long as the Holder
delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the Trading Day immediately preceding
the earlier of clauses (i) and (ii) above (the “Share Delivery Date”) (provided that if the Aggregate Exercise
Price has not been delivered by such date, the Share Delivery Date shall be one (1) Trading Day after the Aggregate Exercise Price
(or notice of a Cashless Exercise) is delivered), the Company shall (X) provided that the Transfer Agent is participating in The
Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, credit such aggregate number of
Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance
account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the
DTC Fast Automated Securities Transfer Program, instruct the Transfer Agent to issue in book-entry form on the books and records
of the Transfer Agent, the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall
be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant
Shares via DTC, if any. Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become
the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such
Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant
Shares, as the case may be. If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the
number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being
acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three (3) Trading Days after
any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase
the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised. No fractional Warrant Shares are to be issued upon the exercise of this Warrant,
but rather the number of Warrant Shares to be issued shall be rounded to the nearest whole number. The Company shall pay any and
all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. The
Company’s obligations to issue and deliver Warrant Shares in accordance with the terms and subject to the conditions hereof
are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent
with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any
setoff, counterclaim, recoupment, limitation or termination. Notwithstanding anything to the contrary herein, except in the case
where an exercise of this Warrant is validly made pursuant to a Cashless Exercise (if permitted), the Company’s failure
to deliver Warrant Shares to the Holder shall not be deemed to be a breach of this Warrant if the Company has not received the
Aggregate Exercise Price pursuant to the requirements of this Section 1(a).

 

    	 	-2-	 

    	 	 	 

    

 

(b)
Exercise Price. For purposes of this Warrant, “Exercise Price” means $1.75 per
share, subject to adjustment as provided herein.

 

(c)
Company’s Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue
to the Holder on or prior to the Share Delivery Date either (I) if the Transfer Agent is not participating in the DTC Fast Automated
Securities Transfer Program, the number of shares of Common Stock to which the Holder is entitled, in book-entry form on the books
and records of the Transfer Agent, or if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program,
to credit the Holder’s balance account with DTC, for such number of shares of Common Stock to which the Holder is entitled
upon the Holder’s exercise of this Warrant or (II) if the Registration Statement (as defined in the Registration Rights
Agreement) covering the resale of the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant
Shares”) is not available for the resale of such Unavailable Warrant Shares and the Company fails to promptly, but in
no event later than as required pursuant to the Registration Rights Agreement, (x) so notify the Holder and (y) deliver the Warrant
Shares electronically without any restrictive legend by crediting such aggregate number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit
/ Withdrawal At Custodian system (the event described in the immediately foregoing clause (II) is hereinafter referred as a “Notice
Failure” and together with the event described in clause (I) above, an “Exercise Failure”), then,
in addition to all other remedies available to the Holder, (X) the Holder, upon written notice to the Company, may void its Exercise
Notice with respect to, and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised
pursuant to such Exercise Notice; provided that the voiding of an Exercise Notice shall not affect the Company’s obligations
to make any payments which have accrued prior to the date of such notice and (Y) if on or after such Trading Day the Holder purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares
of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”),
then the Company shall, within three (3) Trading Days after the Holder’s request and in the Holder’s discretion, either
(i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions and
other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at
which point the Company’s obligation to instruct the Transfer Agent to register such shares of Common Stock in book-entry
form (and to issue such shares of Common Stock) or credit the Holder’s balance account with DTC for such shares of Common
Stock shall terminate, or (ii) promptly honor its obligation to instruct the Transfer Agent to register such shares of Common
Stock in book-entry form or credit the Holder’s balance account with DTC, as applicable, and pay cash to the Holder in an
amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B)
the Closing Sale Price of the Common Stock on the applicable Exercise Date or on the date the Company makes such payment, whichever
is higher. Nothing shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity,
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock)
upon the exercise of this Warrant as required pursuant to the terms hereof.

 

    	 	-3-	 

    	 	 	 

    

 

(d)
Cashless Exercise. Notwithstanding anything contained herein to the contrary, if, beginning June 30, 2020, the Registration
Statement (as defined in the Registration Rights Agreement) covering the resale of the Unavailable Warrant Shares is not available
for the resale of such Unavailable Warrant Shares, the Holder may, in its sole discretion, exercise this Warrant in whole or in
part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of
the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock
determined according to the following formula (a “Cashless Exercise”):

 

	 	Net
    Number = 	(A
    x B) - (A x C)	 
	 	 	D	 

 

For
purposes of the foregoing formula:

 

	 	A=	the total number of shares with respect to which this
Warrant is then being exercised.
	 	 	 
	 	B=	the arithmetic average of the Closing Sale Prices of
the Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice.
	 	 	 
	 	C=	the Exercise Price then in effect for the applicable
Warrant Shares at the time of such exercise.
	 	 	 
	 	D=	the Closing Sale Price of the Common Stock on the date
of the Exercise Notice.

 

For
purposes of Rule 144(d) promulgated under the 1933 Act, as in effect on the date hereof, the Company hereby acknowledges and agrees
that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period
for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Securities
Purchase Agreement.

 

    	 	-4-	 

    	 	 	 

    

 

(e)
Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares to be issued pursuant to the terms hereof, the Company shall promptly issue to the Holder the number of Warrant Shares
that are not disputed and resolve such dispute in accordance with Section 12.

 

(f)
Insufficient Authorized Shares. If at any time while this Warrant remains outstanding the Company does not have a sufficient
number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of
this Warrant at least a number of shares of Common Stock equal to the number of shares of Common Stock as shall from time to time
be necessary to effect the exercise of all of this Warrant then outstanding (the “Required Reserve Amount”
and the failure to have such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized Share
Failure”), then the Company shall promptly take all action necessary to increase the Company’s authorized shares
of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding.
Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized
Share Failure, but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company shall
hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection
with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its reasonable best efforts
to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors
to recommend to the stockholders that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized
Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares
of Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation
by obtaining such consent and submitting for filing with the SEC an Information Statement on Schedule 14C. In the event that upon
any exercise of this Warrant, the Company does not have sufficient authorized shares to deliver in satisfaction of such exercise,
then unless the Holder elects to void such attempted exercise, the Holder may require the Company to pay to the Holder within
three (3) Trading Days of the applicable exercise, cash in an amount equal to the product of (i) the quotient determined by dividing
(x) the number of Warrant Shares that the Company is unable to deliver pursuant to this Section 1(f), by (y) the total number
of Warrant Shares issuable upon exercise of this Warrant (without regard to any limitations or restrictions on exercise of this
Warrant) and (ii) the Black Scholes Value; provided, that (x) references to “the day immediately following the public announcement
of the applicable Fundamental Transaction” in the definition of “Black Scholes Value” shall instead refer to
“the date the Holder exercises this Warrant and the Company cannot deliver the required number of Warrant Shares because
of an Authorized Share Failure” and (y) clause (iii) of the definition of “Black Scholes Value” shall instead
refer to “the underlying price per share used in such calculation shall be the highest Weighted Average Price during the
period beginning on the date of the applicable date of exercise and the date that the Company makes the applicable cash payment.”

 

    	 	-5-	 

    	 	 	 

    

 

2.
ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be
adjusted from time to time as follows:

 

(a)
Adjustment Upon Issuance of Shares of Common Stock. If and whenever on or after the Subscription Date, the Company issues
or sells, or in accordance with this Section 2 is deemed to have issued or sold, any shares of Common Stock (including the issuance
or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding shares of Common Stock deemed
to have been issued or sold by the Company in connection with any Excluded Securities) for a consideration per share (the “New
Issuance Price”) less than a price (the “Applicable Price”) equal to the Exercise Price in effect
immediately prior to such issue or sale or deemed issuance or sale (the foregoing a “Dilutive Issuance”), then
immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the product
of (A) the Exercise Price in effect immediately prior to such Dilutive Issuance and (B) the quotient determined by dividing (1)
the sum of (I) the product derived by multiplying the Exercise Price in effect immediately prior to such Dilutive Issuance and
the number of shares of Common Stock Deemed Outstanding immediately prior to such Dilutive Issuance plus (II) the consideration,
if any, received by the Company upon such Dilutive Issuance, by (2) the product derived by multiplying (I) the Exercise Price
in effect immediately prior to such Dilutive Issuance by (II) the number of shares of Common Stock Deemed Outstanding immediately
after such Dilutive Issuance. For purposes of determining the adjusted Exercise Price under this Section 2(a), the following shall
be applicable:

 

(i)
Issuance of Options. If the Company in any manner grants or sells any Options and the lowest price per share for which
one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible
Securities issuable upon exercise of any such Option is less than the Applicable Price, then such share of Common Stock shall
be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option
for such price per share. For purposes of this Section 2(a)(i), the “lowest price per share for which one share of Common
Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option” shall be equal to the sum of the lowest amounts of consideration (if any) received
or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of the Option, upon exercise
of the Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option less
any consideration paid or payable by the Company with respect to such one share of Common Stock upon the granting or sale of such
Option, upon exercise of such Option and upon conversion exercise or exchange of any Convertible Security issuable upon exercise
of such Option. No further adjustment of the Exercise Price or number of Warrant Shares shall be made upon the actual issuance
of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or upon the actual issuance
of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.

 

    	 	-6-	 

    	 	 	 

    

 

(ii)
Issuance of Convertible Securities. If the Company in any manner issues or sells any Convertible Securities and the lowest
price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof is less than
the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the
Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes of this
Section 2(a)(ii), the “lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise
or exchange thereof” shall be equal to the sum of the lowest amounts of consideration (if any) received or receivable by
the Company with respect to any one share of Common Stock upon the issuance or sale of the Convertible Security and upon conversion,
exercise or exchange of such Convertible Security less any consideration paid or payable by the Company with respect to such one
share of Common Stock upon the issuance or sale of such Convertible Security and upon conversion, exercise or exchange of such
Convertible Security. No further adjustment of the Exercise Price or number of Warrant Shares shall be made upon the actual issuance
of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities, and if any such issue or
sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to
be made pursuant to other provisions of this Section 2(a), no further adjustment of the Exercise Price or number of Warrant Shares
shall be made by reason of such issue or sale.

 

(iii)
Change in Option Price or Rate of Conversion. If the purchase price provided for in any Options, the additional consideration,
if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible
Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time,
the Exercise Price and the number of Warrant Shares in effect at the time of such increase or decrease shall be adjusted to the
Exercise Price and the number of Warrant Shares, which would have been in effect at such time had such Options or Convertible
Securities provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion
rate, as the case may be, at the time initially granted, issued or sold. For purposes of this Section 2(a)(iii), if the terms
of any Option or Convertible Security that was outstanding as of the Subscription Date are increased or decreased in the manner
described in the immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed
issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or
decrease. No adjustment pursuant to this Section 2(a) shall be made if such adjustment would result in an increase of the Exercise
Price then in effect or a decrease in the number of Warrant Shares.

 

(iv)
Calculation of Consideration Received. In case any Option is issued in connection with the issue or sale of other securities
of the Company, together comprising one integrated transaction, (x) the Options will be deemed to have been issued for the Option
Value of such Options and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been
issued or sold for the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable
by the Company pursuant to the terms of such other securities of the Company, less (II) the Option Value. If any shares of Common
Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration
other than cash received therefor will be deemed to be the net amount received by the Company therefor. If any shares of Common
Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration
received by the Company will be the fair value of such consideration, except where such consideration consists of publicly traded
securities, in which case the amount of consideration received by the Company will be the Closing Sale Price of such publicly
traded securities on the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners
of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration
therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is
attributable to such shares of Common Stock, Options or Convertible Securities, as the case may be. The fair value of any consideration
other than cash or publicly traded securities will be determined jointly by the Company and the Required Holders. If such parties
are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the “Valuation
Event”), the fair value of such consideration will be determined within five (5) Business Days after the tenth (10th)
day following the Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Required Holders.
The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses
of such appraiser shall be borne by the Company.

 

    	 	-7-	 

    	 	 	 

    

 

(v) Record
Date. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to
receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to
subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to
be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of
such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase,
as the case may be.

 

(vi)
No Readjustments. For the avoidance of doubt, in the event the Exercise Price has been adjusted pursuant to this Section
2(a) and the Dilutive Issuance that triggered such adjustment does not occur, is not consummated, is unwound or is cancelled after
the facts for any reason whatsoever, in no event shall the Exercise Price be readjusted to the Exercise Price that would have
been in effect if such Dilutive Issuance had not occurred or been consummated.

 

(b)
Voluntary Adjustment By Company. Subject to the applicable listing standards of the Principal Market, the Company may at
any time during the term of this Warrant, with the prior written consent of the Required Holders, reduce the then current Exercise
Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.

 

(c)
Adjustment Upon Subdivision or Combination of Common Stock. If the Company at any time on or after the Subscription Date
subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of
Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately
reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription
Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock
into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased
and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(c) shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

    	 	-8-	 

    	 	 	 

    

 

(d)
Other Events. If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided
for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other
rights with equity features), then the Company’s Board of Directors shall in good faith determine and implement an appropriate
adjustment in the Exercise Price and the number of Warrant Shares (if applicable), as mutually determined by the Company’s
Board of Directors and the Required Holders, so as to protect the rights of the Holder; provided that no such adjustment
pursuant to this Section 2(d) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined
pursuant to this Section 2.

 

(e)
Limitations. Notwithstanding anything herein to the contrary, in no event shall Section 2(a) or 2(b) cause the Exercise
Price to be reduced below $1.26 per share (as such minimum price maybe adjusted for stock splits, stock dividends, recapitalizations
and the like in a manner consistent with Sections 2(c) and 2(d)).

 

3.
RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities (other than stock or securities in which an adjustment is being
made pursuant to Section 2(c)), property, options, evidence of indebtedness or any other assets by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall, upon the exercise of this Warrant,
in whole or in part, be entitled to receive such Distribution to the same extent that the Holder would have received if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
or restrictions on exercise of this Warrant) immediately before the date of which a record is taken for such Distribution, or,
if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution. From the time of any Distribution until this Warrant is exercised or expires, the Company shall hold such
Distribution for the benefit of the Holder and distribute such Distribution to the Holder on the applicable Share Delivery Date
with respect to the portion of this Warrant being exercised.

 

    	 	-9-	 

    	 	 	 

    

 

4.
PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.

 

(a)
Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues
or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
or restrictions on exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or
sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock
are to be determined for the grant, issue or sale of such Purchase Rights.

 

(b)
Fundamental Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor
Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance
with the provisions of this Section 4(b) pursuant to written agreements in form and substance satisfactory to the Required Holders
prior to such Fundamental Transaction, including agreements, if so requested by the Holder, to deliver to each holder of the Reorganization
Warrants in exchange for such Reorganization Warrants a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number
of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and reasonably satisfactory
to the Required Holders, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the occurrence or consummation of such Fundamental
Transaction). Upon the occurrence or consummation of any Fundamental Transaction, and it shall be a required condition to the
occurrence or consummation of any Fundamental Transaction that, the Company and the Successor Entity or Successor Entities, jointly
and severally, shall succeed to, and the Company shall cause any Successor Entity or Successor Entities to jointly and severally
succeed to, and be added to the term “Company” under this Warrant (so that from and after the date of such Fundamental
Transaction, each and every provision of this Warrant referring to the “Company” shall refer instead to each of the
Company and the Successor Entity or Successor Entities, jointly and severally), and the Company and the Successor Entity or Successor
Entities, jointly and severally, may exercise every right and power of the Company prior thereto and shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor
Entities, jointly and severally, had been named as the Company in this Warrant. Upon occurrence or consummation of the Fundamental
Transaction, and it shall be a required condition to the occurrence or consummation of such Fundamental Transaction that, the
Company and the Successor Entity or Successor Entities shall deliver to the Holder confirmation that there shall be issued upon
exercise of this Warrant at any time after the occurrence or consummation of the Fundamental Transaction, as elected by the Holder
solely at its option, shares of Common Stock or shares of capital stock of the Successor Entity and/or Successor Entities (the
“Successor Capital Stock”) or, in lieu of the shares of Common Stock or Successor Capital Stock (or other securities,
cash, assets or other property purchasable upon the exercise of this Warrant prior to such Fundamental Transaction), such shares
of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights),
which for purposes of clarification may continue to be shares of Common Stock, if any, that the Holder would have been entitled
to receive upon the happening of such Fundamental Transaction or the record, eligibility or other determination date for the event
resulting in such Fundamental Transaction, had this Warrant been exercised immediately prior to such Fundamental Transaction or
the record, eligibility or other determination date for the event resulting in such Fundamental Transaction (without regard to
any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. Notwithstanding
the foregoing, (i) the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section
3(b) in writing to permit the Fundamental Transaction without redemption, similar repayment, “cash out” or assumption
of this Warrant (as applicable) and (ii) if holders of Common Stock are given any choice as to the securities, cash or other assets
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as the consideration it receives upon
any exercise of this Warrant following a Corporate Event. In addition to and not in substitution for any other rights hereunder,
prior to the occurrence or consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are
entitled to receive securities, cash, assets or other property with respect to or in exchange for shares of Common Stock (a “Corporate
Event”), the Company shall make appropriate provision to ensure that, and any applicable Successor Entity or Successor
Entities shall ensure that, and it shall be a required condition to the occurrence or consummation of such Corporate Event that,
the Holder will thereafter have the right to receive upon exercise of this Warrant at any time after the occurrence or consummation
of the Corporate Event, shares of Common Stock or Successor Capital Stock or, if so elected by the Holder, in lieu of the shares
of Common Stock or Successor Capital Stock (or other securities, cash, assets or other property) purchasable upon the exercise
of this Warrant prior to such Corporate Event (but not in lieu of such items still issuable under Sections 3 and 4(a), which shall
continue to be receivable on the shares of Common Stock or on the such shares of stock, securities, cash, assets or any other
property otherwise receivable with respect to or in exchange for shares of Common Stock), such shares of stock, securities, cash,
assets or any other property whatsoever (including warrants or other purchase or subscription rights and any shares of Common
Stock) which the Holder would have been entitled to receive upon the occurrence or consummation of such Corporate Event or the
record, eligibility or other determination date for the event resulting in such Corporate Event, had this Warrant been exercised
immediately prior to such Corporate Event or the record, eligibility or other determination date for the event resulting in such
Corporate Event (without regard to any limitations on exercise of this Warrant). Provision made pursuant to the preceding sentence
shall be in a form and substance reasonably satisfactory to the Holder. The provisions of this Section 4(b) shall apply similarly
and equally to successive Fundamental Transactions and Corporate Events. Notwithstanding, anything herein to the contrary, if
a Corporate Event occurs where the holders of shares of Common Stock receive cash and/or securities listed on an Eligible Market,
this Warrant shall no longer be exercisable for shares of Common Stock or Successor Capital Stock (but such items issuable under
Sections 4 and 4(a) shall continue to be receivable).

 

    	 	-10-	 

    	 	 	 

    

 

(c)
Notwithstanding the foregoing, in the event of a Fundamental Transaction other than one in which a Successor Entity that is a
publicly traded corporation whose stock is quoted or listed for trading on an Eligible Market assumes this Warrant such that the
Warrant shall be exercisable for the publicly traded Common Stock of such Successor Entity, at the request of the Holder delivered
before the ninetieth (90th) day after the occurrence or consummation of such Fundamental Transaction, the Company (or
the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after
such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black Scholes
Value of the remaining unexercised portion of this Warrant on the date of such Fundamental Transaction.

 

5.
NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of
Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, and will at all times in good faith carry out all of the provisions of this Warrant and take all action
as may be required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall
not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price
then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long
as any of the Reorganization Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized
and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Reorganization Warrants, the number
of shares of Common Stock as shall from time to time be necessary to effect the exercise of the Reorganization Warrants then outstanding
(without regard to any limitations on exercise).

 

6.
WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital
of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in
such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to
vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise,
prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to
purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder
with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with
the giving thereof to the stockholders; provided, that the Company shall not be required to provide the Holder with such
notices and other information to the extent such notices or other information is filed with the SEC pursuant to its Electronic
Data Gathering, Analysis and Retrieval (EDGAR) system.

 

    	 	-11-	 

    	 	 	 

    

 

7.
REISSUANCE OF WARRANTS.

 

(a)
Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon
the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered
as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and,
if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance
with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

(b)
Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the
loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification
undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of
this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing
the right to purchase the Warrant Shares then underlying this Warrant.

 

(c)
Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right
to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase
such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however,
that no Reorganization Warrants for fractional Warrant Shares shall be given.

 

(d)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant,
the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to
Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common
Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares
then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same
as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

 

8.
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall
be given in accordance with Section 5(h) of the Warrant Reorganization Agreement. The Company shall provide the Holder with prompt
written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and
the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)
promptly upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such
adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with
respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of
any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of
Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided
to the Holder. It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice
shall be definitive and may not be disputed or challenged by the Company.

 

    	 	-12-	 

    	 	 	 

    

 

9.
AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and
the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the
Company has obtained the written consent of the Required Holders.

 

10.
GOVERNING LAW; JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance
with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed
by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The
Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to the Company at the address set forth in Section 5(h) of the Warrant Reorganization Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall
be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction
to collect on the Company’s obligations to the Holder, to realize on any collateral or any other security for such obligations,
or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT
OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

11.
CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and each other party to the Warrant
Reorganization Agreement and shall not be construed against any Person as the drafter hereof. The headings of this Warrant are
for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

 

12. DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile or
electronic mail within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute, as the
case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the
Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination or arithmetic calculation
being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile or electronic mail
(a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and
approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant. The Company shall use its reasonable best efforts to cause at its expense the investment bank or the
accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the
results no later than ten (10) Business Days from the time it receives the disputed determinations or calculations. Such
investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all
parties absent demonstrable error.

 

    	 	-13-	 

    	 	 	 

    

 

13.
REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative
and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including
a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue
actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach
by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may
be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant
shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity
of showing economic loss and without any bond or other security being required.

 

14.
TRANSFER. This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the
consent of the Company, except as may otherwise be required by Section 4(f) of the Warrant Reorganization Agreement and Section
11 of the Registration Rights Agreement.

 

15.
SEVERABILITY. If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues
to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

16.
DISCLOSURE. Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, unless
the Company has in good faith determined that the matters relating to such notice do not constitute material, nonpublic information
relating to the Company or its Subsidiaries (as defined in the Warrant Reorganization Agreement), the Company shall within four
(4) Business Days after any such receipt or delivery publicly disclose such material, nonpublic information on a Current Report
on Form 8-K or otherwise. In the event that the Company believes that a notice contains material, nonpublic information relating
to the Company or its Subsidiaries, the Company so shall indicate to the Holder contemporaneously with delivery of such notice,
and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do
not constitute material, nonpublic information relating to the Company or its Subsidiaries.

 

    	 	-14-	 

    	 	 	 

    

 

17.
CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)
“1933 Act” means the Securities Act of 1933, as amended.

 

(b)
“1934 Act” means the Securities Exchange Act of 1934, as amended.

 

(c)
“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or
more intermediaries controls, is controlled by, or is under common control with, such Person.

 

(d)
“Approved Stock Plan” means any employee benefit plan which has been approved by the Board of Directors of
the Company, pursuant to which the Company’s securities may be issued to any employee, officer, director or consultant for
services provided to the Company.

 

(e)
“Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained
from the “OV” function on Bloomberg determined as of the day immediately following the public announcement of the
applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction
is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for
a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater
of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public
announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date
the Fundamental Transaction is consummated, (iii) the underlying price per share used in such calculation shall be the (x) sum
of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in the
Fundamental Transaction or (y) if no cash or other consideration is being offered in the Fundamental Transaction, the highest
Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive
documentation relating to the applicable Fundamental Transaction and ending on (A) the Trading Day immediately following the public
announcement of such Fundamental Transaction, if the applicable Fundamental Transaction is publicly announced or (B) the Trading
Day immediately following the consummation of the applicable Fundamental Transaction if the applicable Fundamental Transaction
is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.

 

    	 	-15-	 

    	 	 	 

    

 

(f)
“Bloomberg” means Bloomberg Financial Markets.

 

(g)
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City
of New York are authorized or required by law to remain closed.

 

(h)
“Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg,
or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing
trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00
p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading
market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities
exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply,
the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic
bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported
for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such
security as reported in the OTC Link or “pink sheets” by OTC Markets Group Inc. (formerly Pink OTC Markets Inc.).
If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then such dispute shall be resolved pursuant to Section 11. All such determinations to be appropriately
adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable
calculation period.

 

(i) “Common Stock” means (i) the Company’s Common Stock, par value $0.00001 per share, and (ii) any
share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of
such Common Stock.

 

(j)
“Common Stock Deemed Outstanding” means, at any given time, the number of shares of Common Stock actually outstanding
at such time, plus the number of shares of Common Stock deemed to be outstanding pursuant to Sections 2(a)(i) and 2(a)(ii) hereof
regardless of whether the Options or Convertible Securities are actually exercisable at such time, but excluding any shares of
Common Stock owned or held by or for the account of the Company or issuable upon exercise of the Reorganization Warrants.

 

(k)
“Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock.

 

(l)
“Eligible Market” means the Principal Market, the NYSE American LLC, The NASDAQ Global Select Market, The NASDAQ
Global Market or The New York Stock Exchange, Inc.

 

    	 	-16-	 

    	 	 	 

    

 

(m)
“Excluded Securities” means any Common Stock issued or issuable: (i)
in connection with any Approved Stock Plan, provided, that no more than 250,000 shares of Common Stock (as adjusted
for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring after the
Subscription Date) in the aggregate issued to consultants (other than the Advisory Members (as defined in the Securities
Purchase Agreement)) under all Approved Stock Plans shall be deemed Excluded Securities, except as agreed in writing by
the Lead Investor, or if the Lead
Investor or any of its Affiliates then no longer beneficially owns any shares, the Required Holders; (ii) upon exercise of
the SPA Warrants and the Reorganization Warrants; provided, that the terms of such SPA Warrants or Reorganization
Warrants are not amended, modified or changed on or after the Subscription Date, except in accordance with their terms; (iii)
upon exercise of any Options or Convertible Securities which are outstanding on the day immediately preceding
the Subscription Date; provided, that the terms of such Options or Convertible Securities are not amended, modified or
changed to increase the number of such shares issuable thereunder or to decrease the exercise price, exchange price or
conversion price of such securities or to extend the term of such securities; or (iv) pursuant to acquisitions or strategic
transactions (including issuances to vendors, customers or other commercial or strategic partners or potential commercial or
strategic partners) or credit facilities approved by a majority of the disinterested directors of the Company.

 

(n)
“Expiration Date” means January 1, 2023.

 

(o)
“Fundamental
Transaction” means (A) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or otherwise,
in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation)
another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties
or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one
or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to
or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that
is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares
of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with
any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares
of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such
purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of
at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject
Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding
shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock
held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase
agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the Subject
Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding
shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company shall, directly or
indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity
individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3
under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer,
exchange, reduction in outstanding Common Stock, merger, consolidation, business combination, reorganization, recapitalization,
spin-off, scheme of arrangement, reorganization, recapitalization or reclassification
or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued
and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding
shares of Common Stock not held by all such Subject Entities as of the Subscription Date calculated as if any shares of Common
Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented
by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities
to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their shares
of Common Stock without approval of the stockholders of the Company or (C) directly or indirectly, including through Subsidiaries,
Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction
structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary
to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment
of such instrument or transaction.

 

    	 	-17-	 

    	 	 	 

    

 

(p)
“Group” means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in
Rule 13d-5 thereunder.

 

(q)
“Lead Investor” means Ospraie Ag Science LLC.

 

(r)
“Option
Value” means the value of an Option based on the Black and Scholes Option Pricing Model obtained from the “OV”
function on Bloomberg determined as of (A)
the Trading Day prior to the public announcement of the issuance of the applicable Option, if the issuance of such Option is publicly
announced or (B) the Trading Day immediately following the issuance of the applicable Option if the issuance of such Option is
not publicly announced, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate
for a period equal to the remaining term of the applicable Option as of the applicable date of determination, (ii) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of (A) the Trading
Day immediately following the public announcement of the applicable Option if the issuance of such Option is publicly announced
or (B) the Trading Day immediately following the issuance of the applicable Option if the issuance of such Option is not publicly
announced, (iii) the underlying price per share used in such calculation shall be the highest Weighted Average Price of the Common
Stock during the period beginning on the Trading Day prior to the execution of definitive documentation relating to the issuance
of the applicable Option and ending on (A) the Trading Day immediately following the public announcement of such issuance, if
the issuance of such Option is publicly announced or (B) the Trading Day immediately following the issuance of the applicable
Option if the issuance of such Option is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.

 

(s)
“Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible
Securities.

 

(t)
“Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person, including
such entity whose common stock or common shares or equivalent equity security is quoted or listed on an Eligible Market (or, if
so elected by the Holder, any other market, exchange or quotation system), or, if there is more than one such Person or such entity,
such Person or entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

 

    	 	-18-	 

    	 	 	 

    

 

(u)
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

 

(v)
“Principal Market” means The NASDAQ Capital Market.

 

(w)
“Registration
Rights Agreement” means that certain Registration Rights Agreement dated as of the Subscription Date by and between the
Company, the Lead Investor, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval.

 

(x)
“Required Holders” means the holders of shares of Common Stock issued and issuable under all Warrants issuable
pursuant to the Warrant Reorganization Agreement (without regard to any restriction or limitation on the exercise of the Warrants
contained therein) and shall include the Lead Investor so long as the Lead Investor and/or any of its affiliates hold the Lead
Investor Minimum Threshold.

 

(y)
“SEC” means the Securities and Exchange Commission.

 

(z)
“Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on
the Company’s primary Eligible Market with respect to the Common Stock as in effect on the date of delivery of the applicable
Exercise Notice.

 

(aa)
“Subject Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons
or Group.

 

(bb)
“Successor Entity” means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent
Entity) formed by, resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected
by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

(cc)
“Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal
Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market
on which the Common Stock is then traded; provided that “Trading Day” shall not include any day on which the
Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended
from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in
advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time).

 

[Signature
Page Follows]

 

    	 	-19-	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date
set out above.

 

	 	MARRONE BIO INNOVATIONS, INC.
	 	 
	 	By:	 
	 	Name:
    	Pamela
    G. Marrone
	 	Title:	Chief
    Executive Officer

 

    	 	 	 

    	 	 	 

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS 

WARRANT TO PURCHASE COMMON STOCK

 

MARRONE
BIO INNOVATIONS, INC.

 

The
undersigned holder hereby exercises the right to purchase __________shares of Common Stock (“Warrant Shares”) of Marrone Bio
Innovations, Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth
in the Warrant.

 

1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:

 

_________ a
“Cash Exercise” with respect to _________Warrant Shares; and/or

 

_________
a “Cashless Exercise” with respect to ________Warrant Shares.

 

2.
Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant
Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $__________ to the Company in accordance
with the terms of the Warrant.

 

3.
Delivery of Warrant Shares. The Company shall deliver to the holder _________Warrant Shares in accordance with the terms of the Warrant.

 

Date:
___________________, _____________

 

 ______________________________

Name
of Registered Holder

 

	By:	 	 
	Name: 	 	 
	Title:	 	 

 

    	 	 	 

    	 	 	 

    

 

ACKNOWLEDGMENT

 

The
Company hereby acknowledges this Exercise Notice and hereby directs American Stock Transfer & Trust Company to issue the
above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated ___________,
___________ from the Company and acknowledged and agreed to by American Stock Transfer & Trust Company.

 

	 	MARRONE BIO INNOVATIONS, INC. 
	 	 
	 	By:	                    
	 	Name:	 
	 	Title:CERTAIN IDENTIFIED
INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF
PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW

 

SHARE
PURCHASE AGREEMENT

 

BY
AND AMONG

 

MARRONE
BIO INNOVATIONS, INC.,

 

PRO
FARM TECHNOLOGIES OY,

 

THE
CURRENT SHAREHOLDERS,

 

THE
CONVERSION SHAREHOLDERS

 

AND

 

MATTI
TIAINEN

 

AS
SHAREHOLDERS’ REPRESENTATIVE

 

Dated
as of August 7, 2019

 

    	 	 	 

    	 

    

 

TABLE
OF CONTENTS

 

	 	Page
	 	 
	Article
    I PURCHASE AND SALE of Company Shares	1
	1.1	Purchase
    and Sale	1
	1.2	Closing	1
	1.3	Closing
    Payments	4
	1.4	Schedules
    and Adjustments	4
	1.5	Milestone
    Payments.	7
	1.6	Transfer
    Taxes	8
	Article
    II REPRESENTATIONS AND WARRANTIES By THE COMPANY	9
	2.1	Organization
    and Good Standing	9
	2.2	Trade
    Register extract and Company Charter; Minute Books.	10
	2.3	Capitalization.	10
	2.4	Authority
    and Enforceability	11
	2.5	No
    Conflict; Required Consents and Approvals	12
	2.6	Compliance
    with Applicable Law; Permits	12
	2.7	Financial
    Statements	13
	2.8	Absence
    of Changes	13
	2.9	No
    Undisclosed Liabilities	13
	2.10	Litigation	14
	2.11	Employee
    Benefits	14
	2.12	Labor
    Matters	15
	2.13	Real
    Property	17
	2.14	Environmental
    Matters	17
	2.15	Intellectual
    Property	17
	2.16	Taxes	23
	2.17	Material
    Contracts	26
	2.18	Tangible
    Assets	28
	2.19	Insurance	29
	2.20	Anti-Corruption
    Laws	29
	2.21	Product
    Warranties; Product Liability	30
	2.22	Customers
    and Suppliers	30
	2.23	Brokers	30
	2.24	Bank
    Accounts; Powers of Attorney	30
	2.25	Related
    Party Transactions	31

 

    	 	-i-	 

     

    

 

TABLE
OF CONTENTS

(continued)

 

	 	 	Page
	 	 	 
	2.26	Data
    Protection	31
	2.27	Information
    Technology	32
	2.28	International
    Trade Laws	32
	2.29	Representations
    Complete	32
	Article
    III REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDERS	32
	3.1	Ownership
    of Company Securities	32
	3.2	No
    Public Sale or Distribution	33
	3.3	Non-U.S.
    Persons; Reliance on Exemptions	33
	3.4	Information	33
	3.5	Legends	33
	3.6	No
    Governmental Review	34
	3.7	Restricted
    Securities	34
	3.8	Litigation	35
	3.9	Authority	35
	3.10	No
    Conflict	35
	3.11	Brokers’
    and Finders’ Fees	35
	3.12	No
    Knowledge of Company Breaches	36
	3.13	Representations
    Complete	36
	Article
    IV REPRESENTATIONS AND WARRANTIES OF PURCHASER	36
	4.1	Organization
    and Qualification	36
	4.2	Issuance
    of Securities	36
	4.3	Governmental
    Approvals and Consents	37
	4.4	SEC
    Reports and Financial Statements	37
	4.5	Purchaser
    Compliance with Legal Requirements	37
	4.6	Shares
    Consideration	37
	4.7	Absence
    of Certain Changes	38
	4.8	Solvency	38
	4.9	No
    Undisclosed Events, Liabilities, Developments or Circumstances	38
	4.10	Absence
    of Litigation	38
	4.11	Insurance	38
	4.12	Title	38
	4.13	Representations
    Complete	39
	4.14	Capital
    Resources	39

 

    	 	-ii-	 

     

    

 

TABLE
OF CONTENTS

(continued)

 

	 	Page
	 	 
	Article
    V CONDUCT PRIOR TO THE CLOSING	39
	5.1	Affirmative
    Conduct of Business of the Company	39
	5.2	Restrictions
    on Conduct of Business of the Company	40
	5.3	Restrictions
    on Transfer	43
	Article
    VI ADDITIONAL AGREEMENTS	43
	6.1	Notification
    of Certain Matters	43
	6.2	Confidentiality	44
	6.3	Principal
    Market Approval	44
	6.4	Third
    Party Expenses	44
	6.5	Lock-Up	44
	6.6	Release	45
	6.7	Options
    and RSUs	46
	6.8	Tax
    Matters	46
	6.9	Non-Competition
    and Non-Solicitation	46
	6.10	Estonian
    Shares	46
	6.11	Good
    Faith Performance	47
	Article
    VII CONDITIONS TO CLOSING	47
	7.1	Conditions
    to Obligations of Each Party	47
	7.2	Conditions
    to Obligations of Purchaser	47
	7.3	Conditions
    to Obligations of the Company and the Shareholders	49
	Article
    VIII INDEMNIFICATION	50
	8.1	Survival
    of Representations and Warranties	50
	8.2	Indemnification	50
	8.3	R&W
    Policy	53
	8.4	Third
    party claims	53
	8.5	Shareholders’
    Representative	54
	Article
    IX TERMINATION; EXCLUSIVITY; Extension; Waiver.	55
	9.1	Termination	55
	9.2	Effect
    of Termination	56
	9.3	Exclusivity	56
	9.4	Extension;
    Waiver	57
	Article
    X GENERAL PROVISIONS	57
	10.1	Notices	57
	10.2	Interpretation	58
	10.3	Entire
    Agreement; Assignment; Successors	59
	10.4	Severability	59
	10.5	Specific
    Performance and Other Remedies	59
	10.6	Governing
    Law	59
	10.7	Submission
    to Jurisdiction	59
	10.8	Waiver
    of Jury Trial	60
	10.9	No
    Third-Party Beneficiaries	60
	10.10	Amendment
    and Modification	60
	10.11	Attorneys’
    Fees	60
	10.12	Fees
    and Expenses	60
	10.13	Waivers	60
	10.14	No
    Presumption Against Drafting Party	60
	10.15	Counterparts;
    Electronic Signature	60
	ANNEX
    A DEFINED TERMS	A-1

 

    	 	-iii-	 

     

    

 

INDEX
OF EXHIBITS

 

 

	Annex	 	Description
	 	 	 
	Annex
    0	 	Current
    Shareholders and Conversion Shareholders
	Annex
    A	 	Defined
    Terms
	Annex
    B	 	Key
    Individuals and Key Shareholders
	Annex
    C	 	Option
    and RSU Recipients
	Annex
    D	 	Third-Party
    Consents
	Annex
    E	 	Milestone
    Payments
	 	 	 
	Exhibit	 	Description
	 	 	 
	Exhibit
    A	 	Form
    of Joinder
	Exhibit
    B	 	Form
    of Option Award Agreement
	Exhibit
    C	 	Form
    of RSU Award Agreement
	Exhibit
    D	 	Form
    of Translink Representation Statement

 

Schedules

 

Schedule
of Expenses

Signing
Schedule

Distribution
Schedule

Company
Disclosure Schedules

Shareholder
Disclosure Schedules

 

    	 	 	 

    	 

    

 

SHARE
PURCHASE AGREEMENT

 

THIS
SHARE PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of August 7, 2019 by and among Marrone
Bio Innovations, Inc., a Delaware corporation (“Purchaser”), Pro Farm Technologies Oy, a Finnish limited company
(the “Company”), certain of the current shareholders of the Company party hereto (the “Current Shareholders”),
each of the anticipated future shareholders of the Company party hereto (the “Conversion Shareholders” and,
together with the Current Shareholders, the “Shareholders”, in each case as set forth on Annex 0) and
Matti Tiainen as representative of the Shareholders (the “Shareholders’ Representative”). All capitalized
terms that are used but not defined herein shall have the respective meanings ascribed thereto in Annex A.

 

RECITALS

 

WHEREAS,
the Current Shareholders own certain Company Shares issued and outstanding on the date of this Agreement, and the Conversion Shareholders
shall hold additional Company Shares to be issued prior to the Closing (as defined herein) upon exercise of the Company Options
outstanding as of date hereof and conversion of the Agrimax Convertible Loan (such exercise and conversion together referred to
as the “Conversion”);

 

WHEREAS,
the Shareholders desire to sell to Purchaser, and Purchaser desires to purchase from the Shareholders, all of the issued and outstanding
Company Shares owned and, as applicable, to be owned by the Shareholders at Closing on the terms and subject to the conditions
set out in this Agreement; and

 

WHEREAS,
Purchaser, the Company and the Shareholders desire to make certain representations, warranties, covenants and agreements, as more
fully set forth herein, in connection with the Transactions;

 

NOW,
THEREFORE, in consideration of the mutual agreements, covenants and other premises set forth herein, the mutual benefits to be
gained by the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged and accepted, the parties hereby agree as follows:

 

Article
I

PURCHASE AND SALE of Company Shares

 

1.1
Purchase and Sale. Upon and subject to the terms and conditions of this Agreement, each of the Shareholders hereby
sells, transfers, conveys and delivers to Purchaser, and Purchaser hereby purchases from the Shareholders, all of the Shareholders’
right, title and interest in and to the Company Shares, in each case free and clear of all Liens and any other rights or claims
of others, for the consideration set forth in, and to be paid in accordance with, Section 1.3.

 

1.2
Closing. Unless this Agreement is validly terminated pursuant to Section 9.1, the closing of the Transactions
(the “Closing”) shall occur at 5:00 p.m. local time at the offices of Hannes Snellman, Eteläesplanadi
20, 00130 Helsinki, Finland, on the date that is two (2) Business Days following the satisfaction or waiver (if permissible)
of the conditions set forth in Article VII (other than those conditions that by their nature are to be satisfied at the
Closing, but subject to satisfaction or waiver (if permissible) of those conditions), or through the electronic exchange of executed
documents and other closing deliveries via e-mail or facsimile transmission, unless another time or place is mutually agreed upon
in writing by Purchaser, the Shareholders and the Company; provided that, notwithstanding anything the satisfaction of the closing
conditions in this Section 1.2 or Article VII, the Closing shall not occur before September 9, 2019. The date upon which
the Closing actually occurs shall be referred to herein as the “Closing Date.”

 

    	 	-1-	 

     

    

 

(a)
Company Closing Deliverables. At or prior to the Closing, in addition to the other deliveries contemplated by Article
VII, the Company shall execute and deliver, or cause to be executed and delivered to Purchaser, all of the following:

 

(i)
a statement from the board of directors of the Company, dated as of the Closing Date, certifying that attached thereto are correct
and complete copies of each of the following: (i) the Trade Register extract, Certificate of Incorporation or Formation (or similar
document), as applicable, of the Company and each of its Subsidiaries as in effect as of the Closing Date, (ii) the Company Charter,
bylaws or operating agreement (or similar document), as applicable, of the Company and each of its Subsidiaries as in effect as
of the Closing Date is attached thereto, (iii) a certificate from the Finnish register of bankruptcies and restructurings or Certificates
of Good Standing (or similar document), as applicable, of the Company and each of its Subsidiaries from each jurisdiction in which
the Company and each Subsidiary is qualified to do business, in each case, as of a date not more than five (5) days prior to the
Closing Date, (iv) the resolutions of the board of directors of the Company approving the Transactions and all Transaction Documents
to which the Company is a party, including this Agreement, and (v) powers-of-attorney and requisite corporate approvals from each
Shareholder regarding entry into the Transactions, this Agreement and other Transaction Documents, as applicable;

 

(ii)
copy of the updated shareholder register of the Company certified by the then existing board of directors of the Company as of
(i) immediately before and (ii) immediately after Closing;

 

(iii)
copy of the Company’s register of ultimate beneficial owners as of immediately before the Closing;

 

(iv)
a certification signed by a duly authorized officer of the Company in a form reasonably acceptable to Purchaser, certifying to
the effect that the Company Shares are not “U.S. real property interests” within the meaning of section 897 of the
Code (the “FIRPTA Certificate”);

 

(v)
a duly executed resignation (in a form reasonably satisfactory to Purchaser) of Toni Murtoniemi as a director of the Company,
effective at the Closing, confirming that Mr. Murtoniemi has no claims against the Company for director fees for the period
prior to the Closing;

 

(vi)
one or more joinder agreements, in the form attached hereto as Exhibit A (the “Joinder Agreement”),
duly executed by any holder of Company Shares as of the date hereof and as of immediately prior to the Closing and that is not
already a signatory to this agreement (each, a “Joining Shareholder”), upon execution of which each Joining
Shareholder shall be deemed and be treated for all purposes as a Current Shareholder hereunder;

 

(vii)
those third-party consents set forth on Annex D in the agreed form;

 

(viii)
satisfactory evidence of exercise of (x) the Company Options held by TT Metals Oy (y) the waiver by Kalle Virta of the Company
Options held by him and (z) the termination by the Company of the Company Options held by Kalle Virta;

 

(ix)
an extract from the Finnish Trade Register confirming the registration of the shares issued to the Conversion Shareholders;

 

(x)
payoff letters for each of the Closing Repayment Loans, executed by the payee thereof in the agreed form;

 

    	 	-2-	 

     

    

 

(xi)
the investor representation statement by Translink Corporate Finance Oy, in the form attached hereto as Exhibit D
(the “Translink Representation Statement”), duly executed by Translink Corporate Finance Oy (“Translink”);

 

(xii)
evidence of termination of shareholders agreement of the Company, dated September 1, 2017, by and among the parties thereto and
the Pro Farm OÜ shareholders’ agreement by and among the Company, Pro Farm OÜ and Mr. Igor Taganov dated August
5, 2015, in each case except as to certain provisions regarding assignment of intellectual property and other customary clauses,
effective as of the Closing, without any recourse to, or further liability or obligation on the part of, the Company, Pro Farm
OÜ or Purchaser, pursuant to a form that is reasonably satisfactory to Purchaser;

 

(xiii)
evidence of (x) the payment, no later than August 17, 2019, of the second instalment of purchase price to be paid by the Company
after signing in respect of the acquisition of a total of twelve percent (12%) of the total share capital in each of NPO RET LLC,
PSM-1 LLC and Lignohumate LLC respectively (the “Russian Factory Shares”);

 

(xiv)
evidence of repayment by the Company of all outstanding amounts due to Fundu Platform Oy; and

 

(xv) a shareholders’ agreement, in a form reasonably acceptable to the Company, executed by the Company, Richard Edwin
Gurney, and Pro Farm Technologies Comércio de Insumos Agrícolas do Brasil Ltda. 

 

(b)
Purchaser Closing Deliverables. At or prior to the Closing, in addition to the other deliveries contemplated by
Article VII, Purchaser shall execute and deliver, or cause to be executed and delivered to the Shareholders’ Representative,
all of the following:

 

(i)
a certificate of the Secretary of Purchaser, dated as of the Closing Date, certifying that (i) a correct and complete copy of
the Certificate of Incorporation of Purchaser as in effect as of the Closing Date is attached thereto, (ii) a Certificate of Good
Standing of Purchaser issued by the Secretary of State of Delaware as of a date not more than five (5) days prior to the Closing
Date, are attached thereto, and (iii) a copy of the resolutions of Purchaser’s board of directors, authorizing Purchaser’s
execution and delivery of this Agreement and performance of the Transactions, are attached thereto and that such resolutions were
duly and validly adopted and are in full force and effect as of the Closing Date;

 

(ii)
confirmation of the issuance of the Adjusted Closing Stock Consideration, in accordance with Section 1.3(a), into book-entry
positions in the stock ledger maintained by American Stock Transfer & Trust Co., LLC, as Purchaser’s transfer agent
(the “Transfer Agent”);

 

(iii)
evidence of the Principal Market Approval (as defined herein);

 

(iv)
a copy of the R&W Policy;

 

(v)
[Intentionally omitted];

 

(vi)
evidence of wire transfers of the cash payments, payment of Finnish transfer tax, and filing of the Finnish transfer tax notification
to be made pursuant to Section 1.3; and

 

(vii)
copy of unanimous shareholder resolutions of the Company to elect new members of the Board of Directors and auditor.

 

    	 	-3-	 

     

    

 

 

(c)
Closing Actions Simultaneous All actions, deliveries and payments to be taken and made pursuant to Sections 1.2(a),
1.2(b), and 1.3 shall be deemed to occur simultaneously and no action, delivery or payment, or the Closing, shall
be deemed to have occurred or been made until all of the actions, deliveries and payments as set out in Sections 1.2(a),
1.2(b) and 1.3 have been taken and made.

 

1.3
Closing Payments.

 

(a)
Payment of Closing Consideration to Shareholders and Translink. Subject to the terms and conditions of this
Agreement, at the Closing, Purchaser shall pay for the Company Shares purchased hereunder, the Aggregate Closing Consideration
for distribution to the Shareholders as set forth on the Distribution Schedule, which payment shall be satisfied by: (i) delivery
of the Adjusted Cash Consideration via wire transfer of immediately available funds to an account designated by the Shareholders’
Representative, or its designee, and (ii) book entries on the stock ledger maintained by the Transfer Agent of that number of
shares of Purchaser Common Stock as is set forth opposite each Shareholder’s and Translink’s name on the Distribution
Schedule under the column “Adjusted Closing Stock Consideration,” registered in the name of each respective Shareholder
or Translink, as applicable.

 

(b)
Payment of Designated Indebtedness. Subject to the terms and conditions of this Agreement, at the Closing, Purchaser
shall pay or cause to be paid on behalf of the Company, certain of the Indebtedness of the Company set forth on Section 1.3(b)(i)
of the Company Disclosure Schedules (the “Closing Repayment Loans”) to the payees thereof as listed on
the Signing Schedule.

 

(c)
[Reserved].

 

(d)
Payment of Agreed Third Party Expenses. Subject to the terms and conditions of this Agreement, at the Closing, Purchaser
will pay those Third Party Expenses incurred as of the date of this Agreement, in the amounts set out in the Signing Schedule
to the payees thereof set forth in the Schedule of Expenses, plus those additional Third Party Expenses incurred after the date
hereof and to be incurred as of the Closing, and as designated by the Shareholders’ Representative to Purchaser in writing
not less than five (5) Business Days prior to the Closing, provided that such notice shall include reasonable supporting documentation
and calculations therefor, prepared in accordance with the relevant definitions herein, and the total Third Party Expenses shall
not exceed $80,000 without Purchaser’s consent.

 

(e)
Finnish Transfer Taxes. Subject to the terms and conditions of this Agreement, at the Closing, Purchaser will pay
the Finnish Transfer Taxes set out in the Signing Schedule to the Finnish tax authority and file the transfer tax notification
to the Finnish tax authority, which amount the parties agree represents the amount of Finnish Transfer Taxes due at the Closing.
Subject to the terms and conditions of this Agreement, Purchaser undertakes to pay to the Finnish tax authority, and file the
transfer tax notification to the Finnish Tax authority within the statutory time periods with respect to, any additional Finnish
Transfer Taxes due in connection with the issue of any Purchaser Shares to the Shareholders under this Agreement at any time after
Closing when such payments and notifications become due for payment or filing (as appropriate).

 

1.4
Schedules and Adjustments.

 

(a)
Schedules. Concurrently with the execution of this Agreement, the Company is delivering to Purchaser each
of the following:

 

(i)
a schedule (the “Schedule of Expenses”) setting forth (A) all paid and unpaid Third Party Expenses incurred
by or on behalf of the Company as of the date of this Agreement, and (B) all Third Party Expenses anticipated to be incurred or
payable by or on behalf of the Company after the date hereof (whether before or after the Closing).

 

    	 	-4-	 

     

    

 

(ii)
a schedule (the “Signing Schedule”), setting forth in reasonable detail (A) the Company’s good faith
estimate of (x) Cash as at June 30, 2019 and, (y) Indebtedness as at June 30, 2019, and (z) based on the balance of the estimates
concerning (x) and (y) the Net Debt of the Company as at June 30, 2019 (the “Estimated Net Debt”), (B) the
aggregate amount of the Closing Repayment Loans, (D) the total amount of the Finnish Transfer Taxes, (E) the calculation of the
Adjusted Cash Consideration, (F) the calculation of the Adjusted Closing Stock Consideration and (G) the Company’s good
faith estimate of the Milestone Consideration Adjustment, in each case, along with reasonable supporting documentation and calculations
therefor, prepared in accordance with the relevant definitions herein; and

 

(iii)
a schedule (the “Distribution Schedule”) setting forth: (A) the name, address and, if known, email address
of each Shareholder and Translink, (B) whether each such Shareholder is a current or former employee of the Company, (C) the number
of Company Shares held by each such Shareholder (or, in respect of Conversion Shareholders, to be held by such Shareholder immediately
prior to the Closing), (D) the original date of acquisition of each such Shareholder’s Company Shares, (E) the aggregate
purchase price for such Shareholder’s Company Shares, (F) the amount of the Adjusted Cash Consideration to be allocated
to each such Shareholder, (G) the number of shares of Adjusted Closing Stock Consideration to be issued to each such Shareholder
or Translink at the Closing, and (I) the percentage of the Adjusted Milestone Consideration, if any, payable to each such Shareholder
or Translink (each a “Milestone Percentage”). The Distribution Schedule shall include entries for the Conversion
Shareholders and any Shareholders to become party to this Agreement by the execution of Joinder Agreements, and the Distribution
Schedule may only be updated after the date of this Agreement with the consent of Purchaser and the Shareholders’ Representative.

 

(b)
Consideration Adjustments.

 

(i)
The “Cash Consideration Adjustment” shall mean the dollar amount equal to (A) the sum of (x) the total principal
and accrued interest as of the date of this Agreement under the Indebtedness set forth on Section 1.4(b)(i)(A)(x) of the
Company Disclosure Schedule (the “Cash Adjustment Debt”), plus (y) the total principal and accrued interest
as of the date of this Agreement under the Indebtedness set forth on Section 1.4(b)(i)(A)(y) of the Company Disclosure
Schedule (the “Total Consideration Adjustment Debt”), multiplied by the percentage equal to 4.0 divided by
31.8 (the “Cash Percentage”), plus (z) the Estimated Net Debt multiplied by the Cash Percentage, minus (B)
the sum of (x) all cash the Company in good faith represents was in the Company’s and its subsidiaries’ bank accounts
as of June 30, 2019, (y) any Cash received after June 30, 2019 and before the date of this Agreement from the exercise of Company
options and (z) the amount of the Russian Factory Share Payment, less with all elements of the foregoing converted into U.S. dollars
based on the rates quoted by Bloomberg on August 5, 2019, which sum the parties agree equals $1,254,346.

 

(ii)
The “Closing Stock Consideration Adjustment” shall mean the dollar amount equal to the sum of (A) the Total
Consideration Adjustment Debt, multiplied by the percentage equal to 18.5 divided by 31.8 (the “Closing Stock Percentage”),
plus (B) the Estimated Net Debt multiplied by the Closing Stock Percentage, plus (C) twenty five percent (25%) of the estimated
accounting and audit fees to be paid by Purchaser pursuant to Section 1.3(d), as set forth in the Signing Schedule, multiplied
by the percentage equal to 18.5 divided by 27.8, with all elements of the foregoing converted into U.S. dollars based on the rate
quoted by Bloomberg on August 5, 2019, which sum the parties agree equals $687,689.

 

    	 	-5-	 

     

    

 

(iii)
The “Milestone Consideration Adjustment” shall mean the dollar amount equal to the sum of (A) the Total Consideration
Adjustment Debt, multiplied by the percentage equal to 9.3 divided by 31.8, plus (X) the Final Net Debt, minus the amount of the
adjustment described in Section 1.4(b)(i)(A)(y) and minus the amount of the adjustment described in in Section 1.4(b)(ii)(B),
plus (C) twenty five percent (25%) the total U.S. dollar amount of the Shared Third Party Expenses included in the Third Party
Expenses, minus the amount of the adjustment described in Section 1.4(b)(ii)(C), plus (D) one hundred thirty seven and
a half percent (137.5%) the total U.S. dollar amount of principal and interest owed by the Company under the Anderson Loan Documents
the date of this Agreement, plus (E) fifty percent (50%) of the Finnish Transfer Taxes as set forth on the Signing Schedule, plus
(F) the amount, if positive, equal to the amount of the adjustment described in Section 1.4(b)(i)(B)(x) minus the Final
Closing Cash, with all elements of the foregoing converted into U.S. dollars based on the rates quoted by Bloomberg on the date
of the Closing.

 

(c)
Confirmation of Net Debt and Milestone Consideration Adjustment.

 

(i)
As promptly as possible, but in any event by September 30, 2019, Shareholders’ Representative shall prepare and deliver
to Purchaser or its designee a schedule (the “Closing Schedule”) setting forth its good faith calculation of:
(A) actual Cash at June 30, 2019, (B) actual Net Debt of the Company at June 30, 2019, and (C) based on the actual Cash and actual
Net Debt at June 30, 2019, the final amount of the Milestone Consideration Adjustment.

 

(ii)
If Purchaser desires to dispute the Closing Schedule, then within forty-five (45) days following the delivery by the Shareholders’
Representative of the Closing Schedule (the “Dispute Notice Period”), Purchaser shall deliver to the Shareholders’
Representative a written notice (for the purposes of this Section 1.4, a “Dispute Notice”), which shall
set forth in reasonable detail those items in the Closing Schedule that Purchaser disputes, along with reasonable supporting documentation
and calculations therefor. If Purchaser does not deliver a Dispute Notice within the Dispute Notice Period, then the calculations
of Cash and Net Debt (each as at 30 June 2019), and the resulting calculation of the Milestone Consideration Adjustment, shall
be deemed to be accepted by Purchaser as final, and shall thereafter be referred to as the “Final Closing Cash,”
the “Final Net Debt” and the Milestone Consideration Adjustment.

 

(iii)
If the Shareholders’ Representative disputes all or any portion of Purchaser’s proposed modification of the Closing
Schedule or the calculations set forth thereon, then Shareholders’ Representative shall notify Purchaser in writing of such
dispute setting forth in reasonable detail those items that Shareholders’ Representative disputes, and the Shareholders’
Representative and Purchaser shall negotiate in good faith to reach an agreement during the thirty (30)-day period immediately
following the Shareholders’ Representative’s receipt of the Dispute Notice (and all such discussions related thereto
shall, unless otherwise agreed by Purchaser and the Shareholders’ Representative, be governed by Rule 408 of the Federal
Rules of Evidence).

 

(iv)
If, within the thirty (30)-day negotiation period described in Section 1.4(c)(iii) Purchaser and the Shareholders’
Representative are unable to reach an agreement on the Closing Schedule and the calculations set forth thereon, then Purchaser
and the Shareholders’ Representative shall promptly thereafter cause a recognized accounting firm reasonably satisfactory
to Purchaser and the Shareholders’ Representative (an “Accounting Arbitrator”) to review the disputed
items or amounts for purposes of calculating the Milestone Consideration Adjustment. The Accounting Arbitrator shall, under the
terms of its engagement, have no more than thirty (30) days from the date of referral and no more than ten (10) Business Days
from the final submission of information by Purchaser and the Shareholders’ Representative within which to render its written
decision with respect to the disputed items (and only with respect to any unresolved disputed items set forth in the Dispute Notice),
and the calculation of Final Closing Cash, Final Net Debt and the resulting Milestone Consideration Adjustment shall be based
solely on the resolution of such disputed items by the Accounting Arbitrator. The Accounting Arbitrator shall review such submissions
and base its determination solely on such submissions. In resolving any disputed item, the Accounting Arbitrator may not assign
a value to any item greater than the greatest value for such item claimed by either party or less than the least value for such
item claimed by either party. The decision of the Accounting Arbitrator shall be deemed final and binding upon the Parties and
enforceable by any court of competent jurisdiction. Each of Purchaser and the Shareholders’ Representative shall bear that
percentage of the fees, costs and expenses of the Accounting Arbitrator equal to the proportion (expressed as a percentage) of
the dollar value of the disputed amount of the Milestone Consideration Adjustment determined in favor of the other party by the
Accounting Arbitrator. For purposes of this Agreement, “Final Cash” means the Cash at June 30, 2019 as finally
determined pursuant to this Section 1.4(c) and “Final Net Debt” means the Net Debt at June 30, 2019
as finally determined pursuant to this Section 1.4(c).

 

    	 	-6-	 

     

    

 

1.5
Milestone Payments.

 

(a)
Following the Closing, the Shareholders shall be entitled to receive from Purchaser the Milestone Stock Consideration, to the
extent each Milestone is achieved and the corresponding portion of the Adjusted Milestone Consideration becomes due and payable
pursuant to the terms and conditions set forth in this Section 1.5 and Annex E.

 

(b)
On March 31 of each year, commencing in 2021 and through and including 2024, Purchaser shall deliver to the
Shareholders’ Representative a notice (the “Milestone Payment Notice”), describing the percentage of
each Milestone achieved within the prior calendar year, if any (without double counting achievement in prior years), and
setting forth Purchaser’s good faith calculation of the amount, if any, payable in respect of the prior calendar
year’s achievement, which shall equal (i) the percentage of the Distributor Milestone achieved in such calendar year
multiplied by the Adjusted Distributor Milestone Consideration, plus (ii) the percentage of Annual Total Revenue
Milestone achieved in such calendar year multiplied by the Adjusted Annual Total Revenue Milestone Consideration, plus
(iii) the percentage of the Annual EBITDA Milestone achieved in such calendar year multiplied by the Adjusted Annual EBITDA
Milestone Consideration, plus (iv) the percentage of the Debt and Equity Milestone achieved in such calendar year
multiplied by the Adjusted Debt and Equity Milestone Consideration, minus (v) the aggregate amount of any liability of
the Shareholders that relate to all Shareholders and not individual Shareholders under Section 8.2(a), to the extent
not previously reduced from any prior year’s Adjusted Milestone Consideration, and plus (vi) the Estonian Share
Gain, if any, to the extent not previously added to any prior year’s Adjusted Milestone Consideration (the
“Adjusted Milestone Consideration”). The Milestone Payment Notice shall also include a schedule (the
“Milestone Allocation Schedule”) setting forth (A) the portion of the Adjusted Milestone Consideration
allocable to each Shareholder and to Translink, which shall be equal to the Milestone Percentage for each Shareholder or
Translink multiplied by the Adjusted Milestone Consideration, as further reduced for any individual Shareholder by the amount
of any liability that relates to that individual Shareholders and not all Shareholders under Section 8.2(a), to the
extent not previously reduced from such Shareholder’s portion of the Adjusted Milestone Consideration in a prior year
(each such portion, a “Milestone Consideration Allocation”), and (B) the number of shares of
Purchaser Common Stock issuable to each Shareholder and to Translink, which shall be that whole number of shares of Purchaser
Common Stock, rounded down to the nearest share, equal to the quotient obtained by dividing the Milestone Consideration
Allocation for such Shareholder or Translink by the applicable Milestone Share Price (the total shares of Purchaser Common
Stock issuable pursuant to the foregoing calculation in connection with the achievement of the Milestones, the
“Milestone Stock Consideration” and, together with the Adjusted Closing Stock Consideration, the
“Purchaser Shares”).

 

(c)
If the Shareholders’ Representative disputes Purchaser’s calculations as set forth in the Milestone Payment Notice
or the Milestone Allocation Schedule, then the Shareholders’ Representative shall deliver to Purchaser, within five (5)
Business Days following receipt of the Milestone Payment Notice, a written statement, which shall set forth in reasonable detail
those items in the Milestone Payment Notice and Milestone Allocation Schedule that the Shareholders’ Representative disputes,
along with reasonable supporting documentation therefor, which statement shall be a Dispute Notice for the purposes of this Section
1.5. If the Shareholders’ Representative does not deliver such written statement within five (5) Business Days after
receipt of the Milestone Payment Notice, then Purchaser’s calculations as provided in the Milestone Payment Notice and Milestone
Allocation Schedule shall be deemed final and binding on Purchaser, the Shareholders’ Representative and the Shareholders.

 

    	 	-7-	 

     

    

 

(d)
If Purchaser disputes all or any portion of the Shareholders’ Representative’s proposed modification of the Milestone
Payment Notice or the Milestone Allocation Schedule or the calculations set forth thereon, then Purchaser shall notify the Shareholders’
Representative in writing of such dispute setting forth in reasonable detail those items that Purchaser disputes, and the Shareholders’
Representative and Purchaser shall negotiate in good faith to reach an agreement during the thirty (30)-day period immediately
following Purchaser’s receipt of the Dispute Notice (and all such discussions related thereto shall, unless otherwise agreed
by Purchaser and the Shareholders’ Representative, be governed by Rule 408 of the Federal Rules of Evidence).

 

(e)
If, within the thirty (30)-day negotiation period described in Section 1.5(d), Purchaser and the Shareholders’ Representative
are unable to reach an agreement on the Milestone Payment Notice and the Milestone Allocation Schedule and the calculations set
forth thereon, then Purchaser and the Shareholders’ Representative shall promptly thereafter cause an Accounting Arbitrator
to review the disputed items or amounts for purposes of calculating Purchaser Common Stock payable to each Shareholder. The Accounting
Arbitrator shall, under the terms of its engagement, have no more than thirty (30) days from the date of referral and no more
than ten (10) Business Days from the final submission of information by Purchaser and the Shareholders’ Representative within
which to render its written decision with respect to the disputed items (and only with respect to any unresolved disputed items
set forth in the Dispute Notice), and the final Milestone Allocation Schedule and the calculation of Purchaser Common Stock payable
to each Shareholder shall be based solely on the resolution of such disputed items by the Accounting Arbitrator. The Accounting
Arbitrator shall review such submissions and base its determination solely on such submissions. In resolving any disputed item,
the Accounting Arbitrator may not assign a value to any item greater than the greatest value for such item claimed by either party
or less than the least value for such item claimed by either party. The decision of the Accounting Arbitrator shall be deemed
final and binding upon the Parties and enforceable by any court of competent jurisdiction. Each of Purchaser and the Shareholders’
Representative shall bear that percentage of the fees, costs and expenses of the Accounting Arbitrator equal to the proportion
(expressed as a percentage) of the dollar value of the disputed amounts determined in favor of the other party by the Accounting
Arbitrator.

 

(f)
The right of the Shareholders or Translink to receive any portion of the Adjusted Milestone Consideration (A) is solely a contractual
right and is not a security for purposes of any federal or state securities laws (and shall confer upon the Shareholders only
the rights of a general unsecured creditor under applicable state law), (B) will not be represented by any form of certificate
or instrument, (C) does not give the Shareholders, Translink or any of their Affiliates any dividend rights, voting rights, liquidation
rights, preemptive rights or other rights common to holders of a Person’s equity securities, (D) is not redeemable, and
(E) may not be sold, assigned, pledged, gifted, conveyed, transferred or otherwise disposed of except by operation of law or with
Purchaser’s prior written consent (and any transfer in violation of this Section 1.5 shall be null and void.

 

1.6
Transfer Taxes.
All transfer, documentary, sales, use, registration, stamp and other Taxes and fees (including any penalties and interest thereon)
incurred in connection with the Transactions effected by the Parties under this Agreement (including both the sale of the Company
Shares and the issue by Purchaser of any amounts of the Purchaser Shares) (together, “Transfer Taxes”) shall be paid
at the time such Transfer Taxes become due by Purchaser, with respect to all Finnish Transfer Taxes, and by the applicable Shareholders
to which such Transfer Taxes relate, with respect to all other Transfer Taxes. Subject to Purchaser’s obligation to remit
the payment for and file the related notification concerning the Finnish Transfer Taxes pursuant to Section 1.3(e), the Shareholders
shall timely file all necessary Tax Returns and other documentation with respect to all such Transfer Taxes, and if required or
advisable by applicable Legal Requirements, Purchaser shall be permitted to carry out or participate in the execution of any such
Tax Returns and other documentation.

 

    	 	-8-	 

     

    

 

Article
II

REPRESENTATIONS AND WARRANTIES By THE COMPANY

 

Except
as set forth in the corresponding sections or subsections of the disclosure schedule attached hereto (each section of which (i)
qualifies the specifically identified Sections or subsections of this Agreement to which such disclosure schedule relates and
shall be deemed to qualify, and be disclosed and incorporated in, each other Section and subsection of this Agreement solely to
the extent its applicability to such other Section or subsection is reasonably apparent on its face to a reader who is unfamiliar
with the Company and the contents underlying the Company Disclosure Schedules, and (ii) shall be deemed for all purposes to be
part of the representations and warranties made hereunder) (the “Company Disclosure Schedules”), the Company
and the Shareholders hereby, upon the execution of this Agreement and at the Closing, represent and warrant to Purchaser as follows:

 

2.1
Organization and Good Standing.

 

(a)
The Company is a Finnish limited company, validly existing and in good standing under the laws of its place of incorporation or
formation and has the requisite corporate power and authority to own, lease and operate all of its properties and assets and to
carry on its business as it is now being conducted and as proposed to be conducted at the Closing Date. The Company is duly qualified
or licensed as a foreign corporation to do business, and is in good standing (to the extent such concept or a comparable status
is recognized), in each jurisdiction where the character of the properties and assets occupied, owned, leased or operated by it
or the nature of its business makes such qualification or licensing necessary.

 

(b)
A complete and correct list of all Subsidiaries of the Company and their respective jurisdictions of incorporation or formation,
amount of authorized share capital, and record and beneficial owners of outstanding shares therein are set forth in Section
2.1(b) of the Company Disclosure Schedules. Each of the Company’s Subsidiaries is duly organized, validly existing and
in good standing (to the extent such concept or a comparable status is recognized) under the applicable Legal Requirements of
the jurisdiction of its incorporation or formation and has the requisite corporate power and authority to own, lease and operate
all of its properties and assets and to carry on its business as it is now being conducted and as currently proposed to be conducted
at the Closing Date. Each of the Company’s Subsidiaries is duly qualified or licensed as a foreign corporation to do business,
and is in good standing (to the extent such concept or a comparable status is recognized), in each jurisdiction where the character
of the properties and assets occupied, owned, leased or operated by it or the nature of its business makes such qualification
or licensing necessary. Except to the extent set forth in Section 2.1(b) of the Company Disclosure Schedules, neither the
Company nor any of its Subsidiaries owns, or has in the past owned, beneficially or otherwise, directly or indirectly owns any
equity, partnership, membership or similar interest in, or any interest convertible into, exercisable for the purchase of or exchangeable
for any such equity, partnership, membership or similar interest, or is under any current or prospective obligation to form or
participate in, provide funds to, make any loan, capital contribution or other investment in or assume any Liability of, any Person.

 

    	 	-9-	 

     

    

 

2.2
Trade Register extract and Company Charter; Minute
Books.

 

(a)
The Company has made available to Purchaser a complete and correct copy of the Trade Register extract, the Company Charter and
the other certificates of incorporation and the bylaws, or equivalent organizational documents, each as amended to date, of the
Company and each of its Subsidiaries. The Trade Register extract, the Company Charter and such other certificates of incorporation,
bylaws or equivalent organizational documents are in full force and effect. Neither the Company nor any of its Subsidiaries is
in violation of any of the provisions of its certificate of incorporation (including the Company Charter, in the case of the Company),
bylaws or equivalent organizational documents

 

(b)
The Company has made available to Purchaser complete and correct copies of the minutes and resolutions of the Company, and such
minutes and resolutions are in the possession of the Company. The minute books of the Company and its Subsidiaries contain complete
and correct copies of all minutes of meetings of and actions by the shareholders of the Company or its Subsidiaries, the board
of directors (or equivalent governing bodies) of the Company and each of its Subsidiaries, and all committees of such boards (or
equivalent governing bodies) of the Company and its Subsidiaries, and accurately reflect all corporate actions of the Company
and its Subsidiaries which are required by applicable Legal Requirement, their respective certificates of incorporation or bylaws
or other governing documents to be passed upon by the shareholders of the Company or its Subsidiaries, the board of directors
(or equivalent governing bodies) of the Company and each of its Subsidiaries, or any committee of such boards (or equivalent governing
bodies) of the Company and its Subsidiaries.

 

2.3
Capitalization.

 

(a)
At the Closing Date, the registered share capital of the Company is €390,129.16 and there are in total 39,012,916 Company
Shares issued and outstanding.There are in total 36,858,782 Company Shares issued and outstanding on the date hereof. The Shareholders
are legal owners of the Company Shares, which constitute all of the outstanding shares of the Company, are set forth in Section
2.3(a) of the Company Disclosure Schedules, indicating the number and series of Company Shares held by each Shareholder.

 

(b)
Except for (x) the Options set forth in Section 2.3(a) of the Company Disclosure Schedules, (y) the Agrimax Convertible
Loan, which in the aggregate shall convert into 1,391,833 Company Shares effective immediately prior to the Closing, and (z) the
share capital set forth in Section 2.1(b) of the Company Disclosure Schedules and Company Shares and share capital set
forth in Section 2.3(a) of the Company Disclosure Schedules, neither the Company nor any of its Subsidiaries has issued
or agreed to issue, or is obligated to issue, any: (i) share capital or other equity or ownership interest; (ii) option, warrant
or interest convertible into or exchangeable or exercisable for the purchase of Company Shares or other equity or ownership interests,
or plan or program authorizing or contemplating any of the foregoing; (iii) share appreciation right, phantom shares, interest
in the ownership or earnings of the Company or any of its Subsidiaries or other equity equivalent or equity-based or equity-linked
award or right, or plan or program authorizing or contemplating any of the foregoing; or (iv) bond, debenture or other Indebtedness
having the right to vote or convertible or exchangeable for securities having the right to vote. There are no outstanding obligations
of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire, or that relate to the holding, voting or
disposition of or that restrict the transfer of, the issued or unissued shares or share capital or other equity or ownership interests
of the Company or any of its Subsidiaries.

 

(c)
Each Company Share or other equity or ownership interest of the Company (including each Company Share to be issued upon Conversion)
and each of its Subsidiaries: (i) is (or, in the case of Company Shares to be issued upon the Conversion, will be) duly authorized,
validly issued, fully paid and nonassessable, and in the case of its Subsidiaries, each such share or other equity or ownership
interest is owned by the Company or another Subsidiary of the Company, free and clear of all Liens and (ii) has been offered,
sold and delivered by the Company or a Subsidiary of the Company in compliance with all applicable Legal Requirements and any
applicable contractual restrictions. There are no declared or accrued but unpaid dividends or other distributions with respect
to any Company Shares or other security of the Company.

 

    	 	-10-	 

     

    

 

(d)
There are no shareholder agreements, investors rights agreements, voting agreements, voting trusts, right of first refusal and
co-sale agreements, management rights agreements and all other similar agreements or Contracts to which either the Company or
any Subsidiary is a party or by which it is bound relating to the transfer, voting or registration of any shares of capital stock
or any other securities of the Company or any of its Subsidiaries and no shareholder or other security holder of the Company is
party to such an agreement.

 

(e)
The Company has made available to Purchaser complete and correct copies of the shareholder registers of each of the Company and
its Subsidiaries. Such shareholder registers of each of the Company and its Subsidiaries accurately reflect all transactions in
the shares and other equity interests of the Company and its Subsidiaries.

 

(f)
The Company has not issued physical share certificates in respect of the Company Shares.

 

(g)
The Company and its Subsidiaries and the transactions contemplated hereby are not, and by the passage of time will not be, subject
to a right of notice, right of first negotiation, right of first offer or refusal, or any other similar right granted by the Company
(or any of its Affiliates) to and in favor of a third party with respect to an Acquisition Proposal or a potential Acquisition
Proposal or that could otherwise affect, threaten the compliance of any of the exclusivity obligations under Section 9.3,
or cause any delays in the consummation of the transactions contemplated hereby.

 

(h)
Section 2.3(h) of the Company Disclosure Schedules sets forth a detailed list of each party to whom Indebtedness is owed
by the Company and the outstanding amount of such Indebtedness as of the date hereof.

 

2.4
Authority and Enforceability. The Company has all requisite power and authority to enter into this Agreement, any
other agreement contemplated hereby to which it is a party and to consummate the Transactions. The execution and delivery of this
Agreement and any agreements contemplated hereby to which the Company is a party and the consummation of the Transactions have
been duly authorized by all necessary corporate action on the part of the Company (including any approvals required under the
Company Charter) and no further corporate or other action is required on the part of the Company or the Shareholders to authorize
this Agreement or any agreements contemplated hereby to which the Company is a party or to consummate the Transactions. This Agreement
and each of the agreements contemplated hereby to which the Company is a party have been duly executed and delivered by the Company
and assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitute the valid and binding
obligations of the Company enforceable against it in accordance with their respective terms, subject to (x) Legal Requirements
of general application relating to bankruptcy, insolvency, moratorium, the relief of debtors and enforcement of creditors’
rights in general, and (y) rules of law governing specific performance, injunctive relief, other equitable remedies and other
general principles of equity (collectively, the “Enforceability Limitations”).

 

    	 	-11-	 

     

    

 

2.5
No Conflict; Required Consents and Approvals.

 

(a)
The execution, delivery and performance by the Company of this Agreement and each of the other documents and agreements contemplated
hereby to which the Company is or will become a party, and the consummation of the transactions contemplated hereby and thereby,
do not and will not: (i) conflict with or violate the Company Charter or bylaws or equivalent organizational documents of the
Company or any of its Subsidiaries; (ii) conflict with or violate any applicable Legal Requirements; or (iii) result in any material
breach of, or constitute a material default (or an event that, with notice or lapse of time or both, could reasonably be expected
to become a material default or material breach) under, require any consent of or notice to any Person pursuant to, or give to
others any right of termination, amendment, acceleration or cancellation of, or result in the creation of any Lien on any property
or asset of the Company or any of its Subsidiaries pursuant to, or otherwise adversely affect the rights of the Company or any
of its Subsidiaries under, or result in the loss of a material benefit under, any Contract or Company Permit.

 

(b)
The execution, delivery and performance by the Company or any of its Subsidiaries of this Agreement and each of the documents
and agreements contemplated hereby to which the Company or any of its Subsidiaries is or will be a party, and the consummation
of the transactions contemplated hereby and thereby by the Company and its Subsidiaries do not, and the performance of this Agreement
by the Company and its Subsidiaries will not, require any consent, approval, authorization license or permit (each, a “Permit”)
of, or filing with or notification to, any counterparty to a Material Contract, any Governmental Entity for such performance or
in order to prevent the termination of any right, privilege, license or qualification of the Company or any of its Subsidiaries,
except for those consents, approvals, authorizations, permits, filings or notifications listed in Section 2.5(b) of the
Company Disclosure Schedules.

 

2.6
Compliance with Applicable Law; Permits.

 

(a)
Each of the Company and its Subsidiaries is and has at all times been in compliance with all applicable Legal Requirements except
where the failure to be so in compliance would not result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries
has received, nor to the Knowledge of the Company is there any reasonable basis for, any notice, order, complaint or other communication
from any Governmental Entity or any other Person that the Company or any of its Subsidiaries has any Liability under any applicable
Legal Requirement or that it is not or has at any time not been in compliance with any applicable Legal Requirement. No investigation
or review by any Governmental Entity regarding a violation of any applicable Legal Requirements with respect to the Company or
any of its Subsidiaries has occurred, is pending or, to the Knowledge of the Company, threatened, and to the Knowledge of the
Company there is no reasonable basis therefor.

 

(b)
Each of Company and each of its Subsidiaries is in possession of all Permits necessary for the Company or its Subsidiaries to
lawfully own, lease and operate its properties and to lawfully carry on its business as it is now being conducted and is proposed
to be conducted at the Closing Date (the “Company Permits”), a complete and correct list of which is set forth
in Section 2.6(b) of the Company Disclosure Schedules. Each of Company and each of its Subsidiaries is and has at all times
been in material compliance with all such Company Permits. No suspension, cancellation, modification, revocation or nonrenewal
of any Company Permit has occurred, is pending or, to the Knowledge of the Company, threatened, and to the Knowledge of the Company
there is no basis therefor. The Company and its Subsidiaries will continue to have the use and benefit of all Company Permits
following consummation of the Transactions.

 

    	 	-12-	 

     

    

 

2.7
Financial Statements.

 

(a)
Section 2.7(a) of the Company Disclosure Schedules sets forth complete and correct copies of (i) the unaudited (under Finnish
GAAP) balance sheet and income statement of the Company as at fiscal year-end December 31, 2017 and the audited (under Finnish
GAAP) balance sheet and income statement of the Company as at fiscal year-end December 31, 2018 (accompanied by the report thereon
of BDO Oy, the independent auditor of the Company), together with all related notes and schedules thereto (the items in this clause
(i), collectively the “Company Financial Statements”), (ii) the unaudited balance sheet and income statement
of the Company as at March 31, 2019 (the “Interim Balance Sheet Date”) (the items in this clause (ii), collectively
the “Interim Company Financial Statements”) and (iii) the unaudited consolidated balance sheets and the statements
of income as at fiscal year-end December 31, 2017 and December 31, 2018 of the Company and its Subsidiaries, together with all
related notes and schedules thereto (the items in this clause (iii), collectively the “Consolidated Financial Statements”),
and (iv) the unaudited consolidated balance sheet and statements of income of the Company and its Subsidiaries income statement
of the Company as at March 31, 2019 (the items in this clause (iv), collectively the “Interim Consolidated Financial
Statements” and, together with the Company Financial Statements, the Interim Company Financial Statements and the Consolidated
Financial Statements, the “Financial Statements”).

 

(b)
Each of the Financial Statements (i) are complete and correct in all material respects and have been prepared in accordance with
the books and records of the Company and its Subsidiaries, (ii) where such Financial Statements have been audited and subject
to any qualification by the relevant auditor of such audited Financial Statements present a true and fair view of the Company’s
financial position and have been prepared in accordance with Finnish generally accepted accounting principles (fi: hyvä
kirjanpitotapa), including but not limited to the Finnish Accounting Act (No. 30.12.1997/1336, as amended) (“Finnish
GAAP”), with respect to the Company Financial Statements and the Interim Financial Statements, with respect to the Consolidated
Financial Statements and Interim Consolidated Financial Statements, in each case as applied on a consistent basis throughout the
periods indicated (except as may be indicated in the notes thereto) and (iii) fairly present the consolidated financial position
and results of operations of the Company and, with respect to the Consolidated Financial Statements and the Interim Consolidated
Financial Statements, its Subsidiaries as at the respective dates thereof and for the respective periods indicated therein, except
as otherwise noted therein and subject, in the case of the Interim Company Financial Statements and Interim Consolidated Financial
Statements, to normal and recurring year-end adjustments that will not, individually or in the aggregate, be material to the Company
and its Subsidiaries. The statements of income contained in the Financial Statements do not contain any items of special or nonrecurring
income or any other income not earned in the ordinary course of business consistent with past practice, except as expressly specified
therein.

 

2.8
Absence of Changes. Since the Interim Balance Sheet Date (such balance sheet as of the Interim Balance Sheet Date
the “Balance Sheet”), other than actions expressly required to be taken pursuant to this Agreement: (a) the
Company and its Subsidiaries have conducted their businesses only in the ordinary course and in a manner consistent with past
practice; (b) there has not been any event, condition, circumstance, development, change or effect, having, or that would reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect; (c) neither the Company nor any of its Subsidiaries
has suffered any loss, damage, destruction or other casualty affecting any of its material properties or assets, whether or not
covered by insurance; and (d) neither the Company nor any of its Subsidiaries has taken any action that, if taken after the date
of this Agreement, would constitute a breach of any of the covenants set forth in Section 5.1 (Affirmative Conduct of
Business of the Company) and Section 5.2 (Restrictions on Conduct of Business of the Company)

 

2.9
No Undisclosed Liabilities. Except
as and to the extent adequately accrued or reserved against in the Balance Sheet, neither the Company nor any of its Subsidiaries
has any Liability, except for any Liability (a) incurred in the ordinary course of business consistent with past practice since
the date of the Balance Sheet (b) for performance obligations under executory Contracts (other than as a result of a breach thereof)
or (c) incurred by the Company in connection with the transactions contemplated by this Agreement and treated as a Third Party
Expense.

 

    	 	-13-	 

     

    

 

2.10
Litigation.
No Action against the Company or any of its Subsidiaries, or any property or asset of the Company
or any of its Subsidiaries, or any of the directors or officers of the Company or any of its Subsidiaries with regard to their
actions as such, has occurred, is pending or to the Knowledge of the Company threatened, and to the Knowledge of the Company there
is no basis for any such Action. No Action seeking to prevent, hinder, modify, delay or challenge the transactions contemplated
by this Agreement or any of the documents or agreements contemplated hereby has occurred, is pending or to the Knowledge of the
Company threatened, and to the Knowledge of the Company there is no basis for any such Action. There is no outstanding order,
writ, judgment, injunction, decree, determination or award of, or pending or to the Knowledge of the Company threatened investigation
by, any Governmental Entity relating to the Company, any of its Subsidiaries, any of their respective properties or assets, any
of their respective officers or directors, or the transactions contemplated by this Agreement or the documents or agreements contemplated
hereby. There is no Action by the Company or any of its Subsidiaries pending, or which the Company or any of its Subsidiaries
has commenced preparations to initiate, against any other Person and to the Knowledge of the Company there is no basis for any
such Action.

 

2.11
Employee Benefits.

 

(a)
Neither the Company nor any of its Subsidiaries operates any Employee Plan other than stock options granted by the Company to
Kalle Virta and TT Metals Oy owned by Toni Murtoniemi and a Sales Commission Plan concerning all employees of the Company and
its Subsidiaries but in which none of Matti Tiainen, Toni Murtoniemi and Fredrik Engvall operate. For purposes of this Agreement,
“Employee Plan” includes all compensatory arrangements, bonus, stock option, stock purchase, restricted stock,
incentive, deferred compensation, retiree medical or life insurance (other than statutory medical insurances and pensions insurances
required to be provided to employees of the Company or any Subsidiary in accordance with any Legal Requirement), supplemental
retirement, severance or other benefit plans, programs or arrangements.

 

(b)
Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby (either alone
or in combination with any other event) will (i) result in any payment becoming due to any current or former employee, consultant,
independent contractor or director of the Company or any Subsidiary of the Company.

 

(c)
The Company and each Subsidiary has materially complied and materially complies with all service and employment contracts, and
with all relevant Legal Requirements and collective bargaining agreements applicable to employment, labour, working conditions
or relationship between an employer and an employee. No claims, investigations or proceedings concerning breach of any such contracts,
schemes, programs, Legal Requirements or collective bargaining agreements have been or are pending or, to the Knowledge of the
Company, threatened against the Company or any Subsidiary. No circumstances giving rise to any such breach, claims, investigations
or proceedings have arisen.

 

(d)
The Company and each Subsidiary has complied and complies with the Finnish Act on Commercial Representatives and Salesmen (No.
417/1992, as amended) and other equivalent or similar local laws, and has paid all compensations and payments payable thereunder,
and has not terminated any contract with such commercial representative or salesman.

 

(e)
The Company and each Subsidiary has paid all contributions required to be paid for pension liabilities (including liabilities
for part-time, unemployment and disability retirement) under contracts, Legal Requirements or collective bargaining agreements
and has covered by insurance or by making full reserves in the relevant accounts for all unpaid or uncovered current and future
pension liabilities. Neither the Company nor any Subsidiary will incur any pension liability in excess of the contributions paid,
the payment terms of insurance policies and the reserves formed in the Financial Statements for its pension liabilities.

 

    	 	-14-	 

     

    

 

(f)
Neither the Company nor any Subsidiary has entered into any contract or arrangement with or for the benefit of any employee, or
a consultant or other service provider, except for normal service or employment contracts entered into in the Ordinary Course
of Business or otherwise disclosed to Purchaser prior to the date hereof, or has given any guarantee, assets, property, Lien or
letter of comfort to or incurred any other liability or indemnity for the benefit of any employee, or a consultant or other service
provider.

 

2.12
Labor Matters.

 

(a)
List of Employees, Consultants and Service Providers. Section 2.12(a) of the Company Disclosure Schedules
contains a list of the name of each employee, consultant, or other service provider of the Company and each of its Subsidiaries,
and such Person’s (i) work location, (ii) employing entity, (iii) whether such Person is an employee, or a consultant or
other service provider, (iv) job title or position, (v) annualized base salary or regular hourly rate, as applicable (in the case
of an employee) or other compensation details (in case of a consultant or other service provider), (vi) incentive or bonus arrangements,
if any, (vii) taxable fringe benefits, if any, and (viii) date of hire or engagement; provided, that, to the extent applicable
privacy or data protection Legal Requirements would prohibit the disclosure of certain personally identifiable information without
the individual’s consent, Section 2.12(a) of the Company Disclosure Schedules shall specify such legal prohibition
and shall provide such information in de-identified form in compliance with applicable Legal Requirements. No such Person has
terminated or has advised the Company or any of its Subsidiaries of such Person’s intention to terminate such Person’s
relationship or status as an employee, consultant or other service provider of the Company or any of its Subsidiaries for any
reason, including because of the consummation of the transactions contemplated by this Agreement and the Company and its Subsidiaries
have no plans or intentions as of the date hereof to terminate any such employee, consultant or other service provider. All employees,
consultants, or other service providers of the Company and its Subsidiaries are lawfully entitled to work for the Company or the
applicable Subsidiary of the Company without restriction or any visa, permit or consent being required. There are no profit-sharing,
bonus schemes, incentive programs, severance pay, deferred compensation arrangements, holiday entitlements, pensions, retirement
plans or other benefits or liabilities with respect to any employee, or a consultant or other service provider) in excess of those
provided by relevant Laws or collective bargaining agreements, except as set out in Schedule 2.12(a).

 

(b)
Key Individuals. There are no Key Individuals other than those set out in Annex B. No Key Individual has been dismissed
or has announced his/her termination of his/her service or employment in the Company or any Subsidiary.

 

(c)
Classification. Except for the respective Key Individuals performing services under the Consultancy Agreements,
all individuals who are or were performing consulting or other services for the Company or any of its Subsidiaries are or were
correctly classified under all applicable Legal Requirements by the Company or such Subsidiary as either “independent contractors”
(or comparable status in the case of a non-U.S. entity) or “employees” as the case may be. At the Closing Date, with
respect to those individuals still performing consulting services for the Company or any of its Subsidiaries as of the Closing
Date, such individuals will qualify for such classification. All individuals who are or were classified as “employees”
of the Company or any of its Subsidiaries are or were correctly classified under all applicable Legal Requirements by the Company
or such Subsidiary, as exempt or non-exempt, as the case may be.

 

    	 	-15-	 

     

    

 

(d)
Compliance with Laws and Collective Bargaining Agreements. Each of the Company and its Subsidiaries is and
has at all times been in material compliance with all Labor and Employment Laws. Neither the Company nor any of its Subsidiaries
has any Liability under any Labor and Employment Laws and attributable to an event occurring or a state of facts existing prior
to the date hereof, including but not limited to Liability which has been incurred by the Company or any of its Subsidiaries,
but remains to be discharged, for breach of an employment contract with an employee or breach of any Labor and Employment Laws.
There is no collective bargaining agreement or similar agreement currently applicable to the Company or any of its Subsidiaries
other than the Collective agreement for senior salaried employees in the Finnish chemical industries binding on the Company. Each
of the Company and its Finnish Subsidiary is and has at all times been in all respects in compliance with such collective bargaining
agreement.

 

(e)
Claims. There are no Actions or other formal complaints of discrimination (including discrimination based upon sex,
age, marital status, race, national origin, sexual orientation, disability or veteran status) pending or, to the Knowledge of
the Company, threatened before the Equal Employment Opportunity Commission, the National Labor Relations Board, the U.S. Department
of Labor, the U.S. Occupational Health and Safety Administration, the Workers Compensation Appeals Board, or any other Governmental
Entity against the Company pertaining to any employee and, to the Knowledge of the Company, there is no basis therefor. Neither
the Company nor any Subsidiary has terminated any employments on collective grounds or otherwise, nor is obliged to re-employ
or re-engage any employee.

 

(f)
Certain Loans. There are no outstanding loans or advances from the Company or any of its Subsidiaries to employees
or shareholders of the Company or any of its Subsidiaries.

 

(g)
Unions. There is no obligation to inform, consult or obtain consent whether in advance or otherwise of any
labor union, workers council, labor organization or other employee representative body in order to consummate the transactions
contemplated by this Agreement. There is no obligation to inform, consult or obtain consent whether in advance or otherwise of
any labor union, workers council, labor organization or other employee representative body in order to consummate the transactions
contemplated by this Agreement. Neither the Company nor its Subsidiaries are members of any employer’s organization and
has no formal contact with any union or employee organization. Furthermore, the Company or its Subsidiaries have no formal employee
representation, works council or similar in place.

 

(h)
Disputes. (i) No labor strike, lock-out, industrial dispute, trade dispute or other dispute, slow down or stoppage
against the Company or any of its Subsidiaries is pending or, to the Knowledge of the Company, threatened against the Company
or any of its Subsidiaries, (ii) neither the Company nor any of its Subsidiaries is or has been involved in any negotiation regarding
a claim with any labor union or other body representing employees or former employees of the Company or any of its Subsidiaries,
and (iii) neither the Company nor any of its Subsidiaries has ever received any demand letters, civil rights charges, suits, drafts
of suits, complaints or other communications related to claims made by any of its current or former employees or directors, consultants,
or other service providers, whether or not before a Governmental Entity and, to the Knowledge of the Company, there is no basis
therefor.

 

(i)
Early Retirement No resolutions or applications have been made or may reasonably be expected to be made for early
retirement (including part-time, unemployment or disability retirement) of any employee.

 

(j)
Benefits for Past Service. There is no former employee, director or other service provider of the Company
or any of its Subsidiaries who is receiving or is scheduled to receive (or whose spouse or other dependent is receiving or is
scheduled to receive) any benefits (whether from the Company, any of its Subsidiaries or otherwise) relating to such former employee’s
employment or such former director’s or service provider’s service relationship with the Company or any of its Subsidiaries
except as is required under COBRA or by other applicable Legal Requirements.

 

    	 	-16-	 

     

    

 

2.13
Real Property.

 

(a)
Owned Real Property. Neither the Company nor any of its Subsidiaries owns, or has ever owned, any Real Property.

 

(b)
Leased Real Property. Section 2.13(b) of the Company Disclosure Schedules sets forth a complete and correct
list of all Leased Real Property (each, a “Real Property Lease”). The Company and each of its Subsidiaries
have the valid right to occupy and use all Leased Real Property, in each case, free and clear of all Liens and adverse Governmental
Orders. All rent and other sums and charges payable by the Company or any of its Subsidiaries as tenant under the leases of Leased
Real Property are current. Neither the Company nor any of its Subsidiaries has made any material alterations, additions or improvements
to any Leased Real Property that are required to be removed (or of which any landlord or sub-landlord could require removal) at
the termination of the applicable lease term. All of the Leased Real Property is adequately maintained and suitable in all material
respects for the purpose of conducting the business of the Company and its Subsidiaries. No parcel of Leased Real Property is
subject to any decree or order of a Governmental Entity to be sold or is being condemned, expropriated or otherwise taken by any
Governmental Entity nor, to the Knowledge of the Company, has any such action been proposed. Each Real Property Lease will remain
valid and biding in accordance with its terms following the Closing. The Company has made available to Purchaser complete and
correct copies of Real Property Leases, including all modifications, amendment and supplements thereto.

 

2.14
Environmental Matters. Each of the Company and its Subsidiaries is and has at all times been in compliance with
all applicable Environmental Laws. Neither the Company nor any of its Subsidiaries has ever been subject to an investigation or
review regarding a violation of any Environmental Law by any Governmental Entity, or received any notice, letter, complaint or
other communication alleging that the Company or any of its Subsidiaries has any Liability under any Environmental Law or that
the Company or any of its Subsidiaries is not or has at any time not been in compliance with any Environmental Law and, to the
Knowledge of the Company, there is no reasonable basis therefor. There are no past or present events, conditions, circumstances,
activities, practices, incidents, actions, omissions or plans that constitute a violation by the Company or any of its Subsidiaries
of, or are reasonably likely to prevent or interfere with the Company’s or its Subsidiaries’ future compliance with,
any Environmental Laws. None of the properties leased or operated by the Company or any of its Subsidiaries (including soils and
surface and ground waters) is contaminated with any Hazardous Substance.

 

2.15
Intellectual Property.

 

(a)
Fundamental IP Representations.

 

(i)
General

 

(1)
Section 2.15(a)(i)(1) of the Company Disclosure Schedules sets forth, for the Intellectual Property and Intellectual Property
Rights owned by or licensed to the Company and its Subsidiaries, in whole or in part, including jointly with others (and such
schedule specifies whether such Intellectual Property or Intellectual Property Right is owned solely by, owned jointly by, or
licensed to the Company or any of its Subsidiaries), a complete and correct list of all (A) Patents, indicating for each Patent
the applicable owner, jurisdiction, registration number (or application number) and date issued (or date filed), (B) Trademarks,
indicating for each Trademark that is registered or the subject of an application for registration the applicable owner, jurisdiction,
registration number (or application number) and date issued (or date filed) and (C) Copyrights that are registered or the subject
of an application for registration, indicating for each the applicable owner, jurisdiction, registration number (or application
number) and date issued (or date filed) (collectively, “Registered Intellectual Property”). All necessary registration,
maintenance and renewal fees with respect to all Registered Intellectual Property have been paid to date, and all necessary affidavits,
responses, recordations, certificates, and other documents as of the date of this Agreement have been filed for the purposes of
obtaining, maintaining, perfecting, preserving or renewing any of the Registered Intellectual Property. Except to the extent set
out in Section 2.15(a)(i)(1) of the Company Disclosure Schedules, there are no actions that must be taken by the Company
or any of its Subsidiaries within one hundred and twenty (120) days following the Closing, including the payment of any registration,
maintenance or renewal fees, transfer of title fees or compensations, or the filing of any affidavits, responses, recordations,
certificates or other documents, for the purposes of obtaining, maintaining, perfecting, preserving or renewing any of the Registered
Intellectual Property. Each item of Registered Intellectual Property has been prosecuted in compliance in all material respects
with all applicable rules, policies, and procedures of the applicable Governmental Entity.

 

    	 	-17-	 

     

    

 

(2)
All right, title and interest in and to any Intellectual Property relating to the business of the Company and its Subsidiaries
or their reasonably anticipated research and development that is or was created, developed, written, invented, conceived or discovered
by the employees, consultants or contractors and that pursuant to law belong to the Company have been assigned pursuant to law
to the Company without any limitations or encumbrances. There has been no disclosure by the Company or any of its Subsidiaries
or its or their respective current or former employees, consultants, contractors or advisors of its or their respective confidential
information or its or their respective Intellectual Property that would compromise the status or protectibility of such Intellectual
Property or the confidentiality of the confidential information. No present or former employee, officer, consultant, contractor,
or advisor of the Company or any of its Subsidiaries has any ownership, license or other right, title, or interest, directly or
indirectly, in whole or in part, in or to any Company Intellectual Property.

 

(3)
All of the Registered Intellectual Property (other than applications for Patent or for Copyright or Trademark registration) are
valid, subsisting and enforceable. The Company or one of its Subsidiaries is the owner of all right, title and interest in and
to all Registered Intellectual Property (other than Intellectual Property or Intellectual Property Right that is identified in
Section 2.15(a)(i)(1) of the Company Disclosure Schedules as licensed to the Company or one of its Subsidiaries from a
third party) and all other Intellectual Property and Intellectual Property Rights used or otherwise practiced or exploited by
the Company or any of its Subsidiaries (other than Intellectual Property or Intellectual Property Rights that the Company or any
of its Subsidiaries uses under a valid and enforceable Inbound License Agreement) (collectively, the “Owned Intellectual
Property”). All Owned Intellectual Property is free and clear of any and all Liens, covenants, conditions and restrictions
or other adverse claims, rights or interests of any kind or nature and is freely transferable and assignable by the Company or
its applicable Subsidiaries without payment of any kind to any Person. Neither the Company nor any of its Subsidiaries has received
any written notice or claim, nor to the Knowledge of the Company any other notice or claim, challenging the Company’s or
any of its Subsidiaries’ complete and exclusive ownership of any Owned Intellectual Property or suggesting that any other
Person has any claim of legal or beneficial ownership with respect thereto. Neither the Company nor its Subsidiaries have received
any written notice or claim, nor to the Knowledge of the Company any other notice or claim, challenging or questioning the validity
or enforceability of any Intellectual Property or Intellectual Property Right owned or used by the Company or any of its Subsidiaries
or indicating an intention on the part of any Person to bring a claim that any such Intellectual Property or Intellectual Property
Right is invalid, is unenforceable or has been misused, and no Intellectual Property or Intellectual Property Right owned or used
by the Company or any of its Subsidiaries has been challenged or threatened in any way.

 

    	 	-18-	 

     

    

 

(ii)
Patents.

 

(1)
Each Patent of the Company and its Subsidiaries is and has been at all times in compliance with all applicable Legal Requirements
(including payment of correct filing, examination, and maintenance fees and proofs of working or use), other than any requirement
that, if not satisfied, would not result in a revocation or lapse or affect the enforceability of such Patent.

 

(2)
No Patent of the Company or any of its Subsidiaries has been or is now involved in any interference, reissue, reexamination or
opposition proceeding in either the United States Patent and Trademark Office or any corresponding Governmental Entity elsewhere.
No such action has been threatened. No Patent of the Company or any of its Subsidiaries is subject to any compulsory license.

 

(3)
There is no Patent or Copyright of the Company or any of its Subsidiaries which is based on an invention or work of any past or
current director(s), employee(s), consultant(s), contractor(s) or advisor(s) of the Company or any of its Subsidiaries, for which
the Company or any of its Subsidiaries owes any compensation or remuneration to such director(s), employee(s), consultant(s),
contractor(s) or advisor(s) in relation to such invention or work. The Company and its Subsidiaries have complied with all mandatory
provisions under applicable legislation concerning payment of compensation to employees for employee inventions, and there are
no inventions for which the Company or any of its Subsidiaries owes any compensation to its former or current employees. There
is no Patent or other Intellectual Property or Intellectual Property Right on which any part of the business of the Company or
any of its Subsidiaries relies, or of which any part of the business of the Company or any of its Subsidiaries is dependent, in
each case as currently conducted and proposed to be conducted, which is held by a current or former director, employee, consultant,
contractor, or advisor of the Company or any of its Subsidiaries, or any other Person.

 

(iii)
Trade Secrets. The Company and its Subsidiaries have taken all necessary and appropriate steps in accordance with
all applicable Legal Requirements relating to trade secrets to protect their rights in their Trade Secrets. The Company and its
Subsidiaries have taken all necessary and appropriate steps to protect their rights in the Trade Secrets of third parties in accordance
with the terms of any agreements or understandings relating to such third party Trade Secrets to which the Company or any of its
Subsidiaries is a party or which otherwise bind the Company or any of its Subsidiaries.

 

(iv)
Intellectual Property Agreements.

 

(1)
“Inbound License Agreement” means any agreement under which a third party grants, or agrees to grant, to the
Company or any of its Subsidiaries any licenses or other rights in or to any Intellectual Property or any Intellectual Property
Right. Section 2.15(a)(iv)(1) of the Company Disclosure Schedules sets forth a complete and correct list of all Inbound
License Agreements, other than licenses to the Company or any of its Subsidiaries of software that is commercially available on
reasonable terms to any Person for a license fee, royalty or other consideration of no more than $1,000 per copy or user (each,
a “Non-Negotiated Software Contract”).

 

(2)
“Outbound License Agreement” means any agreement under which the Company or any of its Subsidiaries grants,
or agrees to grant, licenses or other rights in or to any Intellectual Property or any Intellectual Property Right. Section
2.15(a)(iv)(2) of the Company Disclosure Schedules sets forth a complete and correct list of all Outbound License Agreements,
other than Contracts entered into with customers and resellers of the Company in the ordinary course of business consistent with
past practice, indicating for each the effective date, title and the parties thereto. Neither the Company nor any of its Subsidiaries
has granted any sublicense to any third party under any Intellectual Property or Intellectual Property Right.

 

    	 	-19-	 

     

    

 

(3)
There is no outstanding or threatened dispute or disagreement with respect to any Inbound License Agreement or any Outbound License
Agreement. Complete and correct copies of all Inbound License Agreements that are required to be listed on Section 2.15(a)(iv)(1)
of the Company Disclosure Schedules and all Outbound License Agreements that are required to be listed on Section 2.15(a)(iv)(2)
of the Company Disclosure Schedules have been made available to Purchaser. Neither the Company nor any of its Subsidiaries
nor, to the Knowledge of the Company, any other party to any Inbound License Agreement or Outbound License Agreement or Outbound
License Agreement, as the case may be is in breach or default of such Inbound License Agreement. The Inbound License Agreements
and Outbound License Agreements are in full force and effect and valid and enforceable in accordance with their terms.

 

(4)
There is no Contract, judicial decree, arbitral award or other provision or requirement that obligates the Company or any of its
Subsidiaries to grant licenses in the future with respect to any currently existing or future Intellectual Property or Intellectual
Property Right.

 

(5)
None of the execution, delivery and performance of this Agreement and each of the other documents and agreements contemplated
hereby, and the consummation of the Transactions, or any Contract to which the Company or any of its Subsidiaries is a party or
is otherwise bound, will give rise under any circumstances to any license, transfer, assignment, grant of rights, restriction,
Lien, covenant, obligation or transaction that relates in any way to any Intellectual Property or Intellectual Property Right
of Purchaser or any of its Affiliates (other than the Company and its Subsidiaries), or to any obligation to license, transfer,
assign, grant rights under, grant any Lien, incur any obligation (including any obligation to pay any royalties or other amounts)
or enter into any other transaction that relates in any way to any such Intellectual Property or Intellectual Property Right.

 

(v)
Sufficiency of Intellectual Property Assets. The Owned Intellectual Property and the Intellectual Property and Intellectual
Property Rights licensed to the Company and its Subsidiaries under the Inbound License Agreements constitute all the Intellectual
Property and Intellectual Property Rights used or otherwise practiced or exploited in the operation of the business of the Company
and its Subsidiaries and constitute all Intellectual Property and Intellectual Property Rights necessary to operate such business
at the Closing Date in substantially the same manner as such business has been operated by the Company and its Subsidiaries prior
thereto.

 

(vi)
No Infringement by the Company. The Company Products and all Intellectual Property and Intellectual Property Rights
used in the business of the Company and its Subsidiaries, and the business of the Company and its Subsidiaries as it is now being
conducted and as currently proposed to be conducted (by the Company and its Subsidiaries or by Purchaser and its Affiliates),
do not infringe, violate, dilute or constitute the unauthorized use of, and have not infringed, violated, diluted or constituted
the unauthorized use of, any rights owned or controlled by any third party, including any Intellectual Property or Intellectual
Property Right of any third party. Except as set forth in Section 2.15(a)(v) of the Company Disclosure Schedules, no Action
has been initiated or pending, and no notice or other claim, dispute, assertion, allegation or action has been received by the
Company or any of its Subsidiaries, alleging that the Company or any of its Subsidiaries have engaged in any activity or conduct
that infringes upon, violates, dilutes or constitutes the unauthorized use of, or has infringed upon, violated, diluted or constituted
the unauthorized use of, the Intellectual Property or Intellectual Property Right of any third party, and there is no basis for
any such Action.

 

    	 	-20-	 

     

    

 

(vii)
No Orders. No Intellectual Property or Intellectual Property Right that is owned by or licensed to the Company or
any of its Subsidiaries is subject to any outstanding order, judgment, injunction, decree, or stipulation restricting the use
or other practice or exploitation thereof by the Company or any of its Subsidiaries or, in the case of Intellectual Property or
Intellectual Property Right licensed by the Company or any of its Subsidiaries to others, restricting the sale, transfer, assignment
or licensing thereof by the Company or any of its Subsidiaries to any Person.

 

(viii)
No Infringement by Third Parties. To the Knowledge of the Company, no third party is misappropriating, infringing,
diluting or violating or has misappropriated, infringed, diluted or violated any Intellectual Property or Intellectual Property
Right owned by or licensed by or to the Company or any of its Subsidiaries. No Action has been initiated or pending, and no notice
or other claim, dispute, assertion, allegation or action has been brought in writing or threatened against any third party by
the Company or any of its Subsidiaries alleging that such third party has engaged in any activity or conduct that misappropriates,
infringes, dilutes or violates any Intellectual Property or Intellectual Property Right owned by or licensed by or to the Company
or any of its Subsidiaries.

 

(ix)
Assignment; Change of Control. Neither the execution, delivery and performance by the Company of this Agreement
and each of the other Transaction Documents, nor the consummation of the transactions contemplated hereby and thereby, will (i)
give rise under any circumstances to any license, transfer, assignment, grant of rights, restriction, Lien, covenant, obligation
or transaction that relates in any way to any Intellectual Property or Intellectual Property Right of the Company and its Subsidiaries,
or to any obligation to license, transfer, assign, grant rights under, grant any Liens, incur any obligation (including any obligation
to pay any royalties or other amounts) or enter into any other transaction that relates in any way to any such Intellectual Property
or Intellectual Property Right, (ii) result in the loss or impairment of, or give rise to any right of any third party to terminate,
any of the rights of the Company or any of its Subsidiaries to own or otherwise relating to any of their Intellectual Property,
Intellectual Property Rights, or rights under any Inbound License Agreement or Outbound License Agreement, or (iii) require the
consent of any Governmental Entity or third party.

 

(x)
Universities and SIGs.

 

(1)
Neither the Company nor any of its Subsidiaries has made any contribution to any SIG or is bound by, or has agreed to be bound
by, any Contract which purports to assign or license or potentially assign or license Intellectual Property or Intellectual Property
Right of the Company or any of its Subsidiaries as a result of any contribution or disclosure to or participation in any SIG.

 

(2)
No SIG (A) owns or otherwise holds or has the right to obtain, any rights to any Owned Intellectual Property or any other Intellectual
Property or Intellectual Property Right invented, developed, authored or registered by, for or in contemplation of the Company
or any of its Subsidiaries, (B) has imposed or purported to impose, or has the right, whether contingent or otherwise, to impose,
any obligations or restrictions on the Company or any of its Subsidiaries (or, following Closing, Purchaser), with respect to
the use, practice, sale, licensing, and other exploitation or granting of any such Intellectual Property or Intellectual Property
Right, or (C) is or may become entitled to, or has the right, whether contingent or otherwise, to receive any fees, royalties
or other payments from the Company or any of its Subsidiaries (or, following Closing, Purchaser), with respect to the use, practice,
sale, licensing and other exploitation or granting of any rights in any such Intellectual Property or Intellectual Property Right.

 

a)
The Intellectual Property and Intellectual Property Rights invented, developed, authored or registered by each employee and consultant,
of the Company and any of its Subsidiaries outside of his or her work with the Company or any of its Subsidiaries (including,
without limitation, in connection with any past or current affiliation with any SIG) does not overlap in any way with any of the
Intellectual Property or Intellectual Property Right he or she invented, developed, authored or registered for, on behalf of,
or in contemplation of the Company or any of its Subsidiaries, in a manner that such SIG owns or otherwise holds or has the right
to obtain, any rights to any Owned Intellectual Property or any other Intellectual Property or Intellectual Property Right invented,
developed, authored, or registered by, for or in contemplation of the Company or any of its Subsidiaries.

 

    	 	-21-	 

     

    

 

(b)
Non-Fundamental Representations

 

(i)
Trademarks.

 

(1)
Each registered Trademark of the Company and its Subsidiaries is and has been at all times in compliance with all applicable Legal
Requirements (including payment of all registration, renewal and other fees and the timely post-registration filing of affidavits
of use and renewal applications and timely filing of affidavits as required to cause such Trademarks to become incontestable)
other than any requirement that, if not satisfied, would not result in a cancellation of the registration of such Trademark or
otherwise affect the use, priority and enforceability of the Trademark in question, the defenses potentially available to any
accused infringer thereof, or the remedies potentially available for infringement thereof.

 

(2)
No registered Trademark of the Company or any of its Subsidiaries has been involved in any opposition or cancellation proceeding
in the United States Patent and Trademark Office or any corresponding non-U.S. trademark office, department, organization, authority
or agency, and no such proceeding has been threatened.

 

(3)
There has been no prior use by any third party of any Trademark used by the Company or any of its Subsidiaries that confers upon
said third party rights that are superior or senior to the rights of the Company and its Subsidiaries in such Trademark, or which
could threaten the validity of such Trademark.

 

(4)
All Trademarks of the Company and its Subsidiaries registered in the United States, or any other location or jurisdiction have
been in continuous use by the Company or one or more of its Subsidiaries in all locations or jurisdictions of such registrations
in the form appearing in, and in connection with the goods and services listed in, the registration certificates or renewal certificates,
as the case may be, for such Trademarks.

 

(5)
Section 2.15(b)(i)(5) of the Company Disclosure Schedules sets forth a complete and correct list of the common law or unregistered
Trademarks of the Company and each of its Subsidiaries. With respect to the Trademarks on such schedule, the Company or one or
more of its Subsidiaries have used such Trademarks and the Company has made available documentation to Purchaser evidencing such
use.

 

(ii)
Copyrights.

 

(1)
Neither the Company nor any of its Subsidiaries has taken any action or failed to take any action (including a failure to disclose
required information to the United States Copyright Office, or any corresponding Governmental Entity elsewhere, in connection
with any registration of a registered copyright therewith), or used or enforced (or failed to use or enforce) any of its Copyrights,
in each case in a manner that would result in the unenforceability of any Copyright of the Company or any of its Subsidiaries.

 

(iii)
Systems. The computer, information technology and data processing systems, facilities and services used by or for
the Company and its Subsidiaries, including all Software, hardware, networks, communications facilities, platforms and related
systems and services (collectively, “Systems”), are reasonably sufficient for the existing and currently anticipated
future needs of the Company and its Subsidiaries, including as to capacity and scalability. All Systems are owned, licensed or
rightfully possessed by, operated by and under the control of the Company and its Subsidiaries.

 

(iv)
Government Contracts. None of the Intellectual Property, Intellectual Property Rights or technology owned by or
exclusively licensed to the Company or any of its Subsidiaries was developed, delivered, or used by the Company or any of its
Subsidiaries under or in connection with any Contract with any Governmental Entity. Except for funding provided to the Company
by Business Finland, all Intellectual Property, Intellectual Property Right or technology owned by or exclusively licensed to
the Company or any of its Subsidiaries was developed at private expense, and no Governmental Entity has obtained, by contract
or otherwise, rights in any Intellectual Property or Intellectual Property Right or technology owned by or exclusively licensed
to the Company or any of its Subsidiaries that will affect the commercial value thereof.

 

    	 	-22-	 

     

    

 

(v)
Universities and SIGs.

 

(1)
Section 2.15(b)(v)(1) of the Company Disclosure Schedule contains a list of each standards-setting organization, university,
college, or other educational institution, industry body, consortium, multi-national, bi-national or international Governmental
Entity or governmental research center, other multi-party special interest group and any other collaborative or other group, including
any of the foregoing that may be organized, funded, sponsored, formed or operated, in whole or part, by any Governmental Entity
(each, a “SIG”), (A) in which the Company or any of its Subsidiaries is currently participating or with or
for which the Company or any of its Subsidiaries is performing research or development, (B) in which the Company or any of its
Subsidiaries has participated or with or for which the Company or any of its Subsidiaries has performed research or development
in the past, or (C) to which the Company or any of its Subsidiaries has applied for future participation in or performance of
research or development with or for, and a listing and description of the membership agreements and other Contracts, bylaws, policies,
rules and similar materials relating to such organizations, bodies and other activities, copies of all of which have been made
available to Purchaser.

 

(2)
No funding, facilities, personnel, Intellectual Property, Intellectual Property Right, research, equipment, or other resources
of any SIG has been used in connection with the invention, development, authorship, or registration of any (A) Owned Intellectual
Property, or (B) other Intellectual Property or Intellectual Property Right invented, developed, authored or registered by, for
or in contemplation of the Company or any of its Subsidiaries.

 

(3)
Without limiting the generality of Section 2.15(b)(v)(2) and Section 2.15(a)(x)(2), except for funding provided
to the Company by Business Finland, neither the Company nor any of its Subsidiaries is now, and has not been since the Company’s
inception, subject to any terms, conditions, requirements or other criteria under any grant, incentive, subsidy, award, participation,
exemption, status, cost sharing arrangement, reimbursement arrangement or other benefit, relief or privilege provided or made
available by or on behalf of or under the authority of any governmental grant programs, or on behalf of or under the authority
of any SIG, in each case, for the financing of research and development.

 

2.16
Taxes.

 

(a)
The Company and its Subsidiaries have duly and timely filed all Tax Returns required to be filed under applicable Legal Requirements
in any jurisdiction in which the Company or such Subsidiary is or has been subject to Tax, and such Tax Returns are true, complete
and correct in all respects.

 

    	 	-23-	 

     

    

 

(b)
Neither the Company nor any of its Subsidiaries has (i) requested or received an extension of time to file any Tax Return (other
than automatic extensions of time for filing any Tax Return that are allowable under applicable Legal Requirements or (ii) waived
any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

 

(c)
The Company and its Subsidiaries have fully and timely paid all Taxes (whether or not shown on any Tax Return or any other Tax
filings) required to be paid, and the Company has adequately provided in the Financial Statements and the Interim Financial Statements
with respect to the Company and its subsidiaries on a consolidated basis (without regard to any footnotes) for all Taxes accrued
through the date of such Financial Statements and Interim Financial Statements that were not yet due and payable as of the date
thereof. All Taxes of the Company or any of its Subsidiaries accrued following the end of the most recent period covered by the
Financial Statements have arisen in the ordinary course of business consistent with past practice and the unpaid Taxes of the
Company and its Subsidiaries will not, as of the Closing Date, exceed that the reserve for Tax liabilities set forth on the face
of the Financial Statements and Interim Financial Statements (rather than in any notes thereto), as adjusted for the passage of
time through the Closing Date. All required estimated Tax payments sufficient to avoid any underpayment penalties have been made
by or on behalf of the Company.

 

(d)
The Company and its Subsidiaries have collected and remitted all applicable sales and use, value added and other indirect Taxes
to the appropriate Taxing Authority in any jurisdiction, whether or not registered to collect Tax in such jurisdiction, or obtained
any applicable sales or use, value added and other indirect Tax exemption certificates necessary to avoid such collection and
remittance obligations.

 

(e)
Each of the Company and its Subsidiaries has complied in all respects with all applicable Legal Requirements relating to the payment
and withholding of Taxes, has withheld and paid to the appropriate Taxing Authority all Taxes required to be withheld and paid
in connection with any amounts paid or owing to any Person, and has complied in all material respects with all information reporting
and backup withholding provisions of applicable Legal Requirements.

 

(f)
No item of income or (f) gain reported by the Company or any of its Subsidiaries for financial accounting purposes in any period
prior to the Closing Date will be required to be included in the taxable income of the Company or such Subsidiary in any period
following the Closing Date, and no item of loss or deduction of the Company or any of its Subsidiaries required to be reported
for financial accounting purposes in any period following the Closing Date was claimed as a deduction from taxable income in any
period prior to the Closing Date. Neither the Company nor any of its Subsidiaries has agreed to or will be required to include
any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending
after the Closing Date as a result of any (i) change in method of accounting for Tax purposes for a taxable period or portion
thereof ending on or prior to the Closing Date made on or prior to the Closing Date; (ii) “closing agreement” as described
in Section 7121 of the Code (or any corresponding or similar provision of state, local or foreign Law) executed on or prior to
the Closing Date; (iii) intercompany transactions or any excess loss account described in Treasury Regulations under Section 1502
of the Code (or any corresponding or similar provision of state, local or foreign Law) entered into on or prior to the Closing
Date; (iv) installment sale or option transaction disposition made on or prior to the Closing Date; (v) prepaid amount received
on or prior to the Closing Date; or (vi) election under Section 108(i) of the Code made on or prior to the Closing Date (or any
corresponding or similar provision of state, local or foreign Law). The transactions contemplated by this Agreement will not give
rise to any Liability for Tax of the Company or any of its Subsidiaries, with the exception of any Transfer Taxes for which either
Purchaser or the Shareholders are liable hereunder.

 

    	 	-24-	 

     

    

 

 

(g) Neither the Company nor
any of its Subsidiaries is or has even been (or has ever owned an interest in) (i) a “United States real property holding
corporation” within the meaning of Section 897(c)(2) of the Code, (ii) a “passive foreign investment company”
within the meaning of Section 1297 of the Code, or (iii) a “controlled foreign corporation” within the meaning of Section
957 of the Code.

 

(h) There have been no audits,
suits, proceedings, investigations, claims, examinations, or other administrative or judicial proceedings concerning any Tax Return
or Taxes of the Company or any of its Subsidiaries, none of the foregoing have been threatened against the Company or its Subsidiaries,
and neither the Company nor its Subsidiaries has received any written notice from any Taxing Authority that it intends to conduct
such an Action. No issue has been raised by a Taxing Authority in any prior examination of the Company or its Subsidiaries which,
by application of the same or similar principles, would reasonably be expected to result in a proposed material deficiency for
any subsequent taxable period. There are no Liens for Taxes upon any of the assets of the Company or any of its Subsidiaries. Neither
the Company nor any of its Subsidiaries has outstanding powers of attorney with respect to Taxes. The Company is not currently
the beneficiary of any Tax exemption, Tax holiday or other Tax reduction or incentive agreement, arrangement or order with any
Taxing Authority. Neither the Company nor any of its Subsidiaries has requested, entered into, or been issued any private letter
ruling, technical advice memoranda or similar ruling from any Taxing Authority.

 

(i) Neither the Company nor
any of its Subsidiaries (i) has been a member of an affiliated, consolidated, combined, unitary or similar group for Tax purposes
(other than a group the common parent of which was the Company) or (ii) is or could reasonably be expected to be liable for the
Taxes of any Person under Treasury Regulation Section 1.1502-6 or any similar provision of state, local or foreign Legal Requirements,
or as a transferee or successor, by contract, by operation of law or otherwise. Neither the Company nor any of its Subsidiaries
is a party to or bound by any obligation under any Tax sharing, Tax allocation, Tax indemnity or similar agreement or arrangement
(other than an agreement entered into in the ordinary course of business the principal purpose of which is not the sharing, allocation
or indemnification of Taxes).

 

(j) The Company is not required
to file U.S. federal income Tax Returns. Any Company Subsidiary that is subject to U.S. federal income taxation has disclosed on
its U.S. federal income Tax Returns all positions taken therein that could give rise to substantial understatement of U.S. federal
income tax within the meaning of Section 6662 of the Code and has not engaged in any “reportable transactions” within
the meaning of Treasury Regulations Section 1.6011-4(b).

 

(k) There is currently no
limitation on the utilization of net operating losses, capital losses, built-in losses, Tax credits or similar items of the Company
or any of its Subsidiaries.

 

(l) Each of the Company and
its Subsidiaries has at all times been resident for Tax purposes in its place of organization and is not and has not at any time
been treated as resident in any other jurisdiction for any Tax purpose (including any double taxation arrangement). Neither the
Company nor any of its Subsidiaries is or has been subject to Tax in any jurisdiction other than its place of organization by virtue
of having a permanent establishment, a permanent representative or other place of business or taxable presence in the jurisdiction.
No claim has been made by a Taxing Authority in a jurisdiction where the Company or any of its Subsidiaries does not file a particular
type of Tax Return or pay a particular type of Tax that the Company or such Subsidiary is required to file such Tax Return or may
be required to pay such Tax in such jurisdiction. Section 2.16(l) of the Company Disclosure Schedules sets forth the jurisdictions
in which the Company and its Subsidiaries have filed income, sales, use or other material Tax Returns.

 

    	 	-25-	 

    	 	 	 

    

 

(m) The Company has delivered
to Purchaser true, complete and correct copies of (i) all governmental, federal, municipal, state and foreign income, franchise
or similar Tax Returns, and all other material Tax Returns, of the Company and each of its Subsidiaries for all tax years issued
since the inception of each of the Company and such Subsidiary, and (ii) any audit or examination report, ruling, closing agreement,
technical advice memorandum, tax holiday or similar document issued since the inception of each of the Company and such Subsidiary
(or otherwise with respect to any audit or proceeding in progress) relating to Taxes of the Company or any of its Subsidiaries.

 

(n) All charges for goods
or services made between the Company and its Subsidiaries, between the Company’s Subsidiaries, or between the Company or
any of its Subsidiaries and a Person that is otherwise under common “control” (within the meaning of Section 482 of
the Code) with the Company or such Subsidiary, satisfy all transfer pricing requirements under applicable Legal Requirements and
none of such charges is subject to adjustment under Section 482 of the Code or under any comparable provision of other applicable
Legal Requirements. The Company and its Subsidiaries have complied with all information reporting and record keeping requirements
under applicable Legal Requirements, including retention and maintenance of required records with respect thereto.

 

(o) Neither the Company nor
any of its Subsidiaries is a party to any joint venture, partnership, limited liability company, or other arrangement or Contract
that would reasonably be expected to be treated as a partnership for any income or other Tax purposes. Neither the Company nor
any of its Subsidiaries has been involved in a third-party transaction with any Person or Persons that purported or was intended
to be a non-taxable transaction (either in whole or in part) and governed (either in whole or in part) by Section 332, Section
351, Section 355, Section 368, Section 721, Section 731 or Section 1031 of the Code (or any corresponding or similar provision
of state, local or foreign Legal Requirements).

 

(p) (1) The Company has held
all the shares of US Subsidiary uninterruptedly for more than one year; (2) the Company has recorded US Subsidiary’s shares
in its Tax Returns as a capital asset, and has not deducted in its Tax Returns the acquisition costs of the shares in US Subsidiary;
and (3) US Subsidiary has never paid dividends to the Company.

 

2.17 Material Contracts.

 

(a) Section 2.17(a)
of the Company Disclosure Schedules sets forth a complete and correct list (grouped according to the subsections below) of all
Contracts of the following nature to which the Company or any of its Subsidiaries is a party or by which the Company or any of
its Subsidiaries, or any of their respective properties or assets, is otherwise bound (including by way of surviving provisions
of otherwise expired or terminated Contracts) (each Contract required to be listed in Section 2.17(a) of the Company Disclosure
Schedules, “Material Contract” and collectively, the “Material Contracts”):

 

(i) (A) any Contract in
respect of the Company’s and its Subsidiaries’ businesses evidencing Indebtedness of the Company or any of its Subsidiaries
for borrowed money or (B) the deferred purchase price of property (whether incurred, assumed, guaranteed or secured by any asset)
in excess of $50,000;

 

(ii) any Contract pursuant
to which the Company or any of its Subsidiaries has provided funds to or made any loan, capital contribution or other investment
in, or assumed, guaranteed or agreed to act as a surety with respect to any Liability of, any Person;

 

(iii) any Contract for
the issuance of any debt or equity security or other ownership interest, or the conversion of any obligation, instrument or security
into debt or equity securities or other ownership interests of, the Company or any of its Subsidiaries, or for the purchase of
any debt or equity security or other ownership interest of any Person;

 

    	 	-26-	 

    	 	 	 

    

 

(iv) any Contract that
purports to limit, curtail or restrict the ability of the Company or any of its Subsidiaries to (A) compete in any way, including
in any geographic area or line of business or with any Person, (B) make sales to or engage or participate with any Person in any
manner, (C) use or enforce any Intellectual Property owned by or exclusively licensed to the Company or any of its Subsidiaries,
or (D) hire or solicit any Person in any manner;

 

(v) any Contract that grants
the other party or any third Person, or otherwise constrains or subjects the Company or any of its Subsidiaries to (A) any exclusive
marketing or other exclusive rights of any type or scope, (B) any “most favored nation” or similar status, (C) any
type of special discount rights, or (D) any right of first refusal, first notice or first negotiation;

 

(vi) any Contract that
requires a consent to or otherwise contains a provision relating to a “change of control,” or that would give rise
to any acceleration or additional rights or obligations under such Contract or prohibit or delay the consummation of the transactions
contemplated by this Agreement or any of the other Transaction Documents;

 

(vii) any Contract pursuant
to which the Company or any of its Subsidiaries is the lessee or lessor of, or holds, uses, or makes available for use to any Person
(other than the Company or a Subsidiary thereof), (A) any Real Property or (B) any tangible personal property;

 

(viii) any executory Contract
for the sale or purchase of any tangible personal property in an amount in excess of $50,000;

 

(ix) Contract obligating
the Company or any of its Subsidiaries to indemnify or hold harmless any Person for amounts that exceed the value of the amounts
paid or payable under the Contract, other than Contracts entered into with customers and resellers of the Company in the ordinary
course of business consistent with past practice;

 

(x) any Contract containing
warranties or guaranties with respect to the performance of any Company Product, other than the Company’s standard warranty
made available to Purchaser;

 

(xi) (A) other than the
Inbound License Agreements set forth in Section 2.15(a)(iv)(1) and (B) the Outbound License Agreements set forth in Section
2.15(a)(iv)(2), any Contract relating in whole or in part to, or that includes (1) any sale, assignment, hypothecation, transfer,
license, option, covenant not to sue, release, immunity, or other grant of rights with respect to or under any Intellectual Property
(other than (x) Non-Negotiated Software Contracts and (y) Contracts entered into with customers and resellers of the Company in
the ordinary course of business consistent with past practice) or (2) any restriction on the Company’s or any of its Subsidiaries’
right to use, practice or otherwise exploit any Owned Intellectual Property;

 

(xii) any Contract with
any Related Party of the Company or any of its Subsidiaries;

 

(xiii) (A) any Contract
with an employee that is not terminable at will and (B) any Contract with a consultant or other service provider for services in
excess of $50,000 on an annual basis;

 

    	 	-27-	 

    	 	 	 

    

 

(xiv) any Contract that
relates to a partnership, joint venture, joint marketing, joint development or similar arrangement with any other Person;

 

(xv) any Contract set forth
or required to be set forth in Section 2.15(b)(v)(1) of the Company Disclosure Schedules;

 

(xvi) any Contract pursuant
to which the Company has acquired or sold a business or entity, or substantially all of the assets of a business or entity, whether
by way of merger, consolidation, purchase of shares, purchase of assets, license or otherwise;

 

(xvii) any Contract relating
to settlement of any Action or administrative or judicial proceeding;

 

(xviii) any Government
Contract;

 

(xix) any Contract with
a Material Customer or a Material Supplier;

 

(xx) any Contract to indemnify
officers, directors, employees or Shareholders;

 

(xxi) any Contract with
any of the Company’s suppliers, customers or clients other than Contracts on the Company’s standard, unmodified form
of supplier, customer or client agreement as made available to Purchaser; and

 

(xxii) any other Contract
not disclosed pursuant to another subsection of this 2.17(a), whether or not made in the ordinary course of business consistent
with past practice, that (A) involves a future or potential Liability or receivable, as the case may be, in excess of $50,000 on
an annual basis or in excess of $100,000 over the current Contract term, (B) has a term greater than one (1) year and cannot be
cancelled by the Company or a Subsidiary of the Company without penalty or further payment and without more than thirty (30) Business
Days’ notice or (C) is material to the business, operations, assets, financial condition, results of operations or prospects
of the Company and its Subsidiaries, taken as a whole.

 

(b) The Company has made
available complete and correct copies of the Material Contracts to Purchaser, including all modifications, amendments and supplements
thereto. Each Material Contract constitutes the valid and legally binding obligation of the Company or a Subsidiary thereof, as
applicable, enforceable in accordance with its terms (subject to any applicable bankruptcy, insolvency, reorganization, moratorium
or similar Legal Requirements now or hereafter in effect relating to creditors’ rights generally or to general principles
of equity), and is in full force and effect in accordance with its terms. There is no breach or default under any Material Contract
either by the Company or any of its Subsidiaries or, to the Knowledge of the Company, by any other party thereto, no event has
occurred that with the giving of notice, the lapse of time, or both would constitute a breach or default thereunder by the Company
or any of its Subsidiaries or, to the Knowledge of the Company, any other party. No party to any Material Contract has given to
the Company or any of its Subsidiaries written or, to the Knowledge of the Company, other notice of, or made a claim against the
Company or any of its Subsidiaries in respect of, any breach or default thereunder.

 

2.18 Tangible Assets.
The Company and its Subsidiaries own, and have good and valid title to all of their respective tangible properties and
assets that are used or held for use in their respective businesses, including all of the assets reflected on the Balance Sheet
or acquired in the ordinary course of business consistent with past practice since the date of the Balance Sheet (except for those
assets sold or otherwise disposed of for fair value since the date of the Balance Sheet in the ordinary course of business consistent
with past practice), in each case free and clear of any Liens, except as reflected on the Balance Sheet and except for such imperfections
of title, if any, that do not interfere with the present value of the subject property.

 

    	 	-28-	 

    	 	 	 

    

 

2.19 Insurance.
Section 2.19 of the Company Disclosure Schedules sets forth a complete and correct list of all insurance policies maintained
by the Company and its Subsidiaries (the “Insurance Policies”). Each Insurance Policy is in full force and
effect and is valid, outstanding and enforceable, and all premiums due thereon have been paid in full. None of the Insurance Policies
will terminate or lapse (or be affected in any other adverse manner) by reason of the transactions contemplated by this Agreement.
Each of the Company and its Subsidiaries has complied with the provisions of each Insurance Policy under which it is the insured
party. No insurer under any Insurance Policy has canceled or generally disclaimed Liability under any such policy or indicated
any intent to do so or not to renew any such policy. No claim currently is pending or threatened under any such policy, and all
prior claims under the Insurance Policies have been filed in a timely fashion. Neither the Company nor any of its Subsidiaries
has established or operated under a formalized self-insurance program.

 

2.20 Anti-Corruption
Laws.

 

(a) None of the Company or
its Subsidiaries, or any of their respective officers, directors, employees, agents, or authorized representatives, or to the Knowledge
of the Company, any other Person acting on behalf of Company or its Subsidiaries (including, but not limited to consultants, distributors,
resellers, and any other business intermediaries) has, directly or indirectly:

 

(i) directly or indirectly,
taken any action which would cause them to be in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any rules
or regulations thereunder, or any applicable anti-corruption or anti-bribery laws, statutes, rules, regulations, ordinances, judgments,
Orders, decrees, injunctions and writs of any Governmental Entity of any jurisdiction (whether by virtue of jurisdiction or organization
or conduct of business) (collectively the “applicable Anti-Corruption Laws”).

 

(ii) offered, paid, promised
to pay, or authorized a payment, of any money or other thing of value (including any fee, gift, sample, travel expense or entertainment)
or any commission payment, or any payment related to political activity, to any of the following Persons for the purpose of influencing
any act or decision of such Person in his official capacity, inducing such Person to do or omit to do any act in violation of the
lawful duty of such official, securing any improper advantage, or inducing such Person to use his influence with a foreign government
or instrumentality thereof to affect or to influence any act or decision of such government or instrumentality, in order to assist
the Company in obtaining or retaining business for or with, or directing the business to, any Person: (i) any Person who is an
agent, representative, official, officer, director, or employee of any non-U.S. government or any department, agency, or instrumentality
thereof (including officers, directors, and employees of state-owned, operated or controlled entities) or of a public international
organization; (ii) any Person acting in an official capacity for or on behalf of any such government, department, agency, instrumentality,
or public international organization; (iii) any political party or official thereof; (iv) any candidate for political or political
party office (such recipients in paragraphs (i), (ii), (iii) and (iv) of this subsection, collectively, “Governmental
Officials”); or (v) any other individual or entity while knowing or having reason to believe that all or any portion
of such money or thing of value would be offered, given, or promised, directly or indirectly, to any Governmental Official.

 

(iii) made any payments
or transfers of value with the intent, or which have the purpose or effect, of engaging in commercial bribery or other unlawful
means of obtaining business.

 

    	 	-29-	 

    	 	 	 

    

 

(b) The books, records and
accounts of the Company and its Subsidiaries have at all times accurately and fairly reflected, in reasonable detail, the transactions
and dispositions of their respective funds and assets. There have never been any false or fictitious entries made in the books,
records or accounts of the Company or any of its Subsidiaries relating to any illegal payment or secret or unrecorded fund, and
neither the Company nor any of its Subsidiaries has established or maintained a secret or unrecorded fund.

 

(c) There is no current,
pending, or, to the Knowledge of the Company, threatened charges, proceedings, investigations, audits, or complaints against the
Company or any of its Subsidiaries or, to the Knowledge of the Company, any director, officer, agent, employee, or any other representative
of the Company or any of its Subsidiaries, with respect to any applicable Anti-Corruption Laws.

 

2.21 Product Warranties;
Product Liability.

 

(a) No warranties have been
given with respect to any Company Product other than those for which complete and correct copies have been made available to Purchaser.
There have not been any deviations from or modification to such warranties and guaranties. Neither the Company nor any of its Subsidiaries
has received any warranty claims, has any warranty claims pending, or, to the Knowledge of the Company, is threatened with any
warranty claims under any Contract and, to the Knowledge of the Company, there is no basis for any such claim. Any representations,
warranties, guarantees or public-facing statements made by or on behalf of the Company or any of its Subsidiaries regarding the
compliance of any Company Product, or the sufficiency or fitness for use of any Company Product for compliance with, applicable
Legal Requirements have been at all times true and correct.

 

(b) The Company has not received
any written or, to the Knowledge of the Company, other notice of a claim against the Company or any of its Subsidiaries alleging
a design or manufacturing defect in any Company Product, in each case, excluding any and all requests for product returns in the
ordinary course of business consistent with past practice.

 

2.22 Customers and
Suppliers. Section 2.22 of the Company Disclosure Schedules sets forth complete and correct lists of (i) (A) the
top ten (10) customers of the Company and its Subsidiaries during each of the past two (2) fiscal years of the Company and year-to-date
for the current fiscal year of the Company (determined on the basis of revenue of the Company and its Subsidiaries, taken as a
whole, attributable to each customer during each such period) (each, a “Material Customer”), and (B) a list
of any significant customers lost since the Interim Balance Sheet Date, and (b) all suppliers of the Company and its Subsidiaries
during each of the past two (2) fiscal years of the Company and year-to-date for the current fiscal year of the Company from which
the approximate total purchases by the Company and its Subsidiaries was in excess of $100,000 during each such period (each a
“Material Supplier”), showing the approximate total purchases by the Company and its Subsidiaries from each
such supplier during such period. Neither the Company nor any of its Subsidiaries has received notices of termination or written
or, to the Knowledge of the Company, other notices of termination from any Material Customer or Material Supplier.

 

2.23 Brokers.
No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection
with the Transactions or any of the other documents and agreements contemplated hereby based upon arrangements made by or on behalf
of the Company or any of its Subsidiaries.

 

2.24 Bank Accounts;
Powers of Attorney. Section 2.24 of the Company Disclosure Schedules sets forth a complete and correct list
showing (a) all banks in which the Company or any of its Subsidiaries maintains a bank account or safe deposit box, together with,
as to each such bank account, the account number, the names of all signatories thereof and the authorized powers of each such signatory
and, with respect to each such safe deposit box, the number thereof and the names of all Persons having access thereto; and (b)
the names of all Persons holding powers of attorney from the Company or any of its Subsidiaries, complete and correct copies of
which have been made available to Purchaser.

 

    	 	-30-	 

    	 	 	 

    

 

2.25 Related Party
Transactions.

 

(a) No Related Party of the
Company or any of its Subsidiaries: (i) owns or has owned, directly or indirectly, any equity or other financial or voting interest
in any competitor, service provider, supplier, licensor, lessor, distributor, independent contractor or customer of the Company
or any of its Subsidiaries or their business; (ii) owns or has owned, directly or indirectly, or has or has had any interest in
any property (real or personal, tangible or intangible) that the Company or any of its Subsidiaries uses or has used in or pertaining
to the business of the Company or any of its Subsidiaries; (iii) has or has had any business dealings or a financial interest in
any transaction with the Company or any of its Subsidiaries or involving any assets or property of the Company or any of its Subsidiaries,
other than business dealings or transactions conducted in the ordinary course of business consistent with past practice at prevailing
market prices and on prevailing market terms; or (iv) is or has been employed by the Company or any of its Subsidiaries.

 

(b) There are no Contracts
by and between the Company or any of its Subsidiaries, on the one hand, and any Related Party of the Company or any of its Subsidiaries,
on the other hand, pursuant to which such Related Party provides or receives any information, assets, properties, support or other
services to or from the Company or any of its Subsidiaries.

 

(c) There are no outstanding
notes payable to, accounts receivable from or advances by the Company or any of its Subsidiaries to, and neither the Company nor
any of its Subsidiaries is otherwise a debtor or creditor of, or has any Liability to, any Related Party of the Company or any
of its Subsidiaries. Since the Interim Balance Sheet Date, neither the Company nor any of its Subsidiaries has incurred any Liability
to, or entered into or agreed to enter into any transaction with or for the benefit of, any Related Party of the Company or any
of its Subsidiaries, other than the transactions contemplated by this Agreement and the other Transaction Documents.

 

2.26 Data Protection.
Section 2.26 of the Company Disclosure Schedules identifies (i) each distinct electronic or other Database containing
(in whole or in part) Personal Data maintained by or for the Company or its Subsidiaries at any time, the types of Personal Data
in each such Database, the means by which such Personal Data was collected, any service provider (including any cloud service provider)
that hosts or otherwise maintains each such Database on its systems, and the security measures and policies that have been adopted
and maintained with respect to each such Database; and (ii) each public-facing Company Privacy Policy in effect at any time, identifying
the period of time during which such Company Privacy Policy was in effect. No Person (including any Governmental Entity) has made
any claim or commenced any Action with respect to loss, damage, or unauthorized access, use, modification, or other misuse of any
such Company Data (and there is no reasonable basis for any such claim or Action). Neither the execution, delivery nor performance
of this Agreement or the other Transaction Documents, nor the consummation of the transactions contemplated by this Agreement,
nor the disclosure of any Company Data to Purchaser or its Affiliates thereafter will violate any Data Protection Requirements.
Each of the Company and its Subsidiaries has at all times made all disclosures to, and obtained any necessary consents from, users,
customers, employees, contractors, and other applicable Persons required by Data Protection Requirements and has filed any required
registrations with the applicable data protection authority, if any.

 

    	 	-31-	 

    	 	 	 

    

 

2.27 Information
Technology. There has been no failure, breakdown or continued substandard performance of any Systems that has caused
a disruption or interruption in or to the operation of the business of the Company or any of its Subsidiaries.

 

2.28 International
Trade Laws. Each of the Company and its Subsidiaries is and has at all times been in compliance with all applicable International
Trade Laws where it is located and where it conducts business. Without limiting the foregoing: (a) each of the Company and its
Subsidiaries has obtained all export licenses and other approvals required for its exports of products required by any International
Trade Law and all such approvals and licenses are in full force and effect; (b) each of the Company and its Subsidiaries is in
compliance with the terms of such applicable export licenses or other approvals; (c) there are no pending or, to the Knowledge
of the Company, threatened claims against the Company or any of its Subsidiaries with respect to such export licenses or other
approvals; and (d) there are no actions, conditions or circumstances pertaining to the Company’s or any of its Subsidiaries’
transactions that would reasonably be expected to give rise to any future Actions against the Company or any of its Subsidiaries
under applicable International Trade Laws.

 

2.29 Representations
Complete. To the Knowledge of the Company, none of the representations or warranties of the Company in this Agreement
or any statement made in any Schedule or certificate furnished by the Company as of the Closing pursuant to this Agreement contains
any untrue statement of a material fact, or omits to state any fact reasonably necessary in order to make the statements contained
herein or therein, in the light of the circumstances under which made, not misleading.

 

2.30 No Other Warranties.
It is specifically stated and agreed that the Company has not made, and the Purchaser has not relied on, any other express
or implied warranties regarding the Shareholders, the Company Shares, the Company or the Subsidiaries or their business other than
those contained in this Section 2 (which excludes, for the sake of clarity, all other express or implied warranties, whether statutory
or otherwise).

 

Article
III

REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDERS

 

Except as set forth in
the corresponding sections or subsections of the disclosure schedules attached hereto (each section of which (i) qualifies the
specifically identified Sections or subsections of this Agreement to which such disclosure schedule relates and shall be deemed
to qualify, and be disclosed and incorporated in, each other Section and subsection of this Agreement solely to the extent its
applicability to such other Section or subsection is reasonably apparent on its face to a reader who is unfamiliar with the Company
and the contents underlying the Shareholder Disclosure Schedules, and (ii) shall be deemed for all purposes to be part of the representations
and warranties made hereunder) (the “Shareholder Disclosure Schedules”), the Company hereby, upon the execution
of this Agreement and at Closing, each Shareholder represents and warrants to Purchaser as follows:

 

3.1 Ownership of
Company Securities. Each Shareholder is the sole legal and beneficial owner of the Company Shares, Company Options or
Convertible Loans designated as being owned by such Shareholder opposite his, her or its name in the relevant column for each
of the date hereof and as at Closing Section 2.3(a) of the Company Disclosure Schedule (the “Company Securities”).
The Company Securities owned by each Shareholder are not subject to any Liens or to any rights of first refusal of any kind, and
no Shareholder has granted any rights to purchase such Company Shares to any other Person. Each Shareholder has the sole right
to transfer the Company Securities owned or to be owned by it to Purchaser. Such Company Securities constitutes all of the Company
Securities owned, beneficially or of record, by such Shareholder, and such Shareholder has no options, warrants or other rights
to acquire or subscribe to Company Shares, other than the Convertible Loans or the Company Options included in the Company Securities,
if applicable. At the Closing, in exchange for the consideration paid pursuant to Section 1.3, Purchaser will receive good
title to each Shareholder’s Company Shares, free and clear of all Liens. No Shareholder nor any prior registered, direct
or beneficial holder of such Company Shares, if any, has previously granted or agreed to grant any ongoing power of attorney in
respect of such Company Shares or entered into any voting trust, vote pooling or other agreement with respect to the right to
vote, call meetings of shareholders or give consents or approvals of any kind as to such Company Shares. There are no outstanding
loans from the Company to such Shareholder other than certain of the Closing Repayment Loans to be repaid at Closing.

 

    	 	-32-	 

    	 	 	 

    

 

3.2 No Public Sale
or Distribution. Each Shareholder is acquiring the Purchaser Shares for its own account and not with a view towards, or
for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the
1933 Act. Such Shareholder does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute
any of the Purchaser Shares.

 

3.3 Non-U.S. Persons;
Reliance on Exemptions. Each Shareholder (i) certifies that such Shareholder is not a “U.S. person” within
the meaning of SEC Rule 902 of Regulation S, as presently in effect, and that such Shareholder is not acquiring the Purchaser Shares
for the account or benefit of any such U.S. person, (ii) agrees to resell the Purchaser Shares only in accordance with the provisions
of Regulation S, pursuant to registration under the 1933 Act, or pursuant to an available exemption from registration and agrees
not to engage in hedging transactions with regard to such Purchaser Shares unless in compliance with the 1933 Act, (iii) agrees
that any certificates or book-entry positions for any Purchaser Shares issued to such Shareholder shall contain a legend to the
effect that transfer is prohibited except in accordance with the provisions of Regulation S, pursuant to registration under the
1933 Act or pursuant to an available exemption from registration and that hedging transactions involving such Purchaser Shares
may not be conducted unless in compliance with the 1933 Act, (iv) agrees that Purchaser is hereby required to refuse to register
any transfer of any Purchaser Shares issued to such Shareholder not made in accordance with the provisions of Regulation S, pursuant
to registration under the 1933 Act, or pursuant to an available exemption from registration. Each Shareholder understands that
the Purchaser Shares are being offered and sold in reliance on specific exemptions from the registration requirements of United
States Legal Requirements and that Purchaser is relying in part upon the truth and accuracy of, and such Shareholder’s compliance
with, the representations, warranties, agreements, acknowledgments and understandings of such Shareholder set forth herein in order
to determine the availability of such exemptions and the eligibility of such Shareholder to acquire the Purchaser Shares.

 

3.4 Information.
Each Shareholder and its advisors, if any, have been furnished with all materials relating to the business, finances and operations
of Purchaser. Each Shareholder and its advisors, if any, have been afforded the opportunity to ask questions of Purchaser. Neither
such inquiries nor any other due diligence investigations conducted by such Shareholder or its advisors, if any, or its representatives
shall modify, amend or affect such Shareholder’s right to rely on Purchaser’s representations and warranties contained
herein. Such Shareholder understands that its investment in the Purchaser Shares involves a high degree of risk and is able to
bear such risk and to afford a complete loss of such investment. Such Shareholder has sought such accounting, legal and tax advice
as it has considered necessary to make an informed investment decision with respect to its acquisition of the Purchaser Shares.

 

3.5 Legends.
Each Shareholder understands that the book-entry or other instruments representing the Purchaser Shares issued hereunder, until
such time as the resale of Purchaser Shares issued hereunder have been registered under the 1933 Act, the book-entry representing
the Purchaser Shares issued hereunder, except as set forth below, shall bear a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of such Purchaser Shares):

 

    	 	-33-	 

    	 	 	 

    

 

“THE TRANSFER OF THESE SECURITIES
IS PROHIBITED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S AS PROMULGATED BY THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION UNDER THE ACT, PURSUANT TO REGISTRATION UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION, AND
HEDGING TRANSACTIONS INVOLVING THESE SECURITIES (INCLUDING ANY SWAP OR ANY OTHER AGREEMENT OR ANY TRANSACTION THAT TRANSFERS, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, THE ECONOMIC CONSEQUENCE OF OWNERSHIP OF THESE SECURITIES, WHETHER ANY SUCH SWAP, AGREEMENT
OR TRANSACTION IS TO BE SETTLED BY DELIVERY OF ALL OR ANY PORTION OF THESE SECURITIES OR ANY OTHER SECURITIES, IN CASH OR OTHERWISE),
MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.”

 

The legend set forth above shall be removed
if (i) in connection with a sale, assignment or other transfer, the holder of such Purchaser Shares provides the Purchaser with
an opinion of counsel, the form and substance of which shall be reasonably acceptable to the Purchaser, to the effect that such
sale, assignment or transfer of the Securities may be made without registration under the applicable requirements of the 1933
Act, (ii) such holder provides the Purchaser with reasonable assurance (including, if requested by the Purchaser, a customary
representation letter reasonably acceptable to the Purchaser) that the Purchaser Shares can be sold, assigned or transferred without
volume or manner of sale restriction pursuant to Rule 144 or (iii) the legend can be removed in accordance with the Act,
the Regulations promulgated thereunder or applicable SEC interpretations thereof.

 

3.6 No Governmental
Review. Each Shareholder understands that no United States Governmental Entity has passed on or made any recommendation
or endorsement of Purchaser or the fairness or suitability of the investment in the Purchaser Shares issuable hereunder, nor have
such authorities passed upon or endorsed the merits of the Transactions

 

3.7 Restricted Securities.
Each Shareholder understands that the Purchaser Shares it is receiving are characterized as “restricted securities”
under the federal securities laws inasmuch as they are being acquired from Purchaser in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the Act only in certain
limited circumstances. In this connection, such Shareholder represents that it is familiar with SEC Rule 144, as presently in effect,
and understands the resale limitations imposed thereby and by the 1933 Act. Such Shareholder understands that the Purchaser Shares
have not been and will not be registered under the 1933 Act and have not been and will not be registered or qualified in any state
in which they are offered, and thus such Shareholder will not be able to resell or otherwise transfer his, her or its Purchaser
Shares unless they are registered under the 1933 Act and registered or qualified under applicable state securities laws, or an
exemption from such registration or qualification is available. Without in any way limiting the representations set forth above,
such Shareholder further agrees not to make any disposition of all or any portion of the Purchaser Shares prior to the date that
is six (6) months from the date of issuance of such Purchaser Shares unless and until transferee has agreed in writing for the
benefit of the Purchaser to be bound by this Section 3.7 and:

 

(a) There is then in effect
a registration statement under the 1933 Act covering such proposed disposition and such disposition is made in accordance with
such registration statement; or

 

    	 	-34-	 

    	 	 	 

    

 

(b) (i) Such Shareholder
shall have notified Purchaser of the proposed disposition and shall have furnished Purchaser with a detailed statement of the circumstances
surrounding the proposed disposition, and (ii) if reasonably requested by Purchaser, such Shareholder shall have furnished Purchaser
with an opinion of counsel reasonably satisfactory to Purchaser that such disposition will not require registration of such shares
under the 1933 Act. It is agreed that Purchaser will not require opinions of counsel for transactions made pursuant to Rule 144
except in unusual circumstances.

 

Notwithstanding the provisions of paragraphs
(a) and (b) above, no such registration statement or opinion of counsel shall be necessary for a transfer that is permitted by
Section 6.5(b) of this Agreement, if the transferee agrees in writing to be subject to the terms hereof to the same extent
as if he, she or it were a Shareholder hereunder.

 

3.8 Litigation.
There is no action, suit, claim or proceeding of any nature pending, or to the knowledge of such Shareholder, threatened, against
such Shareholder, arising out of or relating to (i) such Shareholder’s legal ownership of Company Shares or rights to acquire
Company Shares, (ii) such Shareholder’s capacity as a Shareholder, (iii) the Transactions, (iv) any contribution of assets
(tangible and intangible) by such Shareholder (or any of its Affiliates) to the Company, or (v) any other agreement between such
Shareholder (or any of its Affiliates) and the Company, nor to the knowledge of such Shareholder is there any reasonable basis
therefor. There is no investigation or other proceeding pending or, to the knowledge of such Shareholder, threatened, against such
Shareholder arising out of or relating to the matters noted in clauses (i) through (v) of the preceding sentence by or before any
Governmental Entity, nor to the knowledge of such Shareholder is there any reasonable basis therefor. There is no action, suit,
claim or proceeding pending or, to the knowledge of such Shareholder, threatened, against such Shareholder with respect to which
such Shareholder has a contractual right or a right to indemnification from the Company related to facts and circumstances existing
prior to the Closing, nor, to the knowledge of such Shareholder, are there any facts or circumstances that would reasonably be
expected to give rise to such an action, suit, claim or proceeding.

 

3.9 Authority.
Such Shareholder, if it is an entity, has all requisite power and authority or, if such Shareholder is an individual, has capacity
to enter into this Agreement and any Transaction Documents to which it or he or she, as the case may be, is a party and to consummate
the Transactions. The execution and delivery of this Agreement and any other agreement contemplated hereby to which such Shareholder
is a party and the consummation of the Transactions have been duly authorized by all necessary action on the part of such Shareholder,
or if such Shareholder is an entity, has been consented to by the spouse (if any) of the Shareholder, and no further action is
required on the part of such Shareholder to authorize the Agreement and any agreement contemplated hereby to which such Shareholder
is a party and the Transactions. This Agreement and each of the agreements contemplated hereby to which such Shareholder is a party
has been duly executed and delivered by such Shareholder, and assuming the due authorization, execution and delivery by the other
parties hereto and thereto, constitute the valid and binding obligations of such Shareholder, enforceable against each such party
in accordance with their respective terms, subject to the Enforceability Limitations.

 

3.10 No Conflict.
The execution and delivery by each Shareholder of this Agreement and any Related Agreement to which such Shareholder is a party
and the consummation of the Transactions will not, (a) Conflict with (i) any provision of the articles of incorporation, bylaws
or other charter or organizational documents of such Shareholder if such Shareholder is an entity, ((ii) any Legal Requirement
order applicable to such Shareholder or such Shareholder’s properties or assets (whether tangible or intangible), or (b)
require any consent, waiver, notice or approval from or on behalf of any Person.

 

3.11 Brokers’
and Finders’ Fees. No Shareholder has incurred, and will not incur, directly or indirectly, any liability
for brokerage or finders’ fees or agents’ commissions, fees related to investment banking or similar advisory services
or any similar charges in connection with the Agreement, any agreement contemplated hereby or any of the Transactions, nor will
Purchaser or the Company incur, directly or indirectly, any such liability based on arrangements made by or on behalf of such Shareholder.
Section 3.11 of the Shareholder Disclosure Schedules sets forth the principal terms and conditions of any agreement, written
or oral, with respect to such fees.

 

    	 	-35-	 

    	 	 	 

    

 

3.12 No Knowledge
of Company Breaches. Each Shareholder owning in excess of five percent (5%) of the Company Shares has reviewed the representations
and warranties of the Company contained herein (as may be modified by the Shareholder Disclosure Schedules), and to the knowledge
of such Shareholder, no such representation or warranty (as may be modified by the Shareholder Disclosure Schedules) contains,
or will contain at the Closing, any misrepresentation or is, or will be at the Closing, inaccurate in any respect.

 

3.13 Representations
Complete. None of the representations or warranties of the Company in this Agreement or any statement made in any Schedule
or certificate furnished by the Company as of the Closing pursuant to this Agreement contains any untrue statement of a material
fact, or omits to state any fact reasonably necessary in order to make the statements contained herein or therein, in the light
of the circumstances under which made, not misleading.

 

Article
IV

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Purchaser hereby represents
and warrants to the Company as follows:

 

4.1 Organization
and Qualification. Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the
state of Delaware, and has the requisite power and authorization to own its properties and to carry on its business as now being
conducted and as presently proposed to be conducted. Purchaser is duly qualified as a foreign entity to do business and is in good
standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to
have a Material Adverse Effect. Purchaser has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, and any other agreements contemplated hereby to which it is a party and to consummate the Transactions, and
to issue the Purchaser Shares in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and
the other agreements contemplated hereby and the consummation by Purchaser of the Transactions, including, without limitation,
the issuance of Purchaser Shares, have been duly authorized by Purchaser’s board of directors. This Agreement and the other
agreements contemplated hereby to which Purchaser is a party, have been duly executed and delivered by Purchaser, and constitute
the legal, valid and binding obligations of Purchaser, enforceable against Purchaser in accordance with their respective terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights
and remedies.

 

4.2 Issuance of
Securities. The Purchaser Shares to be issued hereunder, and, upon issuance in accordance with the terms of this Agreement
and the other agreements contemplated hereby, shall be validly issued and free from all preemptive or similar rights (except for
those which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to
the issue thereof and the Purchaser Shares shall be fully paid and nonassessable with the holders being entitled to all rights
accorded to a holder of Purchaser Common Stock. Assuming the accuracy of each of the representations and warranties of each Shareholder
set forth in Article III of this Agreement, the issuance by Purchaser of the Purchaser Shares is exempt from registration
under the 1933 Act.

 

    	 	-36-	 

    	 	 	 

    

 

4.3 Governmental
Approvals and Consents. No consent, waiver, approval, Order or authorization of, or registration with, any Governmental
Entity is required by or with respect to Purchaser in connection with the execution and delivery of this Agreement and any other
agreement contemplated hereby which Purchaser is a party or the consummation of the Transactions, except for obtaining the approval
of The Nasdaq Capital Market (the “Principal Market”) regarding the listing of the Purchaser Shares (the “Principal
Market Approval”).

 

4.4 SEC Reports and
Financial Statements.

 

(a) A true and complete
copy of each annual, quarterly and other report, registration statement, and definitive proxy statement filed by Purchaser with
the SEC since January 31, 2017 and prior to the date hereof (the “Purchaser SEC Documents”) is available on
the website maintained by the SEC at http://www.sec.gov, other than portions in respect of which confidential treatment was granted
by the SEC. As of their respective filing dates, the Purchaser SEC Documents complied in all material respects with the requirements
of the Securities Exchange Act of 1934, as amended (the “1934 Act”), applicable to Purchaser and the rules
and regulations of the SEC promulgated thereunder applicable to the Purchaser SEC Documents, and none of the Purchaser SEC Documents,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading.

 

(b) The financial statements
of Purchaser included in the Purchaser SEC Documents complied as to form in all material respects with the published rules and
regulations of the SEC with respect thereto, were prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto, except in the
case of pro forma statements, or, in the case of unaudited financial statements, except as permitted under Form 10-Q under the
1934 Act) and fairly presented the consolidated financial position of Purchaser and its consolidated subsidiaries as of the respective
dates thereof and the consolidated results of Purchaser’s operations and cash flows for the periods indicated (subject to,
in the case of unaudited statements, normal and recurring year-end audit adjustments)

 

4.5 Purchaser Compliance
with Legal Requirements. Except as disclosed in Purchaser’s SEC Documents, Purchaser is and has been, since January
31, 2017, in compliance with all applicable Legal Requirements, except where failure to be so in compliance would not result in
a Material Adverse Effect. Purchaser has not received, nor is there any reasonable basis for, any notice, order, complaint or other
communication from any Governmental Entity or any other Person that Purchaser has any Liability under any applicable Legal Requirement
or that it is not or has at any time not been in compliance with any applicable Legal Requirement. Except as disclosed in the Purchaser
SEC Documents, since January 31, 2017, no investigation or review by any Governmental Entity regarding a violation of any applicable
Legal Requirements with respect to Purchaser has occurred. To Purchaser’s knowledge, no such investigation or review is pending
or threatened, nor is there is any reasonable basis therefor.

 

4.6 Shares Consideration.

 

(a) The Purchaser Shares
have been duly authorized, and upon consummation of the Transactions and the issuance of such Purchaser Shares pursuant to and
in accordance with the terms hereof, will be validly issued, fully paid and non-assessable.

 

(b) All shares of Purchaser
Common Stock that may be issued upon the exercise of Purchaser Options to be issued by Purchaser in accordance with the terms of
this Agreement will be, when issued in accordance with the terms thereof, legally and validly issued, fully paid and nonassessable.

 

    	 	-37-	 

    	 	 	 

    

 

4.7 Absence of Certain
Changes. Except as disclosed in the Purchaser SEC Documents, since March 31, 2019, (i) there has been no event, occurrence
or development that would reasonably be expected to have Material Adverse Effect, (ii) there have been no (A) sale of assets other
than those in the ordinary course of business, (B) capital expenditures or (C) transactions, in each case individually or in the
aggregate, in excess of $500,000, entered into by Purchaser or any of its Subsidiaries, other than the financing transaction
previously disclosed to the Company, (iii) there has been no dividend or distribution of any kind declared, paid or made by
Purchaser on any class or series of its capital stock and (iv) Purchaser has not incurred any liability in excess of $500,000
other than in the ordinary course of business. Purchaser has not taken any steps to seek protection pursuant to any law or statute
relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does Purchaser have any knowledge
or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual
knowledge of any fact which would reasonably lead a creditor to do so.

 

4.8 Solvency.
Purchaser, after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent. Purchaser
has not been Insolvent at any time from March 31, 2019 to the date hereof. For purposes of this Section 4.8, “Insolvent”
means, with respect to any Person, (i) such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise,
as such debts and liabilities become absolute and matured, (ii) such Person intends to incur or believes that it will incur debts
that would be beyond its ability to pay as such debts mature or (iii) such Person has unreasonably small capital with which to
conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted, and “Insolvency”
shall have the meaning correlative hereto.

 

4.9 No Undisclosed
Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred or exists,
or is contemplated to occur with respect to Purchaser or its business, properties, prospects, operations or financial condition,
that would be required to be disclosed by Purchaser under Legal Requirements relating to an issuance and sale by Purchaser of
its Common Stock and which has not been publicly announced, other than the financing transaction previously disclosed to the
Company.

 

4.10 Absence of
Litigation. Except as disclosed in the Purchaser SEC Documents, there is no action, suit or proceeding, or, to
Purchaser’s knowledge, inquiry or investigation before or by the Principal Market, any Governmental Entity pending or, to
the knowledge of Purchaser, threatened against Purchaser or any of its officers or directors, whether of a civil or criminal nature
or otherwise, in their capacities as such.

 

4.11 Insurance.
Purchaser is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management
of Purchaser believes to be prudent and customary in the businesses in which Purchaser is engaged. Purchaser has not been refused
any insurance coverage sought or applied for and Purchaser has no reason to believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

4.12 Title.
Purchaser has good and marketable title in fee simple to all real property that is material to the business of Purchaser (other
than leased property of the Purchaser described in the following sentence) and good and marketable title to all personal property
owned by them which is material to the business of Purchaser, in each case free and clear of all liens, encumbrances and defects,
except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Any real
property and facilities held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and
enforceable leases, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect.

 

    	 	-38-	 

    	 	 	 

    

 

4.13 Representations
Complete. None of the representations or warranties made by Purchaser in this Agreement, and none of the statements made
in any exhibit, schedule or certificate furnished by Purchaser pursuant to this Agreement contains, or will contain at the Closing,
any untrue statement of a material fact, or omits or will omit at the Closing to state any material fact necessary in order to
make the statements contained herein or therein, in the light of the circumstances under which they were made, not misleading.

 

4.14 Capital Resources.
Purchaser will have sufficient financing at the Closing to pay the Adjusted Cash Consideration, repayment of the Closing
Repayment Loans and the Finnish Transfer Taxes to be paid by the Purchaser at Closing.

 

Article
V

CONDUCT PRIOR TO THE CLOSING

 

5.1 Affirmative Conduct
of Business of the Company. During the period from the date hereof and continuing until the earlier of (a) the termination
of this Agreement pursuant to Article IX (Termination; Exclusivity; Extension; Waiver) or (b) the Closing, the Company
shall, and shall cause its Subsidiaries to:

 

(a) conduct the businesses
of the Company and its Subsidiaries only in the ordinary course of business and in a manner consistent with the Company’s
and its Subsidiaries’ past practice and in compliance in all respects with all applicable Legal Requirements;

 

(b) (b) maintain its existence
in good standing under applicable Legal Requirements;

 

(c) (i) pay in full all outstanding
accounts payable when due (including outstanding invoices for services provided by third parties to the Company and its Subsidiaries)
and pay all other Indebtedness when due, (ii) pay all of its Taxes when due, subject to good faith disputes over such Taxes, (iii)
timely file all Tax Returns required to be filed in a manner consistent with past practice except as otherwise required by applicable
Legal Requirements and pay the expenses of preparation for such Tax Returns, (iv) pay or perform its other obligations when due,
(v) use commercially reasonable efforts collect accounts receivable when due and not extend credit outside of the ordinary course
of business consistent with past practice, (vi) sell products and services consistent with past practices as to license, service
and maintenance terms, and incentive programs, (vii) recognize revenue consistent with past practice and policies, (viii) except
as required under this Agreement or otherwise requested by Purchaser, use commercially reasonable efforts to keep available the
services of its present officers, employees and consultants, and (ix) prosecute and maintain all registrations and applications
to register the Company Intellectual Property, including paying any related fees when due;

 

(d) ensure that each of its
Contracts (other than with Purchaser) entered into after the date hereof will not require the procurement of any consent, waiver
or novation or provide for any change in the obligations of any party in connection with, or terminate as a result of the consummation
of, the Transactions, and shall give reasonable advance notice to Purchaser prior to allowing any Material Contract or right thereunder
to lapse or terminate by its terms;

 

(e) maintain the Company’s
current insurance coverage covering the reasonably anticipated risks of the Company’s business, and upon any damage, destruction
or loss to any of the Company’s assets, apply any and all insurance proceeds received with respect thereto to the prompt
repair, replacement and restoration thereof;

 

    	 	-39-	 

    	 	 	 

    

 

(f) perform in all material
respects their respective obligations under each Material Contract; and

 

(g) pay any accrued bonuses
and other employee compensation payable after the date hereof and before the Closing in the ordinary course of business consistent
with past practice.

 

5.2 Restrictions
on Conduct of Business of the Company. Without limiting the generality or effect of the provisions of Section 5.1,
during the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to Article
IX (Termination; Exclusivity; Extension; Waiver) and the Closing, neither the Company nor any of its Subsidiaries shall,
directly or indirectly, do, propose to any third party to do (other than proposals to Purchaser for the purpose of seeking consent),
cause or permit any of the following (except to the extent expressly provided otherwise in this Agreement or as consented to in
writing by Purchaser):

 

(a) amend or otherwise change
the Company Charter or any of the Company’s other governing documents;

 

(b) issue, sell, pledge,
dispose of, grant or otherwise subject to any Lien, or authorize the issuance, sale, pledge, disposition or otherwise grant, any
Company Shares or any share capital in any of its Subsidiaries, or any options, warrants, convertible securities or other rights
of any kind to acquire any such shares of capital stock, or any other ownership interest, of the Company or any of its Subsidiaries,
except pursuant to the exercise of Company Options outstanding on the date of this Agreement, in accordance with their terms as
existing on the date of this Agreement;

 

(c) transfer, lease, sell,
pledge, license, dispose of or subject to any Lien any assets or properties of the Company or its Subsidiaries, except for sales
and non-exclusive licenses of products or services in the ordinary course of business consistent with past practice;

 

(d) declare, set aside, make
or pay any dividend or other distribution, payable in cash, shares, property or otherwise, with respect to any of its share capital
(other than dividends or distributions made by a Subsidiary of the Company to the Company or another of its Subsidiaries);

 

(e) reclassify, combine,
split, subdivide or redeem, or purchase or otherwise acquire, directly or indirectly, any of its share capital or make any change
to the Company’s capital structure;

 

(f) (i) acquire, directly
or indirectly (including by merger, consolidation, or acquisition of shares or assets or any other business combination), any corporation,
partnership, other business organization or any division thereof or any other business, or any equity interest in any Person; (ii)
incur any Indebtedness, or assume, guarantee or endorse, or otherwise become responsible for (contingently or otherwise), the obligations
of any Person; (iii) make any loans, advances or capital contributions, except for loans or advances for travel expenses and extended
payment terms for customers, in each case subject to applicable Legal Requirements and only in the ordinary course of business
consistent with past practice; (iv) make, authorize, or make any commitment with respect to any single capital expenditure that
is, individually, in excess of $25,000 or is, together with other capital expenditures that the Company or any of its Subsidiaries
has made, authorized or made a commitment with respect to following the date of this Agreement, in excess of $50,000; or (v) make
or direct to be made any capital investments in any Person, other than investments in any Subsidiary of the Company;

 

(g) adopt a plan of complete
or partial liquidation, dissolution, restructuring, recapitalization or other reorganization;

 

    	 	-40-	 

    	 	 	 

    

 

(h) (i) increase or accelerate
the compensation payable or to become payable (including bonus grants and retention payments) to its current and former directors,
officers or employees or other service providers, (ii) grant any severance or termination pay or retention payments or benefits
to, or enter into, amend or terminate any employment, severance, retention, change in control, consulting or termination Contract
with, any current or former director, officer or other employee or other service providers of the Company or its Subsidiaries,
(iii) establish, adopt, enter into, amend or terminate any collective bargaining, bonus, profit-sharing, thrift, compensation,
stock option, restricted stock, pension, retirement, deferred compensation, employment, termination, severance or other plan, Contract,
trust, fund or policy for the benefit of any current or former director, officer or employee or other service providers, (iv) pay
or make, or agree to pay or make, any accrual or other arrangement for, or take, or agree to take, any action to fund or secure
payment of, any severance pension, indemnification, retirement allowance, or other benefit, (v) hire, elect or appoint any director,
officer or key personnel of the Company, or (vi) terminate the employment, change the title, office or position, or materially
reduce the responsibilities of any Key Individual or any other director, officer or key personnel of the Company;

 

(i) announce, implement or
effect any reduction in labor force, lay-off, early retirement program, severance program or other program or effort concerning
the termination of employment of employees of the Company or its Subsidiaries;

 

(j) enter into a new line
of business;

 

(k) make or change any accounting
treatment election, adopt or change any accounting period, adopt or change any accounting method, except in each case as required
by changes in the applicable Legal Requirements as concurred with its independent auditors or at the recommendation of the auditors
of the Company or the relevant Subsidiaries and after notice to Purchaser;

 

(l) make, change or revoke
any Tax election or allow any Tax election previously made to expire, file any amended Tax Return, adopt or change any Tax accounting
method or Tax accounting period, enter into, cancel or modify any agreement with a Taxing Authority, settle any Tax claim or assessment
relating to the Company or any of its Subsidiaries, surrender any right to claim a refund of Taxes, consent to any extension or
waiver of the limitation period applicable to any Tax claim or assessment relating to the Company or any of its Subsidiaries, destroy
or dispose of any books and records with respect to Tax matters relating to periods beginning before the Closing and for which
the statute of limitations is still open or under which a record retention agreement is in place with a Taxing Authority, or take
any other similar action relating to the filing of any Tax Return or the payment of any Tax, if such other similar action would
have the effect of increasing the Liability for Taxes of the Company or any of its Subsidiaries for any period ending after the
Closing Date or decreasing any Tax attribute of the Company or any of its Subsidiaries existing on the Closing Date;

 

(m) negotiate, settle, pay,
discharge or satisfy any Action or Liability (absolute, accrued, asserted or unasserted, contingent or otherwise), including any
litigation, arbitration or other Action, or give any discount, accommodation or other concession other than in the ordinary course
of business consistent with past practice, in order to accelerate or induce the collection of any receivable;

  

    	 	-41-	 

    	 	 	 

    

 

(n) enter into or amend any
Contract that would constitute a Material Contract, amend or modify or consent to the termination of any Material Contract, or
amend or modify, waive or consent to the termination of the Company’s or any of its Subsidiaries’ rights thereunder
or waive, release, or consent to the termination of any claims or rights of material value to the Company or any of its Subsidiaries;
provided, however, that for all purposes of this Section 5.2(n) only, the definition of “Material Contract”
shall not include Contracts entered into in the ordinary course of business consistent with past practice; notwithstanding the
foregoing, “Material Contract” shall include (and in no event shall the Company or any of its Subsidiaries enter into
or amend):

 

(i) any Contract pursuant
to which the Company or its Subsidiaries grants or provides or agrees to grant or provide to any other Person any assignment, hypothecation,
transfer, license, option, covenant not to sue, release, immunity or other right with respect to or under any Intellectual Property
(other than (A) non-exclusive licenses to Company Products granted to customers and distributors in the ordinary course of business
consistent with past practice and (B) non-exclusive and incidental licenses to feedback granted to suppliers in the ordinary course
of business consistent with past practice);

 

(ii) any Contract pursuant
to which the Company or its Subsidiaries establishes with any other Person a joint venture, strategic relationship, or partnership;

 

(iii) any Contract pursuant
to which the Company or its Subsidiaries agrees to create or develop any Intellectual Property, products, or services for any other
Person;

 

(iv) any Contract that
purports to limit, curtail or restrict the ability of the Company or any of its Subsidiaries or Purchaser or any of its Affiliates
to (A) compete in any way, including in any geographic area or line of business or with any Person, (B) make sales to or engage
or participate with any Person in any manner, (C) use or enforce any Intellectual Property owned by or exclusively licensed to
the Company or any of its Subsidiaries, or (D) hire or solicit any Person in any manner;

 

(v) any Contract that grants
the other party or any third Person, or otherwise constrains or subjects the Company or any of its Subsidiaries or Purchaser or
any of its Affiliates to, (A) any exclusive marketing or other exclusive rights of any type or scope, (B) any “most favored
nation” or similar status, (C) any type of special discount rights, or (D) any right of first refusal, first notice, or first
negotiation; or

 

(vi) any Contract that
(A) requires a consent or otherwise containing a provision relating to a “change of control,” or that will give rise
to any acceleration or additional rights or obligation sunder such Contract or prohibit or delay the consummation of the transactions
contemplated by this Agreement or any of the other Transaction Documents; or (B) restricts the Company or any of its Subsidiaries
from assigning such Contract to any of the Company’s Affiliates, other than Contracts entered into with customers and resellers
in the ordinary course of business consistent with past practice;

 

(o) enter into any agreement
for the purchase, lease, sublease or license of Real Property, or any operating lease or any renewals thereof;

 

(p) terminate, cancel, amend
or modify any Insurance Policy that is not promptly replaced by comparable insurance coverage;

 

(q) terminate, waive or cancel
any right or registration of a right, of substantial value, including taking any action that would reasonably be expected to result
in any loss, lapse, abandonment, invalidity or unenforceability of any Intellectual Property;

 

(r) enter into or amend or
otherwise modify any Contract or arrangement with any director, officer or other Affiliate of the Company and its Subsidiaries;

 

(s) commence or settle any
Action other than (i) for the routine collection of invoices consistent with past practice, (ii) in such cases where it in good
faith determines that failure to commence suit would result in the material impairment of a valuable aspect of its business (provided
that it consults with Purchaser prior to the filing of such an Action), or (iii) for a breach of this Agreement;

 

    	 	-42-	 

    	 	 	 

    

 

(t) pay or become liable
to pay any costs or expenses of any Shareholder or Optionholder arising out of or related to the transactions contemplated by this
Agreement or any other documents or agreements contemplated hereby; or

 

(u) announce an intention,
enter into any formal or informal Contract or otherwise make a commitment to take any of the actions described in clauses (a) through
(u) of this Section 5.2, or any action which would reasonably be expected to make any of the Company’s representations
or warranties contained in this Agreement untrue or incorrect (such that the condition set forth in Section 7.2 (Conditions
to Obligations of Purchaser) would not be satisfied) or prevent the Company from performing or cause the Company not to perform
one or more covenants required hereunder to be performed by the Company (such that the condition set forth in Section 7.2
(Conditions to Obligations of Purchaser) would not be satisfied).

 

5.3 Restrictions
on Transfer. Unless this Agreement is validly terminated pursuant to Section 9.1, no Shareholder shall, directly
or indirectly, other than with the prior written consent of Purchaser or expressly permitted under this Agreement:

 

(a) sell, gift, assign, transfer
(including by merger, combination, testamentary disposition, interspousal disposition pursuant to a domestic relations proceeding,
or otherwise by operation of law, unless such transfer cannot be avoided under applicable Legal Requirements), pledge, encumber
or otherwise dispose of any of the Company Shares or Company Options owned by such Shareholder or any voting rights in respect
thereof (each a “Transfer”), or enter into any Contract, with respect to any Transfer;

 

(b) deposit any of the Company
Shares or Company Options owned by such Shareholder into a voting trust or enter into a voting agreement or arrangement or voting
pool with respect to such Company Shares or Company Options or grant any proxy or power of attorney with respect to such Company
Shares or Company Options or call meetings of shareholders of the Company or give consents or approvals of any kind in connection
with such Company Shares or Company Options other than as expressly contemplated in this Agreement; or

 

(c) reduce such Shareholder’s
beneficial ownership of, or interest in (by entering into hedging transactions or otherwise), the Company Shares or Company Options
owned by such Shareholder.

 

Article
VI

ADDITIONAL AGREEMENTS

 

6.1 Notification
of Certain Matters. The Company and each Shareholder, as the case may be, shall give prompt notice to Purchaser of: (a)
the occurrence or non-occurrence of any event, the occurrence or non-occurrence of which is likely to cause any representation
or warranty made by the Company or the Shareholders in this Agreement to be untrue or inaccurate at or prior to the Closing, and
(b) any failure of the Company or any Shareholders to comply with or satisfy any covenant, condition or agreement to be complied
with or satisfied by it hereunder; provided, however, that the delivery of any notice pursuant to this Section
6.1 shall not (i) amend or supplement the Disclosure Schedule or otherwise affect, be deemed to modify, or deemed to prevent
or cure the breach of, any representation or warranty, or covenant, contained herein, (ii) affect the conditions to the obligations
of the parties to consummate the Transactions in accordance with the terms and provisions hereof, (iii) limit or otherwise affect
any remedies available to Purchaser under this Agreement or (iv) constitute an acknowledgment or admission of a breach of this
Agreement by any Party.

 

    	 	-43-	 

    	 	 	 

    

 

6.2 Confidentiality.
Each of the parties hereto hereby agrees that the information obtained in any investigation pursuant to this Section
6.2 or any information obtained pursuant to the notice requirements of Section 6.1, or otherwise pursuant to the negotiation
and execution of this Agreement, the other agreements contemplated here by or the effectuation of the Transaction, shall be governed
by the terms of the Mutual Non-Disclosure Agreement dated as of January 18, 2019 (the “Confidential Disclosure Agreement”),
between the Company and Purchaser, and the Shareholders shall comply with the Confidential Disclosure Agreement as if they were
the Company. In this regard, the Company and the Shareholders acknowledge that the Purchaser Common Stock is publicly traded and
that any information about Purchaser obtained by the Company during the course of its due diligence could be considered to be
material non-public information within the meaning of federal and state securities laws. Accordingly, the Company and the Shareholders
agree not to engage in any discussions or correspondence with respect to, or transactions in, the Purchaser Common Stock in violation
of any Legal Requirement. None of the Company, the Shareholders nor any of their respective representatives shall issue any statement
or communication to any third party (other than its agents that are bound by confidentiality restrictions) regarding the subject
matter or existence of this Agreement, any agreement contemplated hereby or the Transaction, including, if applicable, the termination
of this Agreement or any agreement contemplated hereby and the reasons therefor, without the consent of Purchaser.

 

6.3 Principal Market
Approval. From the date hereof until the earlier of (i) termination of this Agreement in accordance with Section 9.1
or (b) Closing, Purchaser will use its commercially reasonable efforts to promptly obtain and maintain in force for the necessary
period the Principal Market Approval.

 

6.4 Third Party Expenses.
Except as provided for in Section 1.3(d), whether or not the Transactions are consummated, each party shall be
responsible for its own costs and expenses incurred with respect to the negotiation, execution, delivery and performance of this
Agreement and each of the agreements contemplated hereby.

 

6.5 Lock-Up.

 

(a)
Commencing on the Closing Date and ending on the applicable Lock-Up End Date, each Shareholder agrees that such Shareholder will
not, and will cause any of its affiliates (as defined in Rule 144) not to, (A) sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option to purchase, make any short sale or otherwise dispose of or agree to dispose of, directly
or indirectly, any of the Purchaser Shares issuable hereunder, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the 1934 Act and the rules and regulations of the SEC
promulgated thereunder with respect to any shares of Purchaser Common Stock issued hereunder and owned directly by such Shareholder
(including holding as a custodian, (B) enter into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of any of such Purchaser Shares, whether any such transaction above is to be settled
by delivery of shares of Purchaser Common Stock or other securities, in cash or otherwise, or (C) publicly disclose the intention
to do any of the foregoing. The “Lock-Up End Date” with respect to each Shareholder listed on Annex B
hereto (each, a “Key Shareholder”) shall be the date that is twelve (12) months after the Closing Date and with
respect to each other Shareholder shall be the date that is six (6) months after the Closing Date as to twenty five percent (35%)
of the Purchaser Shares issued to such Shareholder at the Closing at twelve (12) months after the Closing Date as to the remaining
seventy five percent (65%) of the Purchaser Shares issued to such Shareholder at the Closing.

 

(b) Notwithstanding the foregoing,
any Shareholder may transfer the shares of Purchaser Common Stock received hereunder (i) as a bona fide gift or gifts, provided
that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein, (ii) to any affiliate of such
Shareholder provided that such affiliate agrees to be bound in writing by the restrictions set forth herein or (iii) to any trust
for the direct or indirect benefit of such Shareholder or the immediate family of such Shareholder, provided that the trustee of
the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that, solely in the case of
clauses (i) and (iii), any such transfer shall not involve a disposition for value. For purposes of this Section 6.5(b),
“immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.

 

    	 	-44-	 

    	 	 	 

    

 

(c) Each Shareholder agrees
and consents to the entry of stop transfer instructions with the Transfer Agent against the transfer of the Purchaser Shares except
in compliance with the foregoing restrictions. Each Shareholder understands and agrees that this Section 6.5 is irrevocable
and shall be binding upon such Shareholder’s heirs, legal representatives, successors, and assigns.

 

6.6 Release.

 

(a) As an inducement to Purchaser
to enter into this Agreement and consummate the Transactions and for other good, valuable and sufficient consideration, each of
the Shareholders, with the intention of binding himself, herself or itself and his or her heirs, executors, administrators and
assigns (the “Releasors”), shall hereby as of the Closing release, acquit and forever discharge the Company,
and each of their past and present Affiliates, Subsidiaries, and Representatives, and all Persons acting by, through, under, or
in concert with such Persons (the “Releasees”), of and from any and all manner of action or actions, cause or
causes of action, suits, arbitrations, demands, debts, contracts, agreements, promises, liability, damages, or Loss of any nature
whatsoever, known or unknown, suspected or unsuspected, fixed or contingent, direct, derivative, vicarious or otherwise, whether
based in contract, tort, or other legal, statutory, or equitable theory of recovery, each as though fully set forth at length herein,
arising out of or relating to the Releasor’s involvement with the Company whether as investor, employee or consultant (hereinafter,
a “Claim”), which the Releasors now have or may hereafter have against the Releasees, or any of them (the “Released
Matters”); provided, however, that nothing set forth in this Section 6.6 shall (i) affect the ability
of any such Shareholder to bring a Claim under this Agreement or any other agreement contemplated hereby, (ii) if any Releasor
is an officer or employee of or consultant to the Company, release, acquit or discharge any rights to any entitlement, salary,
bonus or employment benefits or consultancy fees earned or accrued by or for the benefit of such Releasor prior to the Closing
in respect of services performed by such Releasor as an officer or employee of or consultant to the Company, (iii) if any Releasor
is an officer, director or employee of or consultant to the Company, release, acquit or discharge any rights to any entitlement
to indemnification, contribution or reimbursement of expenses afforded under the Company’s constituent documents or applicable
law arising out of or relating to such Releasor’s service as an officer, director, employee or consultant; or (iv) affect
the ability of any of the Shareholders to bring a Claim with respect to any ordinary course of employment rights or any Contracts
with Purchaser, any Affiliates of Purchaser or the Company that remain in effect after the Closing. Each Shareholder represents
and warrants to the Company and Purchaser that there has been no assignment or other transfer of any interest in any Claim arising
out of or based upon any of the Released Matters which such Shareholder may have against any of the Releasees, and each Shareholder
agrees to indemnify and hold the Releasees harmless from any liability, Claims or attorneys’ fees or expenses incurred as
a result of any Person asserting any such assignment or transfer of any rights or Claims under any such assignment or transfer
from such party.

 

(b) Each Shareholder represents
and warrants to the Company and Purchaser that it has not filed, nor has as of the date hereof, any Claims arising out of or based
upon any of the Released Matters against any of the Releasees. Each Shareholder agrees that if such Shareholder hereafter commences,
joins in, or in any manner seeks relief through any suit arising out of, based upon, or relating to any of the Claims released
hereunder, or in any manner asserts against the Releasees any of the Claims released hereunder, including, without limitation,
through any motion to reconsider, reopen or appeal the dismissal of the suit or action, then such Shareholder will pay to the Releasees
against whom such claim(s) is asserted all damages incurred by such Releasees in defending or otherwise responding to said Claim.

 

    	 	-45-	 

    	 	 	 

    

 

(c) Notwithstanding anything
to the contrary herein, the release set forth in this Section 6.6 shall have no force and effect until payment of the Adjusted
Closing Stock Consideration at the Closing.

 

6.7 Options and RSUs.
Promptly following the Closing Date, Purchaser shall issue to the individuals listed on Annex C hereto (the “Option
and RSU Recipients”) (a) options to purchase such number of shares of Purchaser Common Stock, as set forth opposite
each such Option Recipient’s name on Annex C under the column headed “Options” at an exercise price per
share equal to the closing price of the Company’s common stock on the date of this Agreement, as quoted by the Principal
Market, and (b) restricted stock units settleable for such number of shares of Purchaser Common Stock as set forth opposite each
such Option Recipient’s name on Annex C under the column headed “RSUs,” in each case subject to the terms
and conditions set forth in the Purchaser Option Plan and the option or RSU award agreement in substantially the form attached
hereto as Exhibit B or Exhibit C, as applicable.

 

6.8 Tax Matters.
All amounts paid as an indemnity by one party to another under this Agreement will be treated as adjustments to the Aggregate
Closing Consideration for all Tax purposes, unless as required by “determination” under Section 1313(a) of the Code.

 

6.9 Non-Competition
and Non-Solicitation

 

(a) For a period of two
(2) years from the Closing Date, the Shareholders shall not, and shall cause each of their respective Affiliates not to, engage
in any capacity whatsoever (whether as owner, financier, consultant, adviser, employee, officer, director or otherwise), without
the prior written consent of Purchaser, in any business or other undertaking competing with the business of the Company or its
Subsidiary in Finland, Estonia, the United States, Uruguay, Brazil and Russia or elsewhere as conducted on the Closing Date (the
obligations set forth in this Section 6.9(a), the “Non-Compete”); provided, however, that nothing in
this Section 6.9(a) shall preclude any Shareholder that (i) is not a Key Individual or an affiliate of a Key Individual
and (ii) holds less than two percent (2%) of the Company’s capital stock as of the Closing Date from serving as a passive
investor in less than five percent (5%) of the equity securities of a competing business or continuing to hold equity interests
including options to acquire stock, shares, convertible loans or other similar instruments in or the granting of loans to any
business or other undertaking competing with the business of the Company where such investments were made or loans were advanced
by the relevant Shareholder prior to the date of this Agreement or (iii) in the case of Stolt Consulting AB and its Affiliates,
from continuing those business activities carried on by each of Stolt Consulting and its Affiliates which they
respectively carry on at the date hereof.

 

(b) For a period of two (2)
years from the Closing Date, the Shareholders shall not, and shall cause each of their respective Affiliates not to, solicit for
employment or service or employ or appoint any director, officer, manager or a person in an expert role, consultant or adviser
to the Company or its Subsidiary. The foregoing notwithstanding, no Shareholder shall be precluded from accepting an application
for employment from such person in response to a general bona fide recruitment advertisement (without any solicitation measures),
or an unsolicited approach by such person (the obligations set forth in this Section 6.9(b), the “Non-Solicit”).

 

6.10 Estonian Shares.

 

(a) In the event that at
Closing the Company is not the legal owner of the shares in Pro Farm Oü which, at the date hereof are owned by the estate
of Mr. Taganov (the “Estonian Shares”), the Shareholders shall use their respective reasonable efforts to procure
the transfer ownership of the Estonian Shares to the Company.

 

    	 	-46-	 

    	 	 	 

    

 

(b) The Shareholders agree
to indemnify and hold harmless the Company from and against any and all costs and expenses incurred by the Company from and after
Closing in procuring the registration of the Estonian Shares, including, without limitation, any costs or expenses incurred with
purchasing the Estonian Shares from any third party with a legitimate claim to the shares (including the cost of the payment for
the Estonian Shares and any adverse tax impacts to the Company)If the Estonian Shares cannot be procured by December 31, 2020,
Purchaser and the Shareholder’s Representative shall in good faith negotiate an amount representing a reasonable estimate
of the loss to the Company as a result of the Company not being the registered owner of the Estonian Shares and of the amount which
may be required to be paid to the holder of the Estonian Shares, if any, for the registration of the Estonian Shares (and shall
submit any disputes to the Accounting Arbitrator in accordance with Section 1.5(e)) (the “Estonian Share Value”
and, together with the other the costs, expenses and losses pursuant to this Section 6.10(b), the “Estonian Share
Loss”).

 

(c) Any Estonian Share Loss
shall be entirely satisfied by discounting the value of such Estonian Share from the aggregate Adjusted Milestone Consideration
to be issued to the Shareholders pursuant to Section 1.5(b), provided that to the extent the Estonian Shares are registered
in the name of the Company prior to December 31, 2023, the value of the Estonian Shares so registered (the “Estonian Share
Gain”) shall be added to the Adjusted Milestone Consideration to be issued to the Shareholders pursuant to Section
1.5(b).

 

6.11 Good Faith Performance.
Each Party agrees to act in good faith towards the other Parties to this Agreement in the fulfilment of any obligations,
commitments and undertakings or in the exercise of any rights of such Party under this Agreement.

 

Article
VII

CONDITIONS TO CLOSING

 

7.1 Conditions to
Obligations of Each Party. The respective obligations of the Company, the Shareholders and Purchaser to effect the Closing
shall be subject to the satisfaction, at or prior to the Closing, of the following conditions:

 

(a) Regulatory Approvals.
All approvals of Governmental Entities required to be obtained prior to the Closing in connection with the Transactions shall have
been obtained.

 

(b) No Legal Impediments.
No Legal Requirement (whether temporary, preliminary or permanent) shall be in effect which has the effect of making the Transactions
illegal or otherwise prohibiting or preventing consummation of the Transactions.

 

(c) Principal Market
Approval. Purchaser shall have received the Principal Market Approval and provided evidence thereof to the Company.

 

7.2 Conditions to
Obligations of Purchaser. The obligations of Purchaser to effect the Closing shall be subject to the satisfaction at or
prior to the Closing of each of the following conditions, any of which may be waived, in writing, exclusively by Purchaser:

 

(a) Company Obligations.
(i) the Company shall have performed and satisfied in all material respects each of its obligations hereunder and under the other
agreements contemplated hereby, required to be performed and satisfied by it on or prior to the Closing Date; (ii) each of the
Fundamental Representations shall have been true and correct in all respects as of the date of this Agreement and at and as of
the Closing with the same force and effect as if made as of the Closing (except that representations and warranties that are made
as of a specified date shall be true and correct as of such specified date), (iii) each of the representations and warranties of
the Company contained herein or in any other document or agreement contemplated hereby, other than those set forth in clause (ii)
above shall have been true and correct in all material respects as of the date of this Agreement (except that representations and
warranties that are made as of a specified date shall be true and correct as of such specified date), in each case, without regard
to any qualification as to materiality included therein, and (iv) Purchaser shall have received a certificate signed by a duly
authorized executive officer of the Company to the foregoing effect and to the effect that the conditions specified within this
Section 7.2(a) have been satisfied.

 

    	 	-47-	 

    	 	 	 

    

 

(b) Shareholder Obligations.
(i) The Shareholders shall have performed and satisfied in all material respects each of their obligations hereunder and under
the other agreements contemplated hereby, required to be performed and satisfied by the Shareholders on or prior to the Closing
Date; (ii) each of the representations and warranties of the Shareholders set forth in Section 3.1 (Ownership of Company
Securities), Section 3.9 (Authority), and  Section 3.10 (No Conflict) shall have been true
and correct in all respects as of the date of this Agreement and at and as of the Closing with the same force and effect as if
made as of the Closing (except that representations and warranties that are made as of a specified date shall be true and correct
as of such specified date), and (iii) each of the representations and warranties of the Shareholders contained herein or in any
other document or agreement contemplated hereby, other than those set forth in clause (ii) above shall have been true and correct
in all material respects as of the date of this Agreement and at and as of the Closing with the same force and effect as if made
as of the Closing (except that representations and warranties that are made as of a specified date shall be true and correct as
of such specified date), in each case, without regard to any qualification as to materiality included therein.

 

(c) Notices.
The Company shall have delivered to the applicable third parties and delivered to Purchaser (i) any and all notices required under
the Contracts set forth in Section 2.17(a)(vi) of the Company Disclosure Schedules, in each case, in connection with or
as a result of the Transactions.

 

(d) No Violation.
No Legal Requirements shall have been enacted or exist that would prohibit consummation of the Transactions, the Closing or the
other transactions contemplated by this Agreement or the other agreements contemplated hereby. No temporary restraining order,
preliminary or permanent injunction or other order issued by any court of competent jurisdiction or other Governmental Entity (i)
preventing consummation of the Transactions, the Closing or the other transactions contemplated by this Agreement or the other
agreements contemplated hereby (ii) limiting or restricting Purchaser’s ownership, conduct or operation of the business of
the Company and its Subsidiaries following the Closing shall be in effect. There shall be no pending or threatened any Action seeking
any of the foregoing or any other injunction, restraint or prohibition in connection with the Transactions and the other agreements
contemplated hereby.

 

(e) No Material Adverse
Effect. Since the date hereof, no Material Adverse Effect shall have occurred and be continuing as of the Closing.

 

(f) FIRPTA.
The Company shall have delivered to Purchaser the FIRPTA Certificate.

 

(g)
Key Individual Agreements. The employment agreements and the Managing Director Agreement to be entered into between
the Company and each of the Key Individuals respectively, (including the employee and consultant confidential information and
assignment of inventions agreements appended thereto) on or about the date of this Agreement shall be in full force and effect
as of the Closing and shall not have been repudiated, and no Key Individual shall have terminated his employment with the Company.

 

(h) Ownership.The
Shareholders, including any parties executing Joinder Agreements, shall own all of the outstanding Company Shares, and there shall
be no other outstanding rights to acquire Company Shares, whether by virtue of any previously outstanding rights being exercised
or validly terminated.

 

    	 	-48-	 

    	 	 	 

    

 

(i)
Other Transaction Documents. The Company and the Shareholders Representative shall have executed and delivered to
Purchaser all of the documents and agreements set forth in Section 1.2(a) or otherwise contemplated hereby to which each is a
party, and each such document shall be in full force and effect and shall not have been repudiated.

 

7.3 Conditions to
Obligations of the Company and the Shareholders. The obligations of the Company and the Shareholders to consummate the
Closing are subject to the satisfaction or waiver (to the extent legally permissible) of each of the following conditions any
of which may be waived, in writing, exclusively by the Shareholders’ Representative:

 

(a) Representations
and Warranties. Except as would not be reasonably be expected to prevent consummation of the Transactions, (i) Purchaser
shall have performed and satisfied in all material respects each of its respective covenants and obligations hereunder and under
the other documents and agreements contemplated hereby and required to be performed and satisfied by it on or prior to the Closing
Date, (ii) each of the representations and warranties of Purchaser set forth in Section 4.1 (Organization and Qualification)
shall have been true and correct in all respects as of the date of this Agreement and at and as of the Closing with the same force
and effect as if made as of the Closing (except that representations and warranties that are made as of a specified date shall
be true and correct as of such specified date) and (iii) each of the representations and warranties of Purchaser contained herein
or in any other document or agreement contemplated hereby other than those set forth in clause (ii) above shall have been true
and correct in all material respects as of the date of this Agreement and at and as of the Closing with the same force and effect
as if made as of the Closing (except that representations and warranties that are made as of a specified date shall be true and
correct as of such specified date), in each case, without regard to any qualification as to materiality included therein.

 

(b) No Violation.
No Legal Requirements shall have been enacted or exist that would prohibit consummation of the Transactions, the Closing or the
other transactions contemplated by this Agreement or the other agreements contemplated hereby. No temporary restraining order,
preliminary or permanent injunction or other order issued by any court of competent jurisdiction or other Governmental Entity preventing
consummation of the Transactions, the Closing or the other transactions contemplated by this Agreement or the other agreements
contemplated hereby shall be in effect. There shall be no pending or threatened any Action seeking any of the foregoing or any
other injunction, restraint or prohibition in connection with the Transactions, the Closing, or the other transactions contemplated
by this Agreement.

 

(c)
Other Transaction Documents. Purchaser shall have executed and delivered to the Company and the Shareholders’
Representative all of the documents and agreements set forth in Section 1.2(b) or otherwise contemplated hereby to which each
is a party, and each such document shall be in full force and effect and shall not have been repudiated.

 

    	 	-49-	 

    	 	 	 

    

 

Article
VIII

INDEMNIFICATION

 

 

8.1 Survival of Representations
and Warranties.

 

(a) All of the representations,
warranties, covenants and agreements of Purchaser, the Company and the Shareholders set forth in this Agreement shall survive the
closing and the consummation of the Transactions and continue in full force and effect. Notwithstanding the foregoing or anything
to the contrary contained herein, no party shall be entitled to recover for any Loss (as defined below) arising from or relating
to a breach of the representations and warranties set forth in Article II and Article III unless written notice thereof
is delivered to the other parties on or prior to the Applicable Limitation Date. For purposes of this Agreement the term “Applicable
Limitation Date” shall be the date that is thirty six (36) months after the Closing Date; provided, that the Applicable
Limitation Date with respect to any Loss arising from or related to: (A) a breach of the representations and warranties set forth
in Section 2.1 (Organization and Good Standing), Section 2.3 (Capitalization), Section 2.4 (Authority
and Enforceability), Section 2.5 (No Conflict; Required Consents and Approvals), Section 2.11 (Employee
Benefits), Section 2.15(a) (Intellectual Property Fundamental Representations), Section 2.16 (Taxes),
Section 2.23 (Brokers), Section 3.1 (Ownership of Company Securities), Section 3.9 (Authority)
and Section 3.11 (Brokers’ and Finders’ Fees) (together, the “Fundamental Representations”)
or (B) any breach of any representation or warranty by a Party which results from fraud or willful misconduct; the Applicable Limitation
Date shall be the date that is ninety (90) days following expiration of the applicable statute of limitations with respect to such
breach.

 

8.2 Indemnification.

 

(a) Subject to the limitations
set out in Sections 8.2(d) and 8.2(e), the Shareholders shall, severally and not jointly, indemnify and hold harmless
Purchaser and its directors, managers, officers, employees, Affiliates (including, after the Closing, the Company and its Subsidiaries),
successors and permitted assigns (collectively, as the case may be, the “Purchaser Indemnitees”), against any
Loss, Liability, damage, penalty, fine, Tax, cost or expense, including reasonable legal expenses and costs associated therewith,
whether or not arising out of a third party claim, which they may suffer, sustain or become subject to as a result of, without
duplication:

 

(i) the breach by the Company
or any Shareholder of (A) any of the Fundamental Representations or (B) any covenant or agreement made by the Company or any Shareholder
contained in this Agreement;

 

(ii) any Indemnified Taxes;

 

(iii) fraud or willful
misconduct by or on behalf of any Shareholder, or by or on behalf of the Company (provided that if such fraud or willful
misconduct is by or on behalf of the Company, liability for such losses shall be borne by the Shareholders pro rata based on the
total consideration allocable to such Shareholders pursuant to this Agreement);

 

(iv) (A) the consulting
service fee payments based on the consulting relationship made and/or entered into under the Consultancy Agreements, (B) any claim
that an employee has been misclassified as an independent contractor under an employment or service relationship or otherwise,
including any claims related to failure to withhold income taxes or to pay required pension and social contributions, (C) the Company
Options issued to TT Metals Oy or the exercise thereof, or (D) any amounts, including any amount of any transaction bonus, paid
or to be paid to the employees or consultants of the Company or its Subsidiaries arising out of or relating to the execution and
delivery of this Agreement or the consummation of the transactions thereunder, and any Taxes, withholdings, pension contributions,
social security payments or other payments related thereto;

 

(v) any breach of Section
2.20 (Anti-Corruption Laws), solely to the extent such breaches relate to Russia, Uruguay or Brazil; and

 

(vi) the Estonian Share
Loss.

 

Any knowledge of Purchaser based on due diligence
investigations, any statement in the Company Disclosure Schedules or the Shareholder Disclosure Schedules or otherwise does not
limit the Purchaser Indemnitees right to special indemnity under this Section 8.2 and the limitations set out in Sections
8.2(d) and 8.2(e) do not apply hereto.

 

    	 	-50-	 

    	 	 	 

    

 

(b) Purchaser shall indemnify
and hold harmless the Shareholders against any Losses, Liability, damage, penalty, fine, Tax, cost or expense, including reasonable
legal expenses and costs associated therewith, which he, she or it may suffer, sustain or become subject to as the result of (i)
a breach by Purchaser of any representation or warranty set forth in Article IV, or (ii) the breach by Purchaser of any
covenant or agreement made by Purchaser contained in this Agreement or any document delivered by or on behalf of Purchaser at or
prior to the Closing.

 

(c) For the purposes of Section
8.2(a) and Section 8.2(b), in determining whether there has been a breach of any representation or warranty, and in
calculating the amount of any Loss with respect to any such breach, all qualifications in such representation or warranty referencing
the terms “material,” “materiality,” “Material Adverse Effect” or other terms of similar import
or effect shall be disregarded, other than with respect to (i) Section 2.7(a) and Section 2.7(a) (first sentence),
and (ii) any defined term containing any such term in its title (e.g. “Material Contract”).

 

(d) If any Loss arises from
or relates to breach of a Fundamental Representation, the Purchaser Indemnitees shall be entitled to recover from each Shareholder
severally and not jointly for any Losses in excess of ten million US dollars ($10,000,000). Any such Losses, as well as any Losses
in respect of Section 8.2(a) (iv),(v), (vi) and (vii) shall be entirely satisfied by discounting the value of such
Losses from the aggregate Adjusted Milestone Consideration to be issued to the Shareholders pursuant to Section 1.5(b) (and
for the avoidance of doubt, no Shareholder shall be required to make any payment in cash to any Purchaser Indemnitee in satisfaction
of any such Losses, and no Purchaser Indemnitee, including no Purchaser Indemnitee that is not Purchaser, shall be entitled to
any other consideration from the Shareholders, notwithstanding that only Purchaser is the direct beneficiary of the reduction in
Adjusted Milestone Consideration).

 

(e) Any Person making a claim
for indemnification under this Article VIII (an “Indemnified Party”) must give the indemnifying Party
(the “Indemnifying Party”) written notice of such claim describing such claim and the nature and amount of the
Loss, to the extent that the nature and amount thereof are determinable at such time (a “Claim Notice”) within
forty-five (45) days after the Indemnified Party receives notice from a third party with respect to any matter which may give rise
to a claim for indemnification against the Indemnifying Party (a “Third Party Claim”) or otherwise discovers
the Liability, obligation or facts giving rise to such claim for indemnification; provided, that the failure to notify or delay
in notifying the Indemnifying Party will not relieve the Indemnifying Party of its obligations under this Section 8.2, except
to the extent such claim is materially prejudiced as a result thereof; and provided further, that any claim to be made against
Purchaser on behalf of any Shareholder must be made by the Shareholders’ Representative, and in such case Purchaser shall
be entitled to only give notices to, and to exclusively negotiate with, the Shareholders’ Representative in respect of such
claim. Within thirty (30) days after receipt of a Claim Notice with respect to a Third Party Claim, the Indemnifying Party may,
with the consent of the Indemnified Party in its sole discretion, assume the defense of such matter; provided, that (i) the Indemnifying
Party shall retain counsel reasonably acceptable to the Indemnified Party, (ii) the Indemnified Party may participate in the defense
of such claim, at its own expense, with co-counsel of its choice to the extent that the Indemnified Party believes, in its sole
discretion, that such matter shall affect its ongoing business and (iii) the Indemnifying Party may not consent to the entry of
any judgment with respect to the matter or enter into any settlement with respect to the matter which does not include a provision
whereby the plaintiff or claimant in the matter releases the Indemnified Party from all Liability and obligations with respect
thereto. Otherwise, the Indemnified Party may defend against the matter in any manner that it reasonably may deem appropriate provided
that the Indemnified Party may not consent to the entry of any judgment with respect to the matter or enter into any settlement
with respect to the matter without the prior written consent of the Indemnifying Party (such consent not to be unreasonably withheld,
conditioned or delayed). The Indemnified Party shall cooperate with the Indemnifying Party in all matters arising under this Section
8.2.

 

    	 	-51-	 

    	 	 	 

    

 

(f) In addition to the above,
the following limitations and qualifications shall apply:

 

(i) no liability for any
Shareholder shall arise if and to the extent that any Claim occurs as a result of: (i) any change in accounting policies after
the Closing Date; (ii) any legislation not in force at Closing, or which takes effect retroactively; and (iii) any increase in
the tax rate or any change in the practice of any relevant tax authorities after Closing;

 

(ii) no liability shall
arise for any consequential, indirect or special damages (including for the avoidance of doubt loss of profit);

 

(iii) any loss which is
contingent shall not constitute a Loss and no Claim shall be made in relation to such loss, unless and until such contingent loss
becomes an actual loss;

 

(iv) any Loss shall be
computed on a USD-for-USD basis without regard to any price earnings multiple, discount rates/yields or any other valuation mechanism
employed by Purchaser in calculating the total aggregate amount of the Aggregate Closing Consideration and the Purchaser Shares;

 

(v) no Loss would have
occurred but for anything done or omitted to be done pursuant to this Agreement or otherwise at the written request or with written
approval of Purchaser or its Affiliate or representative; and

 

(vi) Purchaser shall use
its reasonable efforts to mitigate any Loss.

 

(g) For the avoidance of
doubt, Purchaser is not entitled to recover more than once in respect of the same Loss (whether based on the same or different
representation or warranty or other provision of this Agreement or any other agreement entered into in connection with this Agreement).

 

(h) All indemnification payments
made by the Shareholders pursuant to this Section 8.2 will be deemed to be adjustments to the Aggregate Closing Consideration.

 

(i) For purposes of calculating
the amount of Loss incurred by an Indemnified Party for purposes of this Agreement, such amount shall be reduced by (i) the amount
of any insurance proceeds actually paid to such Indemnified Party in respect of such Loss (other than proceeds from the R&W
Policy), net of any deductible amounts, the Indemnified Party’s reasonable estimate of any increase in premiums related thereto
and any costs associated with obtaining such insurance proceeds, and (ii) the amount of any indemnification, contribution, and
other similar payment proceeds actually covered by such Indemnified Party in respect of such Loss net of any costs associated with
obtaining such proceeds.

 

(j) Other than (i) in the
case of fraud or willful misconduct, by signing this Agreement or (ii) to enforce rights of the Company or Purchaser under any
written agreements with an employee or consultant of the Company, Purchaser waives any right to raise any claim against any employee
or consultant of the Company in connection with this Agreement or the pre-signing disclosure process relating to this Agreement.

 

    	 	-52-	 

    	 	 	 

    

 

(k) Each of the Parties acknowledges
and agrees that the indemnification provisions set forth in this Section 8.2 shall be the exclusive remedy of the Parties
with respect to any breaches of the representations, warranties, covenants or agreements set forth in this Agreement, it being
agreed that nothing herein shall limit or impair any Party’s right to obtain specific performance or other injunctive relief
with respect to any such breach of any such representation, warranty, covenant or agreement.

 

(l) Purchaser and the Shareholders
acknowledge and agree that any claim or right of Purchaser under any legislation anywhere in world which would otherwise permit
Purchaser to reject the Company Shares or annul or otherwise rescind this Agreement or render the Transactions void ab initio (including
for the avoidance of doubt a purchaser’s rights under the Finnish Sale of Goods Act (355/1987)) and any rights or remedies
available to a purchaser thereunder shall be expressly excluded and irrevocably waived by Purchaser.

 

8.3 R&W Policy.

 

(a) The Parties acknowledge
that Purchaser has obtained the R&W Policy from the Insurer to protect Purchaser against Losses incurred by Purchaser as a
result of any breach by the Company or the Shareholders of certain representations and warranties set forth in Article II
and Article III. Subject to the terms and conditions of this Section 8.3, from and after the Closing any Loss that
Purchaser may suffer, sustain or become subject to, as a result of a breach by the Company or any Shareholder of any of the representations
or warranties set forth in Article II or Article III (whether or not arising out of a third party claim) shall be
satisfied from the R&W Policy, provided that with respect to Losses resulting from (a breach by the Company or any Shareholder
of a Fundamental Representation, such Losses shall be satisfied first from the R&W Policy, but shall be recoverable in excess
of the R&W Policy as provided in Section 8.2(d), and (ii) in the case of fraud, gross negligence or willful misconduct
this Section 8.3 shall not apply.

 

(b) Neither any Shareholder
nor the Company or any Subsidiary shall have any obligation to pay any part of the insurance premium payable in respect of the
R&W Policy or to contribute to any amount of retention or deductible payable by Purchaser under the R&W Policy.

 

(c) Purchaser further acknowledges
and agrees that the provisions of Section 8.2 and this Section 8.3 shall apply regardless of whether:

 

(i) Purchaser obtains at
or following the Closing maintains the R&W Policy;

 

(ii) the R&W Policy
is revoked, cancelled or modified in any manner after issuance; or

 

(iii) Purchaser makes any
claim under the R&W Policy and such claim is denied by the Insurer.

 

8.4 Third party claims.
Upon receipt of notice by Purchaser of any Third Party Claim, Purchaser shall, in order to maintain the right to bring
a claim against any Shareholder under Section 8.2(d) and receive any compensation from such Shareholder:

 

(a) as soon as practicable,
but in no event later than 90 days after becoming aware of such Third Party Claim, provide written notice thereof to the Shareholders’
Representative; provided that failure to give such notice shall not affect the right to indemnification provided hereunder
except to the extent the interests of the applicable Indemnitors shall have been materially prejudiced as a result of such failure;

 

    	 	-53-	 

    	 	 	 

    

 

(b)
at the cost of the Shareholders, take any commercially reasonable action requested by the Shareholders’ Representative in
connection with defending such Third Party Claim, provided, however, that Purchaser may exercise its sole discretion in
rejecting requests to make its senior executives available;

 

(c)
not settle, compromise or discharge such Third Party Claim without obtaining the prior written consent of the Shareholders’
Representative, such consent not to be unreasonably withheld or delayed,; and

 

(d)
at the cost of the Shareholders, give the Shareholders or the Shareholders’ duly authorized representatives, access to the
personnel of Purchaser and to any relevant premises, accounts, documents and records during normal business hours, to enable the
Shareholders, or the Shareholders’ duly authorized representatives, to examine such claim, premises, accounts, documents
and records and to take copies or photocopies thereof solely for the purpose of analyzing the merits of such Third Party Claim.

 

8.5
Shareholders’ Representative.

 

(a)
The Shareholders hereby appoint the Shareholders’ Representative as their agent and attorney-in-fact, as their sole representative
for and on behalf of the Shareholders and to receive and distribute cash payments, to give and receive notices and communications,
and otherwise in satisfaction of indemnification claims by any Indemnified Party pursuant to this Article VIII, to object
to such payments, to agree to, negotiate, enter into settlements and compromises of, and demand arbitration and comply with orders
of courts and awards of arbitrators with respect to, any indemnification claim hereunder or any dispute between any Indemnified
Party and any Indemnifying Party, in each case relating to this Agreement or the Transactions, and to take all other actions that
are either (i) necessary or appropriate in the judgment of the Shareholders’ Representative for the accomplishment of the
foregoing or (ii) specifically mandated by the terms of this Agreement. The Shareholders’ Representative may not be removed
other than with the consent of a majority of the Shareholders. No bond shall be required of the Shareholders’ Representative,
and the Shareholders’ Representative shall not receive any compensation for its services. Other than in connection with
any claim pursued by an Indemnified Party directly against a Shareholder, notices or communications to or from the Shareholders’
Representative shall constitute notice to or from the Shareholders.

 

(b)
A decision, act, consent or instruction of the Shareholders’ Representative, including an amendment, extension or waiver
of any provision of this Agreement pursuant to Section 9.4 (Extension; Waiver) and Section 10.10 (Amendment
and Modification) and shall constitute a decision of the Shareholders and shall be final, binding and conclusive upon the
Shareholders, and Purchaser may rely upon any such decision, act, consent or instruction of the Shareholders’ Representative
as being the decision, act, consent or instruction of the Shareholders. Purchaser is hereby relieved from any liability to any
person for any acts done by it in accordance with such decision, act, consent or instruction of the Shareholders’ Representative.

 

(c)
The Shareholders’ Representative shall distribute or cause to be distributed, in each case in accordance with the Distribution
Schedule: (i) to each Shareholder the portion of the Adjusted Cash Consideration payable to such Shareholder in respect of such
Shareholder’s Company Shares, pursuant the Distribution Schedule; and (ii) any other monies that may be distributed to the
Shareholders after the Closing on account of their Company Shares.

 

    	 	-54-	 

    	 	 	 

    

 

(d)
The Shareholders’ Representative may rely and act upon any statement, report or opinion prepared by or any advice received
from the auditors, counsel or other professional advisors of the Shareholders’ Representative. Absent fraud or willful misconduct,
the Shareholders’ Representative shall not be responsible or held liable, in each case to any Shareholders for any loss
or damage resulting from so relying or from acting in accordance with this Agreement as the Shareholders’ Representative.
Each Shareholder agrees (i) to jointly and severally indemnify and hold harmless the Shareholders’ Representative and its
officers, directors and security holders from and against any and all losses, claims, damages, costs, expenses (including, without
limitation, legal fees and expenses on a full indemnity basis) and liabilities (collectively, such losses, claims, damages, costs,
expenses and liabilities being the “Indemnified Liabilities”) to which Shareholders’ Representative may
become subject, insofar as such Indemnified Liabilities (or actions, suits, or proceedings, including any inquiry or investigation
or claim, in respect thereof) arise out of, in any way relate to, or result from its acting as Shareholders’ Representative
hereunder and (ii) to reimburse the Shareholders’ Representative and its officers, directors and security holders upon demand
for all legal or other expenses, if any, incurred in connection with its acting as Shareholders’ Representative, other than
in the case of fraud, gross negligence or willful misconduct, provided that the Shareholders’ Representative has
acted in compliance with this Agreement.

 

Article
IX

TERMINATION; EXCLUSIVITY; Extension; Waiver.

 

9.1
Termination. Except as provided in Section 9.2, at any time prior to the Closing, this Agreement may be terminated
and the Transactions abandoned:

 

(a)
by mutual written agreement of Purchaser and the Company;

 

(b)
by either Purchaser or the Company if the Closing shall not have occurred by the forty-five (45) days after the date of this Agreement
or such other date that Purchaser and the Company may agree upon in writing (the “Termination Date”) provided,
however, that the right to terminate this Agreement under this Section 9.1(b) shall not be available to the Company
if a breach of any representation, warranty, covenant or agreement contained in this Agreement by the Company has resulted in
the failure of the Closing to occur before the Termination Date; and provided further, that the right to terminate this
Agreement under this Section 9.1(b) shall not be available to Purchaser if the breach of any representation, warranty,
covenant or agreement contained in this Agreement by Purchaser has resulted in the failure of the Closing to occur before the
Termination Date;

 

(c)
by either Purchaser or the Company, if any Legal Requirement preventing the Closing or the consummation of the Transactions shall
have become final and nonappealable;

 

(d)
by Purchaser, if (i) the Company shall have breached any representation, warranty, covenant or agreement contained herein and
such breach shall not have been cured within ten (10) days after receipt by the Company of written notice of such breach (provided,
however, that no such cure period shall be available or applicable to any such breach which by its nature cannot be cured
or if such breach was intentional) and if not cured within such ten (10) day period and at or prior to the Closing, such breach
would result in the failure of any of the conditions set forth in Section 7.2 (Conditions to Obligations of Purchaser)
to be satisfied, or (ii) the Company shall have breached Section 9.3 (Exclusivity); or

 

(e)
by the Company, if Purchaser shall have breached any representation, warranty, covenant or agreement contained herein and such
breach shall not have been cured within ten (10) days after receipt by Purchaser of written notice of such breach (provided,
however, that no such cure period shall be available or applicable to any such breach which by its nature cannot be cured
or if such breach was intentional) and if not cured within such ten (10) day period and at or prior to the Closing, such breach
would result in the failure of any of the conditions set forth in Section 7.3 (Conditions to Obligations of the Company
and the Shareholders) to be satisfied.

 

    	 	-55-	 

    	 	 	 

    

 

The
party seeking to terminate this Agreement pursuant to this Section 9.1 (other than Section 9.1(a)) shall give written
notice of such termination to the other party.

 

9.2
Effect of Termination.

 

(a)
In the event of termination of this Agreement as provided in Section 9.1, this Agreement shall forthwith become void and
there shall be no Liability or obligation on the part of Purchaser, the Company or the Shareholders, or their respective officers,
directors, shareholders, Affiliates or representatives except as provided in this Section 9.2, if applicable; provided,
however, that that (a) the provisions of this Section 9.2, Sections 6.2 (Confidentiality), Section
6.4 (Third Party Expenses) and Article X (General Provisions) and the Confidential Disclosure Agreement
shall remain in full force and effect and survive any termination of this Agreement and (b) nothing herein shall relieve any party
hereto from Liability in connection with any breach of such party’s representations, warranties or covenants contained herein.

 

(b)
If this Agreement is terminated by Purchaser pursuant to Section 9.1(d)(ii) and the Company and/or the Shareholders consummate
an Alternative Transaction, then the Company shall promptly reimburse Purchaser upon request for all out-of-pocket fees, costs
and expenses (including all attorneys’ fees, accountants’ fees, and investment bankers’ and advisors’
fees) that have been incurred or paid by or on behalf of Purchaser or Purchaser’s Affiliates in connection with the preparation,
negotiation and performance of this Agreement and the due diligence investigation conducted with respect to the Company and its
Subsidiaries.

 

9.3
Exclusivity.

 

(a)
From and after the date hereof until the Closing or termination of this Agreement pursuant to Section 9.1 (Termination)
neither the Company nor the Shareholders’ Representative will, nor will it authorize or permit any of its respective representatives
or shareholders to, directly or indirectly, (i) solicit, initiate, facilitate, support or induce the making, submission or announcement
of any inquiry, expression of interest, proposal or offer that constitutes, or would reasonably be expected to lead to, an Acquisition
Proposal, (ii) enter into, participate in, maintain or continue any communications (except solely to provide written notice as
to the existence of these provisions) or negotiations regarding, or deliver or make available to any Person any non-public information
with respect to, or take any other action regarding, any inquiry, expression of interest, proposal or offer that constitutes,
or would reasonably be expected to lead to, an Acquisition Proposal, (iii) agree to, accept, approve, endorse or recommend (or
publicly propose or announce any intention or desire to agree to, accept, approve, endorse or recommend) any Acquisition Proposal,
(iv) enter into any letter of intent or any other Contract contemplating or otherwise relating to any Acquisition Proposal, or
(v) submit any Acquisition Proposal (other than to the extent contemplated by this Agreement or the Transactions) to the vote
of any Shareholder. The Company and the Shareholders’ Representative will immediately cease and cause to be terminated any
and all existing activities, discussions or negotiations with any Persons conducted prior to or on the date hereof with respect
to any Acquisition Proposal. If any Shareholder or the Shareholders’ Representative, whether in his, her or its capacity
as such or in any other capacity, takes any action that the Company or the Shareholders’ Representative is obligated pursuant
to this Section 9.3 to cause such Shareholder not to take, then the Company or the Shareholders’ Representative shall
be deemed for all purposes of this Agreement to have breached this Section 9.3.

 

(b)
The Company or the Shareholders’ Representative, as the case may be, shall immediately notify Purchaser orally and in writing
after receipt by the Company or the Shareholders’ Representative (or, to the Knowledge of the Company or the knowledge of
the Shareholders’ Representative, by any of its respective representatives or shareholders), of (i) any Acquisition Proposal,
(ii) any inquiry, expression of interest, proposal or offer that constitutes, or would reasonably be expected to lead to, an Acquisition
Proposal, (iii) any other notice that any Person is considering making an Acquisition Proposal, or (iv) any request for nonpublic
information relating to the Company or for access to any of the properties, books or records of the Company by any Person other
than Purchaser not in the ordinary course of business consistent with past practice or that the Company or the Shareholders’
Representative reasonably believes could not be reasonably be expected to lead to an Acquisition Proposal.

 

    	 	-56-	 

    	 	 	 

    

 

9.4
Extension; Waiver. At any time prior to the Closing, Purchaser, on the one hand, and the Company and the Shareholders,
on the other hand, may, to the extent permitted under any applicable Legal Requirements, (a) extend the time for the performance
of any of the obligations of the other party hereto, (b) waive any inaccuracies in the representations and warranties made to
such party contained herein or in any document delivered pursuant hereto, and (c) waive compliance with any of the covenants,
agreements or conditions for the benefit of such party contained herein. Any agreement on the part of a party hereto to any such
extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party. For purposes
of this Section 9.4, the Shareholders agree that any extension or waiver signed by the Shareholders’ Representative
shall be binding upon and effective against all Shareholders whether or not they have signed such extension or waiver.

 

Article
X

GENERAL PROVISIONS

 

10.1
Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on
the date of delivery if delivered personally, (b) if by facsimile, upon electronic confirmation of receipt by facsimile or, if
not transmitted on a Business Day, the first Business Day following transmission, provided that a copy of such notice or
other communication is promptly mailed by registered or certified mail, return receipt requested, postage prepaid, following the
transmission of such facsimile, and sent by email, with the subject line “Project Pecan Notice”, (c) on the first
(1st) Business Day following the date of dispatch if delivered utilizing a next-day service by a nationally recognized
next-day courier (or in the case of any recipients sending or receiving notices outside of the United States, then on the second
(2nd) Business Day following the date of dispatch) or (d) on the earlier of confirmed receipt or the fifth (5th)
Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid.
All notices hereunder shall be delivered to the addresses set forth below:

 

(a)
if to Purchaser, (or to the Company after the Closing) :

 

Marrone
Bio Innovations, Inc.

1540 Drew Avenue

Davis, CA 95618

Telephone: 530-302-8289

Facsimile: 530-302-0189

Attention: Linda V. Moore, General Counsel

 

E-mail:
lmoore@marronebio.com

 

with
a copy to (which copy shall not constitute notice):

 

Morrison
& Foerster LLP

425
Market Street

San
Francisco, California 94105

Attention:
Alfredo Silva

 

Email:
ASilva@mofo.com

 

    	 	-57-	 

    	 	 	 

    

 

(b)
if to the Company (prior to Closing):

 

Pro
Farm Technologies Oy

Vantaankoskentie
14 A,

01670,
Vantaa

Attention: Matti Tiainen, CEO

 

Email:
matti.tiainen@profarm.org

 

with
a copy to (which copy shall not constitute notice):

 

HPP
Attorneys Limited

Bulevardi
1A,

00100,
Helsinki

Attention: Andrew Cotton, Partner

 

Email: Andrew.cotton@hpp.fi

 

with
a copy to the Shareholders’ Representative (which copy shall not constitute notice):

 

Matti
Tiainen

Vantaankoskentie
14 A,

01670,
Vantaa
 

Email: matti.tiainen@profarm.org

 

(c)
if to the Shareholders’ Representative:

 

Matti
Tiainen

Vantaankoskentie
14 A,

01670,
Vantaa

 

Email:
matti.tiainen@profarm.org

 

10.2
Interpretation. The descriptive headings herein are inserted for convenience of reference only and are not intended
to be part of or to affect the meaning or interpretation of this Agreement. All references in this Agreement to Articles, Sections,
Subsections, Annexes, Exhibits and Schedules are references to Articles, Sections, Subsections, Annexes, Exhibits and Schedules,
respectively, in and to this Agreement, unless otherwise specified. All words used in this Agreement will be construed to be of
such gender or number as the circumstances require. The word “or” is not exclusive. The words “include”
or “including” mean “include, without limitation” or “including, without limitation,” as the
case may be, and the language following “include” or “including” shall not be deemed to set forth an exhaustive
list. The words “made available” or words of similar import mean that, on or before 5:00 p.m. Pacific time
on the third (3rd) Business Day immediately preceding the date of this Agreement, the Company has posted complete and
correct copies of such materials to the virtual data room managed by the Company, and Purchaser and its representatives shall
have been granted access to such virtual data room and such materials prior to such time. Any capitalized terms used in any Annex,
Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. All Annexes, Exhibits
and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth
herein.

 

    	 	-58-	 

    	 	 	 

    

 

10.3
Entire Agreement; Assignment; Successors. This Agreement and the other documents and agreements contemplated hereby
(a) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof and supersede
all other prior and contemporaneous agreements and understandings, both written and oral, among the parties with respect to the
subject matter hereof; provided, however, that the Confidential Disclosure Agreement shall not be superseded by
this Agreement and shall remain in effect in accordance with its terms, subject to the provisions of Section 6.2 (Confidentiality)
herein; and (b) may not be assigned by operation of law or otherwise; provided, however, that Purchaser may assign
any or all of its rights and obligations under this Agreement to any Affiliate. Any purported assignment of this Agreement in
contravention of this Section 10.3 shall be null and void and of no force or effect. Subject to the preceding sentences
of this Section 10.3 this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and
their respective successors and assigns. In the event of any conflict or inconsistency between the terms of this Agreement and
the terms of any of the other documents or agreements contemplated hereby, the terms of this Agreement shall prevail.

 

10.4
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced
by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full
force and effect to the fullest extent permitted by applicable Legal Requirements, so long as the economic or legal substance
of the transaction contemplated by this Agreement is not affected in any manner materially adverse to any party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good
faith to modify this Agreement so as to effect the original intent of the parties as closely as possible, in a mutually acceptable
manner, in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the fullest
extent possible.

 

10.5
Specific Performance and Other Remedies. Each party to this Agreement acknowledges and agrees that the other parties
hereto would be irreparably damaged in the event that any of the terms or provisions of this Agreement are not performed in accordance
with their specific terms or otherwise are breached. Therefore, notwithstanding anything to the contrary set forth in this Agreement,
each party to this Agreement hereby agrees that the other parties hereto shall be entitled to obtain an injunction or injunctions
to prevent breaches of any of the terms or provisions of this Agreement or specific performance by any other party under this
Agreement without the necessity of proving the inadequacy of money damages as a remedy, and each party hereto hereby agrees to
waive the defense (and not to interpose as a defense or in opposition) in any such suit that the other parties hereto have an
adequate remedy at law, and hereby agrees to waive any requirement to secure or post any bond in connection with obtaining such
relief. The equitable remedies described in this Section 10.5 shall be in addition to, any other remedies available to
the parties under this Agreement.

 

10.6
Governing Law. This Agreement shall be deemed to be made and in all respects shall be interpreted, construed and
governed by and in accordance with the applicable Legal Requirements of the State of Delaware without regard to the conflicts
of laws principles thereof.

 

10.7
Submission to Jurisdiction. Except as otherwise provided in Section 1.4(c), the parties hereby irrevocably
submit to the jurisdiction of the courts of the State of Delaware and the federal courts of the United States of America located
in the State of Delaware solely in respect of the interpretation and enforcement of the provisions of this Agreement, and in respect
of the transactions contemplated hereby and thereby, and hereby waive, and agree not to assert, as a defense in any Action for
the interpretation or enforcement of this Agreement or of any such other document, that it is not subject thereto or that such
Action may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this
Agreement or any such other document may not be enforced in or by such courts. The parties hereby consent to and grant any such
court jurisdiction over the Person of such parties and over the subject matter of such dispute and agree that mailing of process
or other papers in connection with any such Action in the manner provided in Section 10.1 (Notices) as permitted
by applicable Legal Requirements, shall be valid and sufficient service thereof.

 

    	 	-59-	 

    	 	 	 

    

 

10.8
Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LEGAL
REQUIREMENTS ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER
OR IN CONNECTION WITH THIS AGREEMENT, AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY. Each of the parties
hereto (a) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that
such other party would not, in the event of litigation, seek to enforce that foregoing waiver and (b) acknowledges that it and
the other parties hereto have been induced to enter into this Agreement and the documents referred to in this Agreement, and the
transactions contemplated hereby and thereby, as applicable, by, among other things, the mutual waivers and certifications in
this Section 10.8.

 

10.9
No Third-Party Beneficiaries. Except for the provisions set forth in Article VIII (Indemnification)
and for Translink’s rights to receive Purchaser Shares pursuant to Section 1.3(a) and Section 1.5, this Agreement
shall be binding upon and inure solely to the benefit of each party hereto and its successors and permitted assigns and nothing
in this Agreement is intended to or shall confer upon any other Person any legal or equitable rights, benefits or remedies of
any nature whatsoever under or by reason of this Agreement.

 

10.10
Amendment and Modification. This Agreement may be amended, modified or supplemented by the parties at any time;
provided that this Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise,
except by an instrument in writing specifically designated as an amendment hereto, signed by each of the parties.

 

10.11
Attorneys’ Fees. Except as otherwise provided herein, in the event an Action is brought against a party hereto
relating to this Agreement or to enforce or interpret any provision of this Agreement, the prevailing party, or in the event that
there is no prevailing party, then the substantially prevailing party, shall be entitled to recover reasonable attorneys’
fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled).

 

10.12
Fees and Expenses. Except as otherwise provided, all fees and expenses incurred in connection with or related to
this Agreement and the other documents and agreements contemplated hereby, and the transactions contemplated hereby and thereby
shall be paid by the party incurring such fees or expenses, whether or not such transactions are consummated. For the avoidance
of doubt, the costs of obtaining the R&W Policy (including any premiums, commissions, taxes and other charges, fees or expenses
of the underwriter(s) thereof) shall be borne by Purchaser.

 

10.13
Waivers. No failure or delay of a party in exercising any right or remedy hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce
such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right
or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which
they would otherwise have hereunder. Any agreement on the part of any party to any such waiver shall be valid only if set forth
in a written instrument executed and delivered by such party, and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given.

 

10.14
No Presumption Against Drafting Party. The parties agree that they have been represented by counsel during the negotiation
and execution of this Agreement and, therefore, waive the application of any applicable Legal Requirements or rule of construction
providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.

 

10.15
Counterparts; Electronic Signature. This Agreement may be executed in multiple counterparts, each of which shall
be deemed to be an original but all of which shall constitute one and the same agreement. This Agreement may be executed by facsimile
or electronic (.pdf) signature and a facsimile or electronic (.pdf) signature shall constitute an original for all purposes.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 	-60-	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, Purchaser, the Company, the Shareholders and the Shareholders’ Representative have caused this Agreement
to be executed as of the date first written above.

 

	 	MARRONE BIO INNOVATIONS, INC.
	 	 	 
	 	By:	/s/
    James B. Boyd
	 	Name:	James
    B. Boyd
	 	Title:	President
    and Chief Financial Officer

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	PRO FARM TECHNOLOGIES OY

	 	 
	 	By:	/s/
    Fredrik Engvall               
	 	Name:	Fredrik
    Engvall
	 	Title:	Sole
    Board member
	 	 	 
	 	Address:  Vantaankoskentie 14 A, 01670 Vantaa, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	AGRIMAX VENTURES PTE
    LTD 
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address:  22 North Canal Road, #02-00, 

Singapore 048834

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	TT METALS OY
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address:  Jarintie 4B, 01840 Klaukkala, Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	STOLT
CONSULTING AB

	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:
    	Andrew
    Cotton
	 	Title:
    	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address: BOX 1093, 26222 Ängelhom, Sweden

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	MIKAELS OÜ
	 	 	 
	 	By:	/s/
    Richard Relander
	 	Name:	Rikard
    Relander
	 	Title:	Director
	 	 	 
	 	Address:  Viru Väljak 2, 10111 Tallinn, Estonia

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	GRANNEFELT FINANCE OY
	 	 	 
	 	By:	/s/
    Eva Grannenfelt
	 	Name:	Eeva
    Grannenfelt
	 	Title:	Managing
    Partner
	 	 	 
	 	Address:  Salomonkatu 17 A, 3. krs, 00100 

Helsinki, Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	MATFRED HOLDING OÜ
	 	 	 
	 	By:	/s/
    Matti Tiainen
	 	Name:	Matti
    Tiainen
	 	Title:	Director
	 	 	 
	 	Address:  Pärnu mnt 10, 10148 Tallinn, Estonia

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	KJ-CAPITAL OY
	 	 	 
	 	By:	/s/
    Jens Kyllönen
	 	Name:	Jens
    Kyllönen
	 	Title:	Director                  
	 	 	 
	 	Address: Lönnrotinkatu 3 A 14, 00120 Helsinki, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	LUCROSUM CAPITAL OY
	 	 	 
	 	By:	/s/
    Esko Lahtinen
	 	Name:	Esko
    Lahtinen
	 	Title:	Director
	 	 	 
	 	Address:  Suezinkatu 7 b 35, 00220 Helsinki, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	ANITA PALDANIUS
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:
    	Attorney-at-Law,
    by proxy 
	 	 	 
	 	Address:
Eerikinkatu 15-17 c 39, 00100 Helsinki, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	MIKKO RINTA-JOUPPI
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:
    	Attorney-at-Law,
    by proxy 
	 	 	 
	 	Address:
    Lönnrotinkatu 28 B 28, 00180 Helsinki,

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	JN CAPITAL OY
	 	 	 
	 	By:	/s/
    Jussi Nevalinna
	 	Name:	Jussi
    Nevanlinna
	 	Title:	Director
	 	 	 
	 	Address:
    Neitsytpolku 1 b A 12, 00140 Helsinki, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	KORPI CAPITAL OY
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address:
    Pieni Roobertinkatu 13 b 26, 00130 

Helsinki, Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	WILHELM
VON FRECKELL
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address:  Södra Heikelvägen 8B, 02700 

Grankulla, Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	MAATILA VUORINEN OY
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address: Paimelantie 575, 17120 Paimela, 

Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	AENGSALV OY
	 	 	 
	 	By:	/s/
    Fredrik Engvall
	 	Name:	Fredrik
    Engvall
	 	Title:	Director
	 	 	 
	 	Address:  Mechelininkatu 15 B 34, 00100 

Helsinki, Finland

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	PERTTU JALKANEN
	 	 	 
	 	By:	/s/
    Andrew Cotton
	 	Name:	Andrew
    Cotton
	 	Title:	Attorney-at-Law,
    by proxy
	 	 	 
	 	Address: Carrer Llull 133M5, 08005 Barcelona, 

Spain

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

	 	SHAREHOLDERS’ REPRESENTATIVE
	 	 	 
	 	By:	/s/
    Matti Tiainen                                
	 	  	MATTI
    TIAINEN

 

[Signature
Page to Share Purchase Agreement]

 

    	 

    	 

    

 

ANNEX
0

CURRENT
SHAREHOLDERS AND CONVERSION SHAREHOLDERS

 

Current
Shareholders:

 

	 	●	TT
    Metals Oy
	 	●	Stolt
    Consulting AB
	 	●	Mikaels
    Oü Rekisterinumero
	 	●	Grannefelt
    Finance Oy
	 	●	Matfred
    Holding Oü
	 	●	KJ-Capital
    Oy
	 	●	Lucrosum
    Capital Oy
	 	●	Anita
    Paldanius
	 	●	Mikko
    Rinta-Jouppi 
	 	●	JN
    Capital Oy
	 	●	Korpi
    Capital Oy
	 	●	Wilhelm
    von Frenckell
	 	●	Maatila
    Vuorinen Oy 
	 	●	Aengsalv
    Oy
	 	●	Perttu
    Jalkanen

 

Conversion
Shareholders:

 

	 	●	TT
    Metals Oy
	 	●	Richard
    Gurney
	 	●	Agrimax
    Ventures

 

Shareholders
to execute Joinder:

 

	 	●	Estate
    of Igor Taganov (or heirs)

 

    	 	 	 

     

    

 

ANNEX
A

DEFINED
TERMS

 

“1933
Act” means the Securities Act of 1933, as amended.

 

“Acquisition
Proposal” means, with respect to the Company, any agreement, offer, proposal or bona fide indication of interest (other
than this Agreement or any other offer, proposal or indication of interest by Purchaser), or any public announcement of intention
to enter into any such agreement or of (or intention to make) any offer, proposal or bona fide indication of interest, relating
to, or involving: (i) any acquisition or purchase from the Company, or from any Shareholders, by any Person or Group of more than
a fifteen percent (15%) interest in the total outstanding voting securities of the Company or any merger, consolidation, business
combination or similar transaction involving the Company; (ii) any sale, lease, mortgage, pledge, exchange, transfer, license
(other than in the ordinary course of business consistent with past practice), acquisition, or disposition of more than fifteen
percent (15%) of the assets of the Company in any single transaction or series of related transactions; or (iii) any liquidation,
dissolution, recapitalization or other significant corporate reorganization of the Company, or any extraordinary dividend, whether
of cash or other property (any such transaction, an “Alternative Transaction”).

 

“Action”
means an action, audit, charge, claim, complaint, demand, grievance, hearing, inquiry, investigation, litigation, mediation, proceeding,
subpoena or suit, whether civil, criminal, administrative, judicial or investigative, whether formal or informal, whether public
or private, commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity or private arbitrator
or mediator.

 

“Adjusted
Annual EBITDA Milestone Consideration” means the Annual EBITDA Milestone Consideration, minus the percentage
equal to 2.0 divided by 9.3 multiplied by the Milestone Consideration Adjustment.

 

“Adjusted
Annual Total Revenue Milestone Consideration” means the Annual Total Revenue Milestone Consideration, minus the
percentage equal to 3.0 divided by 9.3 multiplied by the Milestone Consideration Adjustment.

 

“Adjusted
Cash Consideration” means the Initial Cash Consideration minus the Cash Consideration Adjustment, which the parties
agree equals $2,745,654.

 

“Adjusted
Closing Stock Consideration” means a total number of shares of Purchaser Common Stock equal to (A) (i) the Initial Closing
Stock Consideration minus the Closing Stock Consideration Adjustment, divided by (ii) $1.3952, rounded to the nearest share,
minus (B) the number of restricted stock units listed on Annex C, which the parties agree equals 12,766,851 shares
of Purchaser Common Stock.

 

“Adjusted
[***] Milestone Consideration” means the [***] Milestone Consideration, minus the percentage equal
to 3.0 divided by 9.3 multiplied by the Milestone Consideration Adjustment.

 

“Adjusted
Debt and Equity Milestone Consideration” means the Debt and Equity Milestone Consideration, minus the percentage
equal to 1.3 divided by 9.3 multiplied by the Milestone Consideration Adjustment.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly, through one or more intermediaries controls,
is controlled by or is under common control with the first-mentioned Person. For the purposes of this definition, “control,”
including the terms “controlled by” and “under common control with,” means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through
the ownership of voting securities, as trustee or executor, as general partner or managing member, by Contract or otherwise, including
the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar
body governing the affairs of such Person.

 

    	 	-A-1-	 

     

    

 

“Aggregate
Closing Consideration” means the Adjusted Cash Consideration plus the Adjusted Closing Stock Consideration.

 

“Agrimax
Convertible Loan” means the convertible loan held by Agrimax Ventures PTY.

 

“Anderson
Loan Documents” means the Loan Agreement and the Security Agreement, each dated April 8, 2019 and by and between Mr.
Dwight Anderson and the Company.

 

“Annual
EBITDA Milestone Consideration” means $2,000,000.

 

“Annual
Total Revenue Milestone Consideration” means $3,000,000.

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks are open for business in both San Francisco, California
and Helsinki, Finland between the hours of 8:00 a.m. and 5:00 p.m. local time.

 

“Cash”
means the aggregate amount of all unrestricted cash and cash equivalents of the Company and each of its Subsidiaries.

 

“COBRA”
means Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Company
Charter” means the Articles of Association of the Company as per August 6, 2019.

 

“Company
Data” means any Personal Data or other data maintained by or for the Company or its Subsidiaries, including but not
limited to any data maintained or processed by Company or its Subsidiaries on behalf of their customers.

 

“Company
Intellectual Property” means any and all Intellectual Property and Intellectual Property Rights that are used, held
for use or practiced by the Company or any of its Subsidiaries, including any Intellectual Property and Intellectual Property
Rights incorporated into or otherwise used, held for use or practiced in connection with (or planned to be incorporated into or
otherwise used, held for use or practiced in connection with) any Company Products.

 

“Company
Option” means each option, warrant or other right to purchase Company Shares outstanding as of the date of this Agreement.

 

“Company
Products” means any and all products or services manufactured, designed, offered, licensed, provided, sold, distributed
or otherwise exploited by or for the Company or any of its Subsidiaries, and any and all products or services under design or
development (or already designed or developed) by or for the Company or any of its Subsidiaries, together with any related documentation,
materials, or information.

 

    	 	-A-2-	 

     

    

 

“Company
Shares” means all the issued and outstanding shares of the Company as at the date of this Agreement.

 

“Consultancy
Agreements” means the consultancy agreements between the Company and TT Metals Oy dated August 1, 2017, the Company
and Dandy Group Oy dated September 1, 2017, and the Company and Aengsalv Oy dated September 1, 2017.

 

“Contract”
means any contract, agreement, instrument, option, lease, license, sales and purchase order, warranty, note, bond, mortgage, indenture,
obligation, commitment, binding application, arrangement or understanding, whether written or oral, express or implied, in each
case as amended and supplemented from time to time.

 

“Convertible
Loans” means the convertible loan held by Cork Agriculture and the Agrimax Convertible Loan.

 

“Data
Protection Requirements” means all applicable Legal Requirements, relating to privacy, data protection and data security,
including with respect to the collection, storage, transmission, transfer (including cross-border transfers), disclosure and use
of Personal Data (including Personal Data of employees, contractors, and third parties).

 

“Debt
and Equity Milestone Consideration” means $1,300,000.

 

“Distributor”
means [***]. 

 

“Distributor Milestone Consideration” means
$3,000,000.

 

“Environmental
Law” means any applicable Legal Requirements relating to (i) releases or threatened releases of Hazardous Substances
or materials containing Hazardous Substances; (ii) the manufacture, handling, transport, use, treatment, storage or disposal of
Hazardous Substances or materials containing Hazardous Substances; or (iii) pollution or protection of the environment, health,
safety or natural resources.

 

“Governmental
Entity” means any federal, national, supranational, state, provincial, local or similar government, governmental, regulatory,
administrative or quasi-governmental authority, branch, office agency, commission or other body, or any court, tribunal, or arbitral
or judicial body (including any grand jury), whether domestic or foreign.

 

“Group”
has the meaning set forth in Section 13(d) of the 1934 Act, as amended, the rules and regulations thereunder and related case
law.

 

“Hazardous
Substances” means (i) those substances defined in or regulated under the Hazardous Materials Transportation Act, the
Resource Conservation and Recovery Act, the Comprehensive Environmental Response, Compensation and Liability Act, the Clean Water
Act, the Safe Drinking Water Act, the Atomic Energy Act, the Federal Insecticide, Fungicide, and Rodenticide Act and the Clean
Air Act, and their state counterparts, as each may be amended from time to time, and all regulations thereunder; (ii) petroleum
and petroleum products, including crude oil and any fractions thereof; (iii) natural gas, synthetic gas, and any mixtures thereof;
(iv) polychlorinated biphenyls, asbestos and radon; (v) any other pollutant or contaminant; and (vi) any substance, material or
waste regulated by any Governmental Entity pursuant to any Environmental Law.

 

    	 	-A-3-	 

     

    

 

“Indebtedness”
means the sum of the following, whether or not contingent or due and payable: (i) indebtedness of the Company or any of its Subsidiaries
for borrowed money, including convertible debt; (ii) obligations of the Company or any of its Subsidiaries evidenced by bonds,
debentures, notes or other similar instruments; (iii) obligations of the Company in respect of letters of credit, notes, bonds,
debentures, derivatives or other similar instruments (or reimbursement agreements in respect thereof); (iv) obligations of the
Company or any of its Subsidiaries to pay the deferred and unpaid purchase price of property or services, which purchase price
is due more than three (3) months after the date of placing such property in service or taking delivery thereof and title thereto
or the completion of such services, including deposits in transit and the cash used to purchase the shares in the Russian factory
(the “Russian Factory Share Payment”); (v) capitalized lease obligations of the Company or any of its Subsidiaries;
(vi) indebtedness of third parties which is either guaranteed by the Company or any of its Subsidiaries or secured by any Lien
on the assets of the Company or any of its Subsidiaries (including, for example, any factoring arrangements); (vii) any accounts
payable of the Company or any of its Subsidiaries that are more than 30 days overdue; (viii) any non-recurring provisions; (ix)
any contingent liabilities; (x) any salary accruals relating to Brazilian operations; (xi) Third Party Expenses other than the
Shared Third Party Expenses; (xii) any acceleration, termination fees, pre-payment fees, balloons or similar payments on any of
the foregoing; (xiii) all accrued interest on any of the foregoing; and (xiv) in the nature of a guarantee of any of the foregoing.
Notwithstanding the foregoing, “Indebtedness” shall not include (A) the Convertible Loans or (B) accounts payable,
accruals, and other liabilities not yet due that do not represent indebtedness and are incurred in the ordinary course of business
consistent with past practice, if less than 30 days overdue.

 

“Indemnified
Taxes” means (a) Taxes for which the Company or any Subsidiary is liable for any Pre-Closing Tax Period, (b) Taxes of
any Person for which the Company or any Subsidiary is liable by reason of a transaction, event or status occurring or existing
on or prior to the Closing Date, including as a result of such other Person failing to discharge its primary liability for Taxes
and (c) Taxes resulting from the transactions contemplated by this Agreement, including any Transfer Taxes for which the Indemnifying
Party is liable pursuant to Section 1.3. For purposes of the foregoing, in the case of a Straddle Period, the amount of
Taxes of the Company or a subsidiary that are allocable to the portion of a Straddle Period ending on and including the Closing
Date shall be determined by assuming that the Straddle Period consisted of two taxable years or periods, one of which ended at
the close of the Closing Date and the other of which began at the beginning of the day following the Closing Date and (i) Taxes
based on, or computed with respect to, net income or earnings, gross income or earnings, capital or net worth, or any other Taxes
resulting from or imposed on, sales, receipts, uses, transfers or assignments of property or other assets, payments or accruals
to other Persons (including wages) or any other similar transaction or transactions of the Company for the Straddle Period shall
be allocated between such two taxable years or periods on a “closing of the books basis” by assuming that the books
of the Company were closed at the close of the Closing Date and (ii) in the case of all other Taxes, such Taxes shall be apportioned
between such two taxable years or periods on a daily basis.

 

“Initial
Closing Stock Consideration” means Eighteen Million, Five Hundred Thousand Dollars ($18,500,000).

 

“Initial
Closing Cash Consideration” means Four Million Dollars ($4,000,000).

 

“Intellectual
Property” means any and all (i) technology, formulae, algorithms, procedures, processes, methods, techniques, know-how,
ideas, creations, inventions, discoveries, and improvements (whether patentable or unpatentable and whether or not reduced to
practice); (ii) technical, engineering, manufacturing, product, marketing, servicing, financial, supplier, personnel, and other
information and materials; (iii) customer lists, customer contact and registration information, customer correspondence, and customer
purchasing histories; (iv) specifications, designs, models, devices, prototypes, schematics, and development tools; (v) Software,
websites, content, images, graphics, text, photographs, artwork, audiovisual works, sound recordings, graphs, drawings, reports,
analyses, writings, and other works of authorship and copyrightable subject matter (collectively, “Works of Authorship”);
(vi) databases and other compilations and collections of data or information (collectively, “Databases”); (viii)
trademarks, service marks, logos, and design marks, trade dress, trade names, fictitious and other business names, and brand names,
together with all goodwill associated with any of the foregoing (collectively, “Trademarks”); (viii) domain
names, uniform resource locators and other names and locators associated with the Internet (collectively, “Domain Names”);
(ix) information and materials not generally known to the public, including trade secrets and other confidential and proprietary
information (“Trade Secrets”); and (x) tangible embodiments of any of the foregoing, in any form or media whether
or not specifically listed herein.

 

    	 	-A-4-	 

     

    

 

“Intellectual
Property Rights” means any and all rights, which may exist or be created under the laws of any jurisdiction in the world
(whether statutory, common law or otherwise), relating to, arising from, or associated with Intellectual Property, including:
(i) patents and patent applications, utility models and applications for utility models, inventor’s certificates, and invention
disclosure statements (collectively, “Patents”); (ii) copyrights and all other rights associated with respect
to Works of Authorship and all registrations thereof and applications therefor (including moral and economic rights, however denominated)
(including rights to modify the works and transfer the rights) (collectively, “Copyrights”); (iii) other rights
with respect to Software, including registrations thereof and applications therefor; (iv) industrial design rights and registrations
thereof and applications therefor; (v) rights with respect to Trademarks, and all registrations thereof and applications therefor;
(vi) rights with respect to Domain Names, including registrations thereof and applications therefor; (vii) rights with respect
to Trade Secrets, including rights to limit the use or disclosure thereof by any Person; (viii) rights with respect to Databases,
including registrations thereof and applications therefor; (ix) publicity and privacy rights, including all rights with respect
to use of a Person’s name, signature, likeness, image, photograph, voice, identity, personality, and biographical and personal
information and materials; and (x) any rights equivalent or similar to any of the foregoing.

 

“International
Trade Laws” means any law, regulations, order, permit or other decision or requirement having the force or effect of
law and as amended from time to time, of any Governmental Entity, concerning the importation, exportation, reexportation or transfer
of products (including hardware, software, technology and services), the terms and conduct of international transactions, including
without limitation all applicable export control, sanctions, and customs Laws in any jurisdiction in which the Company and its
subsidiaries conduct business.

 

“IRS”
means the United States Internal Revenue Service.

 

“Key
Individuals” means any director, officer or employee of the Company or any Subsidiary having a key position or management
responsibility at the Company or any Subsidiary, each of which is listed on Annex B.

 

“Knowledge
of the Company” or any similar phrase means, with respect to any fact or matter, the actual knowledge of the officers
of the Company and its Subsidiaries and the individuals set forth on Annex B, and the knowledge such individuals would
be expected to have after reasonable inquiry of the relevant matter.

 

“Labor
and Employment Laws” means all applicable Legal Requirements regarding labor and employment, including those related
to terms and conditions of employment, wages and hours, leaves of absence, collective bargaining, equal opportunity, occupational
health and safety, workers’ compensation, immigration, individual and collective consultation, notice of termination and
redundancy and the payment of social security and other Taxes, in each case.

 

“Leased
Real Property” means all Real Property leased, subleased or licensed to the Company or any of its Subsidiaries or which
the Company or any of its Subsidiaries otherwise has a right or option to use or occupy.

 

    	 	-A-5-	 

     

    

 

“Legal
Requirement” means any applicable Finnish, Estonian, European Union, United States or other federal, state, local or
other statute, law, treaty, ordinance, regulation, ruling, directive, rule, code, executive order, injunction, judgment, decree,
writ, order or other requirement, including any successor provisions thereof, of any Governmental Entity.

 

“Liability”
means, with respect to any Person, any debt, duty, liability or obligation of such Person of any kind, character or description,
whether known or unknown, absolute or contingent, matured or unmatured, asserted or unasserted, accrued or unaccrued, disclosed
or undisclosed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested,
executory, determined, determinable or otherwise and whether or not the same is required to be accrued on the financial statements
of such Person.

 

“Lien”
means any encumbrance, charge, claim, limitation, condition, equitable interest, mortgage, lien, option (including any right to
acquire, right of pre-emption or conversion), pledge, hypothecation, security interest, title retention, easement, encroachment,
exclusive license, right of first refusal or negotiation, adverse claim or restriction of any kind, including any restriction
on or transfer or other assignment, as security or otherwise, of or relating to use, quiet enjoyment, voting, transfer, receipt
of income or exercise of any other attribute of ownership, or any agreement to create any of the foregoing; provided, however,
that the term “Lien” shall not include (i) statutory liens for Taxes that are not yet delinquent (and for which
there are adequate accruals on the Financial Statements and Interim Financial Statements) and (ii) statutory or common law liens
in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies.

 

“Loss”
or “Losses” means any and all deficiencies, judgments, settlements, Actions, assessments, Liabilities, losses,
damages, Taxes, interest, fines, penalties, costs, expenses (including legal, accounting and other costs and expenses of professionals)
incurred in connection with investigating, defending, settling or otherwise satisfying any of the foregoing or matters arising
out of or relating to the foregoing, and in seeking indemnification therefor.

 

“Managing
Director Agreement” means the managing director agreement to be entered into by and between the Company and Matti Tiainen
on or about the date hereof.

 

“Material
Adverse Effect” with respect to any Person means any change, claim, event, violation, inaccuracy, circumstance or effect
(each, an “Effect”) that, individually or taken together with all other Effects, and regardless of whether
such Effect constitutes an inaccuracy in the representations or warranties made by, or a breach of the covenants, agreements or
obligations of, such Person herein, (i) is, or would reasonably be likely to be or become, materially adverse in relation to the
near-term or longer-term condition (financial or otherwise), assets (including intangible assets), Liabilities, business, prospects,
capitalization, employees, operations or results of operations of such Person and its subsidiaries, taken as a whole, except to
the extent that any such Effect directly results from: (A) changes in general economic conditions or in the capital or financial
markets, including changes in interest or exchange rates (provided that such changes do not affect such Person disproportionately
as compared to such Person’s competitors), (B) changes affecting the industry generally in which such Person operates (provided
that such changes do not affect such Person disproportionately as compared to such Person’s competitors), (C) changes in
applicable Legal Requirements, US GAAP or any authoritative interpretation thereof (provided that such changes do not affect such
Person disproportionately as compared to such Person’s competitors), or (D) any action expressly permitted or expressly
required by this Agreement, or (ii) adversely affects, or would reasonably be likely to adversely affect, such Person’s
ability to perform or comply with the covenants, agreements or obligations of such Person herein or to consummate the Transactions
in accordance with this Agreement or applicable Legal Requirements.

 

    	 	-A-6-	 

     

    

 

“Milestones”
means the Distributor Milestone, the Annual Total Revenue Milestone, the Debt and Equity Milestone, and the Annual EBITDA Milestone.

 

“Milestone
Share Price” means the greater of (1) the volume weighted average closing sale price of one share of Purchaser Common
Stock as reported on the Principal Market for the thirty (30) consecutive trading days ending on December 31 of the calendar year
with respect to which the Adjusted Milestone Consideration is due, or (2) $1.25 per share (as adjusted as appropriate to reflect
any stock splits, stock dividends, combinations, reorganizations, reclassifications or similar events).

 

“Net
Debt” means all Indebtedness as at June 30, 2019, other than the Third Party Expenses, which shall be in the amounts
set out in the Schedule of Expenses, as to paid and unpaid Third Party Expenses as of the date of this Agreement, plus any additional
Third Party Expenses actually incurred whether before or after the date of this Agreement that are not reflected on the Schedule
of Expenses, and excluding the Cash Adjustment Debt, the Total Consideration Adjustment Debt and any debt under the Anderson Loan
Documents.

 

“Order”
means any order, judgment, injunction, ruling, edict, or other decree, whether temporary, preliminary or permanent, enacted, issued,
promulgated, enforced or entered by any Governmental Entity.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other
legal entity including any Governmental Entity.

 

“Personal
Data” means information related to an identified or identifiable natural person (such as name, street address, telephone
number, e-mail address, photograph, financial account number, social security number, customer or account number, government-issued
identifiers, online identifiers and any other data used or intended to be used to directly or indirectly identify, contact or
precisely locate a person).

 

“Pre-Closing
Tax Period” means (a) any taxable period ending on or before the Closing Date and (b) the portion of any Straddle Period
that ends on the Closing Date.

 

“Purchaser
Common Stock” means the common stock, par value $0.0001 per share, of Purchaser.

 

“Purchaser
Option Plan” means Purchaser’s 2013 Stock Incentive Plan as in effect immediately prior to the Closing.

 

“R&W
Policy” means that certain the representations and warranties insurance policy purchased by Purchaser and bound as of
the date hereof pursuant to the Binder Agreement, dated as of the date hereof, by and between Purchaser, as named insured, and
Liberty Surplus Insurance Corporation.

 

“Real
Property” means all land, together with all buildings, structures, improvements and fixtures located thereon, including
all electrical, mechanical, plumbing and other building systems, fire protection, security and surveillance systems, telecommunications,
computer, wiring, and cable installations, utility installations, water distribution systems, and landscaping, together with all
easements and other rights and interests appurtenant thereto (including air, oil, gas, mineral, and water rights).

 

“Related
Party” with respect to any specified Person, means: (i) any Affiliate of such specified Person, or any director, executive
officer, general partner or managing member of such Affiliate; (ii) any Person who serves as a director, executive officer, partner,
member or in a similar capacity of such specified Person; (iii) any Immediate Family member of a Person described in clause (ii);
or (iv) any other Person who holds, individually or together with any Affiliate of such other Person and any member(s) of such
Person’s Immediate Family, more than 5% of the outstanding equity or ownership interests of such specified Person. For the
purposes of this definition, “Immediate Family,” with respect to any specified Person, means such Person’s
spouse, Purchasers, children and siblings, including adoptive relationships and relationships through marriage, or any other relative
of such Person that shares such Person’s home.

 

    	 	-A-7-	 

     

    

 

“SEC”
means the Securities and Exchange Commission.

 

“Shared
Third Party Expenses” means all Third Party Expenses relating to accounting matters.

 

“Software”
means any and all (1) computer programs, including any and all software implementations of algorithms, heuristics, models and
methodologies, whether in source code or object code, (2) testing, validation, verification and quality assurance materials, (3)
Databases, conversions, interpreters, and compilations, including any and all data and collections of data, whether machine readable
or otherwise, (4) descriptions, schematics, flow charts and other work product used to design, plan, organize and develop any
of the foregoing, (5) all documentation, including user manuals, web materials and architectural and design specifications and
training materials, relating to any of the foregoing, (6) software development processes, practices, methods and policies recorded
in permanent form, relating to any of the foregoing, and (7) performance metrics, sightings, bug and feature lists, build, release
and change control manifests recorded in permanent form, relating to any of the foregoing.

 

“Straddle
Period” means any taxable period that includes (but does not end on) the Closing Date.

 

“Subsidiary”
of the Company, Purchaser or any other Person means any corporation, partnership, limited liability company, registered local
office, association, trust, unincorporated association or other legal entity of which the Company, Purchaser or any such other
Person, as the case may be (either alone or through or together with any other Subsidiary), (i) owns, directly or indirectly,
50% or more of the share capital or other equity interests that are generally entitled to vote for the election of the board of
directors or other governing body of such corporation or other legal entity, or (ii) has the contractual or other power to designate
a majority of the board of directors or other governing body (and, where the context permits, includes any predecessor of such
an entity).

 

“Tax”
means (i) any direct or indirect federal, state, local, municipal, U.S. or non-U.S. net income, gross income, capital gains, gross
receipts, profits, capital, estimated, sales, use, ad valorem, value added, registration, transfer, franchise, profits, license,
lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property (real or
personal), production, unclaimed property, escheat, windfall profits, customs, duties or other taxes, contributions, rates, levies
(including social security), fees, assessments or charges of any kind whatsoever, whether disputed or not, together with any interest
and any penalties, additions to tax or additional amounts with respect thereto, (ii) any Liability for payment of amounts described
in clause (i) whether as a result of transferee Liability, of being a member of an affiliated, consolidated, combined, unitary
or similar group for any period, or otherwise through operation of law, and (iii) any Liability for the payment of amounts described
in clauses (i) or (ii) as a result of any Tax sharing, Tax indemnity or Tax allocation agreement or any other express or implied
agreement to indemnify any other Person.

 

“Tax
Return” means any return, election, form, certificate, declaration, notice, report, statement, information return or
statement or other document (including any schedules thereto and including any amendment thereof) filed or required to be filed
with respect to Taxes, including any amendments thereof, and including any schedules and attachments thereto.

 

“Taxing
Authority” means any Governmental Entity having authority with respect to Taxes.

 

    	 	-A-8-	 

     

    

 

“Third
Party Claim” means any claim in writing made by a third party (including any authorities) against Purchaser or the Company
that may result in a Shareholder being required to compensate Purchaser in accordance with Section 8.2(d).

 

“Third
Party Expenses” means all fees and expenses incurred by the Company, its Subsidiaries or any Shareholder (to the extent
borne by the Company or any of its Subsidiaries) in connection with this Agreement and the other Transaction Documents and the
transactions contemplated hereby and thereby, including (i) all legal, Tax, accounting, financial advisory, investment banking,
consulting fees and expenses and other like fees and expenses of third parties incurred by the Company and its Subsidiaries (including
on behalf of a Shareholder) in connection with the negotiation, documentation and effectuation of the terms and conditions of
this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, (ii) all fees and expenses
paid or payable in respect of third party waivers and consents or Contract amendments and terminations required to effect the
Closing as contemplated by this Agreement, (iii) the employer portion of any payroll and withholding Taxes payable in connection
with payments made in respect of Company Options, (iv) all compensatory payments (together with all Taxes, including the employer
portion of any payroll and withholding Taxes, and/or other costs paid or payable in connection with such payments) made by, or
obligation for payment by, the Company solely or partially as a result of the transactions contemplated hereby or a termination
of employment or engagement that occurs on or prior to the Closing, pursuant to any Contract or applicable Legal Requirement or
otherwise, including, bonus, separation, severance, redundancy, termination or similar-type benefits contemplated by this Agreement
or the documents and agreements contemplated hereby, to any current or former or retired employee, director, consultant or independent
contractor of the Company or the beneficiary or dependent of such Person, and (v) any retention bonus payment entitlement provided
by Purchaser or an Affiliate of Purchaser (together with all Taxes, including the employer portion of any payroll and withholding
Taxes, and/or other costs paid or payable in connection with such payments). For the avoidance of doubt, Third Party Expenses
shall not include any Indebtedness.

 

“Transaction
Documents” means collectively the Managing Director Agreement and the employment agreements entered into with the other
Key Individuals (including the employee and consultant confidential information and assignment of inventions agreements appended
thereto, respectively), and the other documents and agreements contemplated hereby.

 

“Transactions”
means the transactions contemplated by this Agreement and the agreements, documents, certificates and instruments being delivered
pursuant to this Agreement.

 

“US
GAAP” means generally accepted accounting principles for financial reporting in the United States in effect from time
to time.

 

“US
Subsidiary” means Pro Farm Inc.

 

Terms
not defined in this Annex A have the meanings ascribed to such terms in the following Sections of the Agreement:

 

	Term	 	Section
	1934
    Act	 	Section
    4.4(a)
	Accounting
    Arbitrator	 	Section
    1.4(c)(iv)
	Actual
    Net Debt	 	Section
    1.4(c)(i)
	Agreement	 	Preamble
	Annual
    EBITDA Milestone	 	Annex
    E

 

    	 	-A-9-	 

     

    

 

	Term	 	Section
	Annual
    EBITDA Milestone Stock Consideration	 	Section
    1.5(b)
	Annual
    Total Revenue Milestone	 	Annex
    E
	Annual
    Total Revenue Milestone Stock Consideration	 	Section
    1.3(g)(ii)
	Adjusted
    Milestone Consideration	 	Section
    1.5(b)
	applicable
    Anti-Corruption Laws	 	Section
    2.20(a)(ii)
	Applicable
    Limitation Date	 	Section
    8.1(a)
	Balance
    Sheet	 	Section
    2.7(a)
	Cap	 	Section
    8.2(d)
	Cash
    Adjustment Debt 	 	Section
    
	Cash
    Consideration Adjustment	 	Section
    1.4(b)(i)
	Claim	 	Section
    6.6
	Claim
    Notice	 	Section
    8.2(e)
	Closing	 	Section
    1.2
	Closing
    Date	 	Section
    1.2
	Closing
    Repayment Loans	 	Section
    1.3(b)
	Closing
    Schedule	 	Section
    1.4(c)(i)
	Company	 	Preamble
	Company
    Disclosure Schedules	 	Article
    II
	Company
    Permits	 	Section
    2.6(b)
	Company
    Securities	 	Section
    3.1
	Confidential
    Disclosure Agreement	 	Section
    6.2
	Conversion
    Shareholders	 	Recitals
	Debt
    and Equity Milestone 	 	Annex
    E
	Debt
    and Equity Milestone Stock Consideration	 	Section
    1.3(g)(ii)
	Dispute
    Notice	 	Section
    1.4(c)(ii)
	Dispute
    Notice Period	 	Section
    1.4(c)(ii)
	Distribution
    Schedule	 	Section
    1.4(a)(iii)
	Distributor Milestone	 	Annex E
	Distributor Milestone Stock Consideration	 	Section 1.5(b)
	Employee
    Plan	 	Section
    2.11(a)
	Enforceability
    Limitations	 	Section
    2.4
	Equity
    Injection	 	Section
    1.3(c)
	Estimated
    Net Debt	 	Section
    1.4(a)(i)
	Estonian
    Share Loss	 	Section
    6.10(b)
	Estonian
    Share Value	 	Section
    6.10(b)
	Estonian
    Shares	 	Section
    6.10(a)
	Final
    Cash	 	Section
    1.4(c)(iv)
	Final
    Closing Cash	 	Section
    1.4(c)(ii)
	Final
    Indebtedness	 	Section
    1.4(c)(ii)
	Final
    Net Debt	 	Section
    1.4(c)(ii)
	Financial
    Statements	 	Section
    2.7(a)
	Finnish
    GAAP	 	Section
    2.7(b)
	FIRPTA
    Certificate	 	Section
    1.2(a)(ii)
	Fundamental
    Representations	 	Section
    8.1(a)
	Governmental
    Officials	 	Section
    2.20(a)(ii)
	immediate
    family	 	Section
    6.5(b)
	Inbound
    License Agreement	 	Section
    2.15(a)(iv)(1)
	include	 	Section
    10.2

 

    	 	-A-10-	 

     

    

 

	Term	 	Section
	including	 	Section
    10.2
	Indemnified
    Liabilities	 	Section
    8.5(d)
	Indemnified
    Party	 	Section
    8.2(e)
	Indemnifying
    Party 	 	Section
    8.2(e)
	Independent
    Auditor’s Resolution	 	Section
    1.5(d)
	Insolvency	 	Section
    4.8
	Insolvent	 	Section
    4.8
	Insurance
    Policies	 	Section
    2.19
	Interim
    Balance Sheet Date	 	Section
    2.7(a)
	Interim
    Financial Statements	 	Section
    2.7(a)
	Joinder
    Agreement	 	Section
    1.2(a)(vi)
	Joining
    Shareholder	 	Section
    1.2(a)(vi)
	Key
    Individual	 	Recitals
	Key
    Shareholder	 	Section
    6.5(a)
	Lock-Up
    End Date	 	Section
    6.5(a)
	made
    available	 	Section
    10.2
	Material
    Contract(s)	 	Section
    2.17(a)
	Material
    Customer	 	Section
    2.22
	Material
    Supplier	 	Section
    2.22
	Milestone
    Allocation Schedule	 	Section
    1.5(b)
	Milestone
    Consideration Allocation	 	Section
    1.5(b)
	Milestone
    Consideration Adjustment	 	Section
    1.4(b)(iii)
	Milestone
    Payment Notice	 	Section
    1.5(b)
	Milestone
    Percentage	 	Section
    1.4(a)(iii)
	Non-Compete	 	Section
    6.9(a)
	Non-Negotiated
    Software Contract	 	Section
    2.15(a)(iv)(1)
	Non-Solicit	 	Section
    6.9(b)
	Optionholders	 	Preamble
	Option
    and RSU Recipients	 	Section
    6.7
	Outbound
    License Agreement	 	Section
    2.15(a)(iv)(2)
	Owned
    Intellectual Property	 	Section
    2.15(a)(i)(3)
	Permit	 	Section
    2.5(b)
	Principal
    Market	 	Section
    4.3
	Principal
    Market Approval	 	Section
    4.3
	Purchaser	 	Preamble
	Purchaser
    Disclosure Schedules	 	Article
    IV
	Purchaser
    Indemnitees	 	Section
    8.2(a)
	Purchaser
    Options	 	Section
    6.7
	Purchaser
    SEC Documents	 	Section
    4.4(a)
	Purchaser
    Shares	 	Section
    1.5(b)
	Real
    Property Lease	 	Section
    2.13(b)
	Registered
    Intellectual Property	 	Section
    2.15(a)(i)(1)
	Released
    Matters	 	Section
    6.6(a)
	Releasees	 	Section
    6.6(a)
	Releasors	 	Section
    6.6(a)
	Shareholder
    Disclosure Schedules	 	Article
    III
	Shareholders	 	Preamble
	Shareholders’
    Representative	 	Preamble
	SIG
    	 	Section
    2.15(a)(x)

 

    	 	-A-11-	 

     

    

 

	Term	 	Section
	Signing
    Schedule	 	Section
    1.4(a)(i)
	Schedule
    of Expenses	 	Section
    1.4(a)(i)
	Systems	 	Section
    2.15(b)(iii)
	Termination
    Date	 	Section
    9.1(b)
	Third
    Party Claim	 	Section
    8.2(e)
	Total
    Consideration Adjustment	 	Section
    1.4(b)
	Transfer	 	Section
    5.3(a)
	Transfer
    Agent	 	Section
    1.2(b)(ii)
	Transfer
    Taxes	 	Section
    1.3(e)
	Translink
    Representation Statement	 	Exhibit
    D
	Translink
    Milestone Stock 	 	Section
    1.5(f)
	 	 	 

 

    	 	-A-12-	 

     

    

 

Annex
B

Key
Individuals and Key shareholders 

 

[***]

 

    	 	-B-1-	 

     

    

 

Annex
C

Option
and RSU Recipients

 

[***]

 

    	-C-1-

    	 

    

 

Annex
d

third-party
consents

 

[***]

 

    	-D-1-

    	 

    

 

Annex
E

Milestone
Payments

 

	 	1.	Distributor Milestone.
    The “Distributor Milestone”
    means that the Company and its Subsidiaries (which, for all purposes of this Annex D, shall include any Subsidiaries of the
    Company as of the date of this Agreement that remain under common ownership and control with Purchaser or the Company) have
    achieved an aggregate gross profit from Distributor, including any Distributor group companies and their affiliates, of [***]
    from January 1, 2020 through December 31, 2023. 

 

	 	a.	For
    purposes of this Clause 1, “gross profit” means, [***].
	 	 	 
	 	b.	In
    the year, if any, in which the cumulative gross profit from Distributor during the period set forth above has reached [***],
    100% of the Distributor Milestone shall be deemed to have been achieved for the purposes of Section 1.5(b) of the
    Agreement. In any other year, the percentage of the Distributor Milestone achieved shall be deemed to be zero (0%)
    for the purposes of Section 1.5(b) of the Agreement.

 

	 	 	[***]

	 	 	 
	 	2.	Annual
    Total Revenue Milestone. The “Annual Total Revenue Milestone” means that the Company and its Subsidiaries
    achieve aggregate revenue, other than revenue received from Distributor or any Distributor group companies and their affiliates,
    of [***] from January 1, 2020 through December 31, 2023.

 

	 	a.	For
    purposes of this Clause 2, “revenue” means, [***]

 

	 	b.	The
    percentage of the Annual Total Revenue Milestone achieved for the 2020 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 2(b) above, divided by [***];
    or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	c.	The
    percentage of the Annual Total Revenue Milestone achieved for the 2021 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 2(b) above, divided by [***];
    or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	d.	The
    percentage of the Annual Total Revenue Milestone achieved for the 2022 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 2(b) above, divided by [***]; or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	e.	The
    percentage of the Annual Total Revenue Milestone achieved for the 2023 calendar year shall be higher of the two: 1) equal
    25% times the following percentage: (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 2(b)
    above, divided by [***]; or (y) if such percentage is less than 50%, zero (0%), or 2) the following
    percentage: (x) if greater than 50%, the sum of all revenue for 2020, 2021, 2022 and 2023, divided by [***],
    minus each of the percentages resulting from Clause 2(b), Clause 2(c) and Clause 2(d) above; or (y) if
    such percentage is less than 50%, zero (0%).

 

    	-E-1-

    	 

    

 

	 	f.	Further
    notwithstanding the foregoing, the total percentages of Annual Total Revenue Milestone achievement may not exceed 100%, and
    the percentage of actual Annual Total Revenue Milestone Achievement in any calendar year shall be reduced accordingly for
    the purposes of Section 1.5(b) of the Agreement. 

 

	 	 	[***]

	 	 	 
	 	3.	Annual
    EBITDA Milestone. The “Annual EBITDA Milestone” means if the Company and its subsidiaries earn aggregate
    annual EBITDA of [***] from January 1, 2020 through December 31, 2023.

 

	 	a.	For
    purposes of this Clause 3, “EBITDA” means [***].
    
	 	 	 
	 	b.	The
    percentage of the Annual EBITDA Milestone achieved for the 2020 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 3(b) above, divided by [***];
    or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	c.	The
    percentage of the Annual EBITDA Milestone achieved for the 2021 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 3(b) above, divided by [***];
    or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	d.	The
    percentage of the Annual EBITDA Milestone achieved for the 2022 calendar year shall equal 25% times the following percentage:
    (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 3(b) above, divided by [***];
    or (y) if such percentage is less than 50%, zero (0%). 
	 	 	 
	 	e.	The
    percentage of the Annual EBITDA Milestone achieved for the 2023 calendar year shall be higher of the two: 1) equal 25% times
    the following percentage: (x) if greater than 50%, the revenue for such year, calculated pursuant to Clause 3(b) above,
    divided by [***]; or (y) if such percentage is less than 50%, zero (0%), or 2) the following percentage: (x) if greater
    than 50%, the sum of all revenue for 2020, 2021, 2022 and 2023, divided by [***], minus each of the percentages
    resulting from Clause 3(b), Clause 3(c) and Clause 3(d) above; or (y) if such percentage is less than
    50%, zero (0%). 
	 	 	 
	 	f.	Further
    notwithstanding the foregoing, the total percentages of Annual EBITDA Milestone achievement may not exceed 100%, and the percentage
    of actual Annual EBITDA Milestone Achievement in any calendar year shall be reduced accordingly for the purposes of Section
    1.5(b) of the Agreement. 

 

	 	 	[***]

	 	 	 
	 	4.	Debt
    and Equity Milestone. The “Debt and Equity Milestone” means that the Company and its Subsidiaries shall
    have raised no more than an aggregate [***] debt [***] or equity financing during the period from the Closing to December
    31, 2023. 

 

	 	a.	For
    the purpose of this Clause 4, [***] debt shall mean [***].
	 	 	 
	 	b.	In
    any event, the percentage of the Debt and Equity Milestone achieved shall be zero (0%) for each of 2020, 2021 and 2022 for
    the purposes of Section 1.5(b) of the Agreement.

 

    	-E-2-

    	 

    

 

	 	c.	If
    the Company and its Subsidiaries have not raised more than an aggregate of [***] long-term interest-bearing
    debt or equity financing during the period from the Closing to 31 December 2023, 100% of the Debt and Equity Milestone shall
    be deemed to have been achieved for the 2023 calendar year for the purposes of Section 1.5(b) of the Agreement. 
	 	 	 
	 	d.	If
    the Company and its Subsidiaries have raised an aggregate of more than [***] but less than [***]
    long-term interest-bearing debt or equity financing during the period from the Closing to December 31, 2023, the percentage
    of the Debt and Equity Milestone achieved for the 2023 calendar year for the purposes of Section 1.5(b) of the Agreement
    shall be equal to 100% minus (i) two (2) times the incremental amount raised divided by (ii) [***].
	 	 	 
	 	e.	If
    the Company and its Subsidiaries have raised an aggregate of [***] or more in long-term interest-bearing
    debt or equity financing during the period from the Closing to December 31, 2023, the percentage of the Debt and Equity Milestone
    achieved for the 2023 calendar year for the purposes of Section 1.5(b) of the Agreement shall be equal to zero (0%).
    

 

	 	 	[***]

	 	 	 
	 	5.	Determination
    Methodologies. In determining whether each Milestone has been achieved:

 

	 	a.	Determination
    of whether each Milestone has been achieved is independent of the determination of whether the other Milestones have been
    achieved.
	 	 	 
	 	b.	[***]

	 	 	 
	 	c.	[***]

	 	 	 
	 	d.	[***]

	 	 	 
	 	e.	[***].

 

    	-E-3-

    	 

    

 

EXHIBIT
A

JOINDER
TO SHARE PURCHASE AGREEMENT AS A SHAREHOLDER

 

The
undersigned hereby agrees to become a party to and bound by that certain Share Purchase Agreement (the “Share Purchase
Agreement”), dated as of August 7, 2019, by and among Marrone Bio Innovations, Inc., a Delaware corporation, Pro Farm
Technologies Oy, a Finnish limited company, each of the shareholders of the Company party thereto, certain future shareholders
of the Company party thereto, and Matti Tiainen as representative of the Shareholders, and agrees to become a “Shareholder”
for purposes of the Share Purchase Agreement, and to be bound by the terms and conditions of the Share Purchase Agreement in the
same manner and to the same extent as the Shareholders who were originally parties to the Share Purchase Agreement. This Joinder
to Share Purchase Agreement as a Shareholder shall take effect and shall become an integral part of the Share Purchase Agreement
immediately upon its execution and delivery to the Company.

 

The
terms used but not defined in this Joinder to Share Purchase Agreement as a Shareholder have the meanings set forth in the Share
Purchase Agreement.

 

IN
WITNESS WHEREOF, this JOINDER TO SHARE PURCHASE AGREEMENT AS A SHAREHOLDER has been duly executed by or on behalf of the undersigned
as of the date below written.

 

	[Name of Shareholder]
	 	 	 
	By:	              	 
	Name:
    	 	 
	Its:
    	 	 
	Date:
    	 	 

 

    	 	-Exh. A-1-	 

     

    

 

EXHIBIT
B

FORM
OF OPTION AWARD AGREEMENT

 

    	-Exh. B-1-

    	 

    

 

EXHIBIT
C

FORM
OF RSU AWARD AGREEMENT

 

    	-Exh. C-1-

    	 

    

 

EXHIBIT
D

TRANSLINK
REPRESENTATION STATEMENT

 

This
representation statement is being delivered in connection with a right to receive certain shares (the “Securities”)
of Common Stock of Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), pursuant to that certain
Share Purchase Agreement (the “Share Purchase Agreement”), dated as of August 7, 2019, by and among the Company, Pro
Farm Technologies Oy, a Finnish limited company, each of the shareholders of the Company party thereto, certain future shareholders
of the Company party thereto, and Matti Tiainen as representative of the Shareholders. Capitalized terms used and not defined
herein have the meanings set forth in the Share Purchase Agreement. In consideration for the right to receive the Securities,
Translink Corporate Finance Oy (“Translink”) agrees and represents for the benefit of the Company as follows:

 

1)
Translink represents that it is a limited liability company duly organized, validly existing and in good standing under the
laws of Finland (Business ID: 1535364-2) and has the requisite power and authority to make the representations and agreements
set forth in this representation statement.

 

2)
Translink is acquiring the Securities for its own account and not with a view towards, or for resale in connection with, the
public sale or distribution thereof, except pursuant to sales registered or exempted under the Securities Act of 1933, as
amended (the “1933 Act”). Translink does not presently have any agreement or understanding, directly or
indirectly, with any Person to distribute any of the Securities.

 

3)
Translink (i) certifies that Translink is not a “U.S. person” within the meaning of SEC Rule 902 of Regulation S,
as presently in effect, and that Translink is not acquiring the Securities for the account or benefit of any such U.S.
person, (ii) agrees to resell the Securities only in accordance with the provisions of Regulation S, pursuant to registration
under the 1933 Act, or pursuant to an available exemption from registration and agrees not to engage in hedging transactions
with regard to such Securities unless in compliance with the 1933 Act, (iii) agrees that any certificates or book-entry
positions for any Securities issued to Translink shall contain a legend to the effect that transfer is prohibited except in
accordance with the provisions of Regulation S, pursuant to registration under the 1933 Act or pursuant to an available
exemption from registration and that hedging transactions involving such Securities may not be conducted unless in compliance
with the 1933 Act, (iv) agrees that the Company is hereby required to refuse to register any transfer of any Securities
issued to Translink not made in accordance with the provisions of Regulation S, pursuant to registration under the 1933 Act,
or pursuant to an available exemption from registration. Translink understands that the Securities are being offered and sold
in reliance on specific exemptions from the registration requirements of United States Legal Requirements and that the
Company is relying in part upon the truth and accuracy of, and Translink’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of Translink set forth herein in order to determine the
availability of such exemptions and the eligibility of Translink to acquire the Securities.

 

4)
Translink is aware of the Company’s business affairs and financial condition and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Securities.

 

5)
Translink understands that the book-entry or other instruments representing the Securities issued hereunder, until such time
as the resale of Securities issued hereunder have been registered under the 1933 Act, the book-entry representing the
Securities issued hereunder, except as set forth below, shall bear a restrictive legend in substantially the following form
(and a stop-transfer order may be placed against transfer of such Securities):

 

“THE
TRANSFER OF THESE SECURITIES IS PROHIBITED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S AS PROMULGATED BY THE UNITED
STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE ACT, PURSUANT TO REGISTRATION UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM REGISTRATION, AND HEDGING TRANSACTIONS INVOLVING THESE SECURITIES (INCLUDING ANY SWAP OR ANY OTHER AGREEMENT OR ANY TRANSACTION
THAT TRANSFERS, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, THE ECONOMIC CONSEQUENCE OF OWNERSHIP OF THESE SECURITIES, WHETHER
ANY SUCH SWAP, AGREEMENT OR TRANSACTION IS TO BE SETTLED BY DELIVERY OF ALL OR ANY PORTION OF THESE SECURITIES OR ANY OTHER SECURITIES,
IN CASH OR OTHERWISE), MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.”

 

    	-Exh. D-1-

    	 

    

 

The
legend set forth above shall be removed if (i) in connection with a sale, assignment or other transfer, the holder of such Securities
provides the Company with an opinion of counsel, the form and substance of which shall be reasonably acceptable to the Company,
to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements
of the 1933 Act, or (ii) such holder provides the Company with reasonable assurance (including, if requested by the Company, a
customary representation letter reasonably acceptable to the Company) that the Securities can be sold, assigned or transferred
without volume or manner of sale restriction pursuant to Rule 144.

 

6)
Translink understands that no United States Governmental Entity has passed on or made any recommendation or endorsement of
the Company or the fairness or suitability of holding the Securities issuable pursuant to the Share Purchase Agreements, nor
have such authorities passed upon or endorsed the merits of the transactions contemplated by the Share Purchase Agreement or
this representation statement.

 

7)
Translink understands that the Securities it is receiving are characterized as “restricted securities” under the
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the Act only in
certain limited circumstances. In this connection, Translink represents that it is familiar with SEC Rule 144, as presently
in effect, and understands the resale limitations imposed thereby and by the 1933 Act. Translink understands that the
Securities have not been and will not be registered under the 1933 Act and have not been and will not be registered or
qualified in any state in which they are offered, and thus Translink will not be able to resell or otherwise transfer its
Securities unless they are registered under the 1933 Act and registered or qualified under applicable state securities laws,
or an exemption from such registration or qualification is available. Without in any way limiting the representations set
forth above, Translink further agrees not to make any disposition of all or any portion of the Securities prior to the date
that is six (6) months from the date of issuance of such Securities unless and until transferee has agreed in writing for the
benefit of the Company to be bound by this Section 7 and:

 

	 	a)	There
    is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made
    in accordance with such registration statement; or
	 	 	 
	 	b)	(i)
    Translink shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed
    statement of the circumstances surrounding the proposed disposition, and (ii) if reasonably requested by the Company, Translink
    shall have furnished the Company with an opinion of counsel reasonably satisfactory to the Company that such disposition will
    not require registration of such shares under the 1933 Act. It is agreed that the Company will not require opinions of counsel
    for transactions made pursuant to Rule 144 except in unusual circumstances.

 

Notwithstanding
the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be necessary for a
transfer that is permitted by Section 6.5(b) of the Share Purchase Agreement, mutatis mutandis, if the transferee agrees
in writing to be subject to the terms hereof to the same extent as if he, she or it were Translink hereunder.

 

    	-Exh. D-2-

    	 

    

 

8)
Commencing on the Closing Date and ending on the applicable Lock-Up End Date, each Shareholder agrees that such Shareholder will
not, and will cause any of its affiliates (as defined in Rule 144) not to, (A) sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option to purchase, make any short sale or otherwise dispose of or agree to dispose of, directly
or indirectly, any of the Securities issuable hereunder, or establish or increase a put equivalent position or liquidate or decrease
a call equivalent position within the meaning of Section 16 of the 1934 Act and the rules and regulations of the SEC promulgated
thereunder with respect to the Securities, (B) enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of any of the Securities, whether any such transaction above is to be settled
by delivery of shares of Common Stock or other securities, in cash or otherwise, or (C) publicly disclose the intention to do
any of the foregoing. The “Lock-Up End Date” with respect to 99,465 of the Securities issued at the Closing
Date shall be the date that is twelve (12) months after the Closing Date and with respect to the remainder of the Securities shall
be the date that is six (6) months after the Closing Date. Notwithstanding the foregoing, Translink may transfer the Securities
(i) as a bona fide gift or gifts, provided that the donee or donees thereof agree to be bound in writing by the restrictions set
forth herein or (ii) to any affiliate of Translink provided that such affiliate agrees to be bound in writing by the restrictions
set forth herein, provided that any such transfer pursuant to clause (i) shall not involve a disposition for value. Translink
understands and agrees that this Section 8 is irrevocable and shall be binding upon such Translinks legal representatives,
successors, and assigns.

 

9)
Translink agrees and acknowledges that the provisions of Article X of the Share Purchase Agreement shall apply mutatis
mutandis to this representation statement.

 

	TRANSLINK
    CORPORATE FINANCE OY	 
	 	 	 
	By:	 	 
	Name:	Jari
    Lauriala	 
	Its:
    	CEO,
    Board Member	 
	Date:	 	 

 

    	-Exh. D-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]